
<html lang="en"     class="pb-page"  data-request-id="9d53ec35-cf99-466e-a180-1c24eeb3cd40"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c02171;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules" /></meta><meta name="dc.Creator" content="Stephanie L.  Slania" /></meta><meta name="dc.Creator" content="Deepankar  Das" /></meta><meta name="dc.Creator" content="Ala  Lisok" /></meta><meta name="dc.Creator" content="Yong  Du" /></meta><meta name="dc.Creator" content="Zirui  Jiang" /></meta><meta name="dc.Creator" content="Ronnie C.  Mease" /></meta><meta name="dc.Creator" content="Steven P.  Rowe" /></meta><meta name="dc.Creator" content="Sridhar  Nimmagadda" /></meta><meta name="dc.Creator" content="Xing  Yang" /></meta><meta name="dc.Creator" content="Martin G.  Pomper" /></meta><meta name="dc.Description" content="Fibroblast activation protein (FAP) has become a favored target for imaging and therapy of malignancy. We have synthesized and characterized two new (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based ..." /></meta><meta name="Description" content="Fibroblast activation protein (FAP) has become a favored target for imaging and therapy of malignancy. We have synthesized and characterized two new (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 17, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02171" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02171" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02171" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02171" /></link>
        
    
    

<title>Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02171" /></meta><meta property="og:title" content="Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0008.jpeg" /></meta><meta property="og:description" content="Fibroblast activation protein (FAP) has become a favored target for imaging and therapy of malignancy. We have synthesized and characterized two new (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based small molecules for imaging of FAP, QCP01 and [111In]QCP02, using optical and single-photon computed tomography/CT, respectively. Binding of imaging agents to FAP was assessed in six human cancer cell lines of different cancer types: glioblastoma (U87), melanoma (SKMEL24), prostate (PC3), NSCLC (NCIH2228), colorectal carcinoma (HCT116), and lung squamous cell carcinoma (NCIH226). Mouse xenograft models were developed with FAP-positive U87 and FAP-negative PC3 cells to test pharmacokinetics and binding specificity in vivo. QCP01 and [111In]QCP02 demonstrated nanomolar inhibition of FAP at Ki values of 1.26 and 16.20 nM, respectively. Both were selective for FAP over DPP-IV, a related serine protease. Both enabled imaging of FAP-expressing tumors specifically in vivo. [111In]QCP02 showed high uptake at 18.2 percent injected dose per gram in the U87 tumor at 30 min post-administration." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02171"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02171">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02171&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02171&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02171&amp;href=/doi/10.1021/acs.jmedchem.0c02171" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 4059-4070</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02170" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02188" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Stephanie L. Slania</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephanie L. Slania</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephanie+L.++Slania">Stephanie L. Slania</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Deepankar Das</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deepankar Das</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deepankar++Das">Deepankar Das</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ala Lisok</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ala Lisok</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ala++Lisok">Ala Lisok</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yong Du</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong Du</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Du">Yong Du</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Zirui Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zirui Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zirui++Jiang">Zirui Jiang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ronnie C. Mease</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ronnie C. Mease</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ronnie+C.++Mease">Ronnie C. Mease</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Steven P. Rowe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven P. Rowe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div><div class="loa-info-affiliations-info">Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+P.++Rowe">Steven P. Rowe</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Sridhar Nimmagadda</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sridhar Nimmagadda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div><div class="loa-info-affiliations-info">Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#97e4f9fefafaf6f0a6d7fdfffafeb9f2f3e2"><span class="__cf_email__" data-cfemail="8bf8e5e2e6e6eaecbacbe1e3e6e2a5eeeffe">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sridhar++Nimmagadda">Sridhar Nimmagadda</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6413-7191" title="Orcid link">http://orcid.org/0000-0002-6413-7191</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Xing Yang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xing Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#9ce5fdf2fbe4f5f2fbaeacadabdcfef6f1e9b2f9f8e9b2fff2"><span class="__cf_email__" data-cfemail="ccb5ada2abb4a5a2abfefcfdfb8caea6a1b9e2a9a8b9e2afa2">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xing++Yang">Xing Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5186-4990" title="Orcid link">http://orcid.org/0000-0001-5186-4990</a></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Martin G. Pomper</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin G. Pomper</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div><div class="loa-info-affiliations-info">The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div><div class="loa-info-affiliations-info">Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#84e9f4ebe9f4e1f6c4eeece9edaae1e0f1"><span class="__cf_email__" data-cfemail="e18c918e8c918493a18b898c88cf848594">[emailÂ protected]</span></a>. Phone: 410-955-2789.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+G.++Pomper">Martin G. Pomper</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6753-3010" title="Orcid link">http://orcid.org/0000-0001-6753-3010</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02171&amp;href=/doi/10.1021%2Facs.jmedchem.0c02171" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 4059â4070</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 17, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 December 2020</li><li><span class="item_label"><b>Published</b> online</span>17 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02171" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02171</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4059%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DStephanie%2BL.%2BSlania%252C%2BDeepankar%2BDas%252C%2BAla%2BLisok%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.0c02171%26title%3DImaging%2Bof%2BFibroblast%2BActivation%2BProtein%2Bin%2BCancer%2BXenografts%2BUsing%2BNovel%2B%25284-Quinolinoyl%2529-glycyl-2-cyanopyrrolidine-Based%2BSmall%2BMolecules%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4070%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02171"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">914</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02171" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Stephanie&quot;,&quot;last_name&quot;:&quot;L. Slania&quot;},{&quot;first_name&quot;:&quot;Deepankar&quot;,&quot;last_name&quot;:&quot;Das&quot;},{&quot;first_name&quot;:&quot;Ala&quot;,&quot;last_name&quot;:&quot;Lisok&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Du&quot;},{&quot;first_name&quot;:&quot;Zirui&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Ronnie&quot;,&quot;last_name&quot;:&quot;C. Mease&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;P. Rowe&quot;},{&quot;first_name&quot;:&quot;Sridhar&quot;,&quot;last_name&quot;:&quot;Nimmagadda&quot;},{&quot;first_name&quot;:&quot;Xing&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;G. Pomper&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4059-4070&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02171&quot;},&quot;abstract&quot;:&quot;Fibroblast activation protein (FAP) has become a favored target for imaging and therapy of malignancy. We have synthesized and characterized two new (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based small molecules for imaging of FAP, QCP01 and [111In]QCP02, using optical and single-photon computed tomography/CT, respectively. Binding of imaging agents to FAP was assessed in six human cancer cell lines of different cancer types: glioblastoma (U87), melanoma (SKMEL24), prostate (PC3), NSCLC (NCIH2228), colorectal carcinoma (HCT116), and lung squamous cell carcinoma (NCIH226). Mouse xenograft models were developed with FAP-positive U87 and FAP-negative PC3 cells to test pharmacokinetics and binding specificity in vivo. QCP01 and [111In]QCP02 demonstrated nanomolar inhibition of FAP at Ki values of 1.26 and 16.20 nM, respectively. Both were selective for FAP over DPP-IV, a related serine protease. Both enabled imaging of FAP-expressing tumors specifically in vivo. [111In]QCP02 showed high uptake at 18.2 percent in&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02171&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02171" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02171&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02171" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02171&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02171" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02171&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02171&amp;href=/doi/10.1021/acs.jmedchem.0c02171" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02171" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02171" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02171%26sid%3Dliteratum%253Aachs%26pmid%3D33730493%26genre%3Darticle%26aulast%3DSlania%26date%3D2021%26atitle%3DImaging%2Bof%2BFibroblast%2BActivation%2BProtein%2Bin%2BCancer%2BXenografts%2BUsing%2BNovel%2B%25284-Quinolinoyl%2529-glycyl-2-cyanopyrrolidine-Based%2BSmall%2BMolecules%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D4059%26epage%3D4070%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=290997" title="Biological imaging">Biological imaging</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Fibroblast activation protein (FAP) has become a favored target for imaging and therapy of malignancy. We have synthesized and characterized two new (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based small molecules for imaging of FAP, <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b>, using optical and single-photon computed tomography/CT, respectively. Binding of imaging agents to FAP was assessed in six human cancer cell lines of different cancer types: glioblastoma (U87), melanoma (SKMEL24), prostate (PC3), NSCLC (NCIH2228), colorectal carcinoma (HCT116), and lung squamous cell carcinoma (NCIH226). Mouse xenograft models were developed with FAP-positive U87 and FAP-negative PC3 cells to test pharmacokinetics and binding specificity <i>in vivo</i>. <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b> demonstrated nanomolar inhibition of FAP at <i>K</i><sub>i</sub> values of 1.26 and 16.20 nM, respectively. Both were selective for FAP over DPP-IV, a related serine protease. Both enabled imaging of FAP-expressing tumors specifically <i>in vivo</i>. [<sup>111</sup>In]<b>QCP02</b> showed high uptake at 18.2 percent injected dose per gram in the U87 tumor at 30 min post-administration.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Fibroblast activation protein (FAP) is highly upregulated at sites of active tissue remodeling, including wound healing, fibrosis, and cancer.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1â4)</a> It is a member of the dipeptidyl peptidase (DPP) family of serine proteases known for their unique ability to cleave prolyl bonds two residues from the N-terminus.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> FAP has the ability to cleave after prolyl bonds within peptides (not just at the N-terminus), which enables it to act as a collagenase and cleave type I collagen.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6â9)</a> The collagenase activity of FAP is a major driver in the remodeling of the extracellular matrix (ECM) in a variety of diseases, including cancer.<a onclick="showRef(event, 'ref7 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref9 ref10">(7,9,10)</a> While FAP expression in normal tissues is minimal, it is highly upregulated in cancer, with  presence in over 90% of epithelial tumors.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">In cancer, FAP has emerged as a distinct marker of cancer-associated fibroblasts (CAFs) and a key regulator and driver of the tumor microenvironment (TME). CAFs are one of the largest components of the TME and promote tumor growth and cell invasion by secreting pro-inflammatory factors and growth factors as well as remodeling the ECM.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> In addition to cells within the TME, FAP expression can be present within malignant epithelial cells.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> FAP promotes tumor growth through ECM remodeling, which leads to the formation of an active cancer stroma, essential for cancer cell invasion and metastasis.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> This has been observed clinically, where FAP expression was increased at the invasive front of tumor samples of colorectal cancer, further supporting its role in invasion and metastasis.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> FAP also contributes to the formation of an immunosuppressive TME by enabling tumor-promoting inflammation.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Due to the important roles FAP plays in the TME, there is increasing interest in utilizing it as a target for imaging and therapy.</div><div class="NLM_p">Clinical studies show that FAP expression has prognostic value in a variety of cancers. In pancreatic cancer, FAP expression is related directly to poor clinical outcome. Patients with pancreatic cancer and high FAP expression have lower chances of overall and disease-free survival.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In non-small-cell lung cancer (NSCLC), a larger percentage of cells staining positively for FAP and a higher FAP-staining grade were both significant predictors of poor overall survival.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Henry <i>et al.</i> observed similar results in colon cancer, where patients with high levels of tumor stromal FAP expression were more likely to progress and develop metastases.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> These results, generated from biopsy specimens, have motivated the search for ways to interrogate FAP concentration <i>in vivo</i>, preferably non-invasively so that repeat measurements would be possible.</div><div class="NLM_p">Antibody-based imaging agents targeting FAP were first tested clinically over 25 years ago,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> with immuno-positron emission tomography (PET) of FAP having more recently been used in preclinical models, such as to delineate rheumatoid arthritis.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> However, the small-molecule FAP-targeting agents have captured the most attention recently. Such compounds, if suitably functionalized, promise to have superior and modifiable pharmacokinetics, enabling imaging soon after injection, among other advantages of using drug-like molecules for imaging.</div><div class="NLM_p">A variety of small-molecule FAP inhibitors have been functionalized for imaging. MIP-1232, based on a boronic acid FAP inhibitor, demonstrated its ability to bind FAP-positive SK-MEL-187 (melanoma) xenografts.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> However, boronic acid FAP inhibitors often have affinity for multiple prolyl peptidases related to FAP, limiting the specificity of these agents.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Lindner <i>et al.</i> recently developed theranostic agents<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> based on the specificity of the (4-quinolinoyl)-glycyl-2-cyanopyrrolidine nucleus of general structure <b>2</b> targeting FAP (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), originally reported by Jansen <i>et al</i>.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> While the radiodinated inhibitor <b>FAPI-01</b> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) suffered from rapid deiodination, radiometal complexes of <b>FAPI-02</b> or <b>FAPI-04</b> (<sup>68</sup>Ga or <sup>177</sup>Lu, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) exhibited high and rapid uptake in FAP-expressing cells and mouse xenograft models.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Early clinical studies of those agents in pancreatic, head and neck, colon, lung, and breast cancers indicate that both [<sup>68</sup>Ga]<b>FAPI-02</b> and [<sup>68</sup>Ga]<b>FAPI-04</b> can be used to detect FAP expression in primary tumors as well as metastatic lesions and indicate the potential of FAP-targeted imaging to visualize the components of the TME.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Roy <i>et al.</i> have also recently leveraged the 2-cyanopyrolidine moiety for FAP binding, but utilized a pyridine rather than a quinoline to link to a variety of imaging and therapeutic functionalities to good effect.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. FAP Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Despite the use of FAP-targeted small-molecule PET agents in clinical studies, a comprehensive preclinical evaluation has not been carried out to ascertain an optimal compound for clinical use. Here, we build toward a more complete understanding of these agents with the preclinical development of two novel FAP-targeted imaging agents based on the (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold, <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b>. These agents are equipped for near-infrared fluorescence (NIRF) and single-photon emission computed tomography (SPECT) imaging, respectively. <b>QCP01</b> and <b>QCP02</b> share the same (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold as <b>FAPI-02</b> but differ in the linking group using a flexible linear linker instead of one containing a semi-rigid piperazine moiety, potentially allowing for better penetration into the binding site. Also, the chelating group, 2-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra acetate (DOTA-GA) in <b>QCP02</b>, contains an additional carboxylate group compared to the chelator in <b>FAPI-02</b> and <b>FAPI-04</b>, increasing affinity for radiometals, including <sup>111</sup>In.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> We chose <sup>111</sup>In as the imaging radionuclide because of the high affinity to DOTA-GA, its ready detectability with SPECT by virtue of two emitted photons (171 and 245 keV), and its long physical half-life (2.8 days), which could accommodate lengthy imaging times after administration if needed.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> We evaluated the affinity and specificity of these agents <i>in vitro</i> and studied their abilities to image cancer xenografts in mouse models. Additionally, to examine further the role of FAP in cancer, we analyzed the FAP expression profiles in the Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) data sets.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemical Synthesis</h3><div class="NLM_p">The FAP binding reactive moiety was synthesized by coupling 6-hydroxyquinoline-4-carboxylic acid (<b>3</b>) with glycine methyl ester hydrochloride to give <b>4</b>. Alkylation of <b>4</b> with <i>tert</i>-butyl-1-(3-bromopropyl)carbamate produced <b>5</b>, which underwent basic hydrolysis to give acid <b>6</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Compound <b>6</b> was coupled with (<i>S</i>)-2-pyrrolidine carbonitrile hydrochloride to produce the common intermediate <b>7</b>. <b>QCP01</b> was prepared by acid deprotection of <b>7</b> to produce intermediate <b>8</b>, which was conjugated with IRDye 800CW-NHS (LI-COR Biosciences, Lincoln, NE) under basic conditions. Similarly, <b>QCP02</b> was prepared by conjugation with DOTA-GA(<i>t</i>-Bu)<sub>4</sub>-<i>N</i>-hydroxysuccinimide (NHS),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> followed by acid hydrolysis of the <i>ter</i>t-butyl ester groups. Complexation of non-radioactive <sup>113/115</sup>In (III) and radioactive <sup>111</sup>In (III) with <b>QCP02</b> was carried out in 0.2 M sodium acetate buffer (pH 5.5â6.0) at 70 Â°C, followed by purification with reverse-phase semi-preparative high-performance liquid chromatography (HPLC). The isolated yields of [<sup>113/115</sup>In]<b>QCP02</b> and [<sup>111</sup>In]<b>QCP02</b> were 79 and 69â74%, respectively (<i>n</i> = 4). The radiochemical purity of [<sup>111</sup>In]<b>QCP02</b> was >95%, as measured by radio-HPLC (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf" class="ext-link">Figure S1</a>). Both <b>QCP02</b> and <b>QCP01</b> were sterile-filtered and formulated in saline solution prior to use.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Synthesis of <b>QCP01</b> and <b>QCP02</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) glycine methyl ester hydrochloride, HOBt, HBTU, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, RT, 6 h, 76%; (b) 3-(Boc-amino) propyl bromide, Cs<sub>2</sub>CO<sub>3</sub>, DMF, RT, 16 h, 54%; (c) LiOH, H<sub>2</sub>O/THF, RT, 6 h, 99%; (d) (<i>S</i>)-pyrrolidine-2-carbonitrile hydrochloride, HOBt, HBTU, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, RT, 6 h, 80%; (e) TFA/CH<sub>2</sub>Cl<sub>2</sub>, RT, 1 h; (f) IRDye 800CW-NHS ester, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, RT, 2 h, 81% (total yield e and f); (g) 1. DOTA-GA(<i>t</i>-Bu)<sub>4</sub>-NHS, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, RT, 4 h, 2. TFA/H<sub>2</sub>O/TES, RT, 1 h, 35%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> FAP Inhibitory Capacity</h3><div class="NLM_p last">To determine potency toward FAP, we measured the inhibitory capacity of <b>QCP01</b> and [<sup>113/115</sup>In]<b>QCP02</b> against a fluorogenic FAP substrate (Ala-Pro-AMC) of human recombinant FAP (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf" class="ext-link">Figure S2</a>). <b>QCP01</b> demonstrated low nanomolar inhibition of FAP with a <i>K</i><sub>i</sub> of 1.26 nM (95% confidence interval: 0.95â1.67 nM). [<sup>113/115</sup>In]<b>QCP02</b> also showed strong inhibition, with a <i>K</i><sub>i</sub> value of 16.20 nM (95% confidence interval: 10.34â26.37 nM). These results demonstrated the FAP binding potential of the synthesized compounds and showed that functionalization of the inhibitor scaffold did not substantially affect its inhibition of FAP <i>in vitro</i>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> FAP Expression in Human CCLE Database-Derived and Primary Tumor-Derived TCGA Data Sets</h3><div class="NLM_p">Due to the prominent role FAP plays in cancer and the lack of understanding of its expression across the cancer spectrum, we wanted to gain a detailed picture of FAP expression in cancer cell lines as well as in primary tumor samples. To do so, we obtained gene expression data on FAP from 1047 cancer cell lines from the CCLE database to examine the heterogeneity of FAP expression across cancer cell types. Cancer cell lines that showed high FAP expression include fibroblast-like, glioma, melanoma, osteosarcoma, and upper aerodigestive cancers (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). Low FAP expression was seen in a variety of leukemia and lymphoma subtypes as well as in prostate cancer. Using these results, we chose six cancer cell lines of different cancer types for <i>in vitro</i> studies from the high- and low-expression subtypes.</div><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FAP expression in human cancers. FAP mRNA expression in human cancer cell lines from the CCLE (A) and in human primary tumors from TCGA (B) was analyzed. FAP mRNA expression in primary tumors and normal tissues from TCGA data was also analyzed (C); NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer; DLBCL = diffuse large B-cell lymphoma; AML = acute myeloid leukemia; CML = chronic myelogenous leukemia; PAAD = pancreatic cancer; BRCA = breast cancer; MESO = mesothelioma; HNSC = head and neck cancer; LUAD = lung adenocarcinoma; LUSC = lung squamous cell carcinoma; STAD = stomach cancer; UCS = uterine carcinosarcoma; ESCA = esophageal cancer; READ = rectal cancer; DLBC = large-B-cell lymphoma; COAD = colon cancer; SKCM = melanoma; CHOL = bile duct cancer; BLCA = bladder cancer; CESC = cervical cancer; UCEC = endometrioid cancer; OV = ovarian cancer; KIRC = kidney clear cell carcinoma; TGCT = testicular cancer; THCA = thyroid cancer; GBM = glioblastoma; PRAD = prostate cancer; ACC = adrenocortical cancer; PCPG = pheochomocytoma; LIHC = liver cancer; LGG = lower-grade glioma; KIRP = kidney papillary cell carcinoma; UVM = ocular melanomas; KICH = kidney chromophobe; THYM = thymoma; LAML = acute myeloid leukemia.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Further analysis of the TCGA data set allowed us to examine FAP expression in primary tumor samples across 32 different cancers. Similar to the CCLE results, we observed that FAP expression in primary tumor samples varied across cancer types (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). High FAP expression was seen in pancreatic ductal adenocarcinoma, a cancer where  stroma is known to play a prominent role.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Other cancers including breast, mesothelioma, and head and neck also showed high FAP expression. In contrast, low FAP expression was seen in thymoma and acute myeloid leukemia. Additionally, when comparing FAP expression between primary tumor and normal solid tissue samples, we saw that in a majority of cancer types, FAP expression was higher in primary tumors compared to the corresponding normal tissue (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C). Further analysis of FAP expression in primary melanoma and metastases showed a trend in increase in FAP expression in metastases but had no statistical significance (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf" class="ext-link">Figure S4</a>).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> <i>In Vitro</i> Fluorescence</h3><div class="NLM_p">All six selected cell lines were tested for FAP expression by flow cytometry (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf" class="ext-link">Figure S3</a>) and observed to have variable FAP expression levels (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). For <i>in vitro</i> binding studies, binding of <b>QCP01</b> was observed in all three FAP-positive cell lines (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). <b>QCP01</b> binding was observed at concentrations as low as 1.56 nM and exhibited concentration-dependent binding that was saturated at 50 nM. In contrast, no specific binding of <b>QCP01</b> was observed in FAP-negative cell lines at any of the concentrations tested. This was further illustrated in the binding curves, which showed that the FAP-negative cell lines exhibited minimal binding of <b>QCP01</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A).</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>In vitro</i> binding and specificity of <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b>. (A) Cells incubated with various concentrations (range: 50â0.78 nM) of <b>QCP01</b> were imaged with the LI-COR Pearl Impulse Imager to assess binding of the agent in various FAP-positive (+) and FAP-negative (â) cell lines (left). Doseâresponse curves of <b>QCP01</b> binding in FAP-positive cell lines (NCIH2228, U87, and SKMEL24) and FAP-negative cell lines (PC3, NCIH226, and HCT116) were generated (right). (B) Cells were incubated with 0.037 MBq [<sup>111</sup>In]<b>QCP02</b> and were washed with cold phosphate-buffered saline (PBS). The radioactivity of the cell pellets was measured and normalized to the incubated dose; ****, <i>P</i> < 0.0001. (C) Cells incubated with 25 nM <b>QCP01</b> were incubated with various concentrations of either a DPP-IV and FAP inhibitor, Val-boroPro, or a DPPIV-only inhibitor, sitagliptin. The binding of <b>QCP01</b> was measured, and semi-log inhibitorâresponse curves were generated for both Val-boroPro (left) and sitagliptin (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cellular binding of [<sup>111</sup>In]<b>QCP02</b> was also assessed <i>in vitro</i>. After incubation with [<sup>111</sup>In]<b>QCP02</b> and subsequent washing, FAP-positive U87 cells demonstrated over 30% binding of the incubated dose of [<sup>111</sup>In]<b>QCP02</b> (0.037 MBq) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). In contrast, FAP-negative PC3 cells showed 0.01% binding of the incubated dose. This difference in binding of [<sup>111</sup>In]<b>QCP02</b> was significant between the FAP-positive and FAP-negative cell lines, with a <i>P</i>-value of <0.001.</div><div class="NLM_p last">To examine the specificity of our compounds further, inhibition studies were performed in the FAP-positive cell lines (U87, NCIH228, and SKMEL24) using <b>QCP01</b>. Cells were pretreated with either Val-boroPro (IC<sub>50</sub>; FAP: 0.066 Â± 0.011 Î¼M, DPP-IV: 0.022 Â± 0.001 Î¼M)<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> or sitagliptin, (IC<sub>50</sub>; FAP: >100 Î¼M, DPP-IV: 0.04 Â± 0.001 Î¼M),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> followed by incubation with <b>QCP01</b>. When pretreated with Val-boroPro, FAP-positive cell lines demonstrated dose-dependent inhibition of the fluorescence signal, indicating decreased binding of <b>QCP01</b> with increasing concentration of Val-boroPro (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). In contrast, <b>QCP01</b> binding by FAP-positive cell lines was not inhibited by pretreatment with sitagliptin. These results show that <b>QCP01</b> binds to FAP and not DPP-IV when binding to target cells since inhibition of DPP-IV alone did not affect binding of <b>QCP01</b>. Taken together, the results establish the specificity of <b>QCP01</b> to bind FAP <i>in vitro</i>.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> NIRF Imaging of <b>QCP01</b> in a Murine Xenograft Model</h3><div class="NLM_p">To evaluate the ability of <b>QCP01</b> to bind FAP <i>in vivo</i> and to gain insight into its biodistribution, we performed NIRF imaging in tumor-bearing mice. NIRF imaging results illustrated the pharmacokinetic behavior of <b>QCP01</b><i>in vivo</i>. Emission from intact, living, and unshaven tumor-bearing mice demonstrated uptake of <b>QCP01</b> in  U87 xenografts at 30 min after injection (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf" class="ext-link">Figure S5</a>). This uptake persisted up to 5 h after injection, with washout after 24 h. PC3 tumors showed mild uptake of <b>QCP01</b> at 30 min after injection until 5 h, with washout at 24 h. <b>QCP01</b> uptake in normal tissues was observed to a mild degree (moderate in the kidney) at 30 min after injection and washed out slowly over time. At 5 h after injection, post-mortem studies were performed to enable exposure of organs for NIRF imaging (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Although difficult to quantify as the image is planar, one can observe increased binding of <b>QCP01</b> in the FAP-positive U87 xenograft compared to that in the FAP-negative PC3 xenograft. This difference was further pronounced in the <i>ex vivo</i> organ tissue, with the excised U87 tumor consistently showing higher <b>QCP01</b> uptake than the PC3 tumor at 5, 24, and 48 h after injection.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. NIRF imaging of <b>QCP01</b> in a tumor-bearing mouse. NOD/SCID mice bearing FAP-positive U87 (red) and FAP-negative PC3 (white) tumor xenografts (<i>n</i> = 4) were injected with 5 nmol of <b>QCP01</b><i>via</i> the tail vein, followed by serial NIRF imaging on the LI-COR Pearl Impulse Imager. Representative images of <b>QCP01</b> full body (left) distribution at 5 h after injection and organ-specific (right) distribution at 5, 24, and 48 h after injection are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> SPECT-CT Imaging and Biodistribution of [<sup>111</sup>In]<b>QCP02</b> in a Murine Xenograft Model</h3><div class="NLM_p">SPECT-CT imaging showed high and specific uptake of [<sup>111</sup>In]<b>QCP02</b> in U87 xenografts (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) as early as 1 h post injection and was retained for up to 10 h. In contrast, low uptake of [<sup>111</sup>In]<b>QCP02</b> in the PC3 xenografts was observed at all imaging time points, further demonstrating the <i>in vivo</i> specificity of [<sup>111</sup>In]<b>QCP02</b> for FAP. <i>Ex</i><i>vivo</i> biodistribution of [<sup>111</sup>In]<b>QCP02</b> correlated with the observed SPECT-CT imaging results (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf" class="ext-link">Table S1</a>). [<sup>111</sup>In]<b>QCP02</b> uptake in the U87 xenograft was 3â4-fold higher than that in the PC3 xenograft (16.09 Â± 4.17 vs 4.12 Â± 0.36% ID/g at 1 h, <i>P</i> < 0.0012) at all time points. At as early as 5 min, the tumor uptake in U87 was over 10% ID/g, which peaked at 30 min post injection (18.16 Â± 11.67% ID/g) and remained between 16 and 8% ID/g for up to 6 h. In contrast, the PC3 tumor uptake was less than 5% ID/g at all time points, which was similar to the radioactivity in blood. Washout of the radiotracer in U87 tumors was observed by 28 h post injection. Additionally, co-injection of non-radioactive <b>QCP02</b> with [<sup>111</sup>In]<b>QCP02</b> significantly reduced radiotracer uptake in U87 xenografts (7.63 Â± 1.39 vs 0.55 Â± 0.23% ID/g; <i>P</i> < 0.0001), establishing the specific binding of the radiotracer to FAP. Altogether, the results establish the ability of <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b> to bind FAP <i>in vivo</i> and clear rapidly from non-target tissues.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Serial SPECT-CT imaging of [<sup>111</sup>In]<b>QCP02</b> in a tumor-bearing mouse. A NOD/SCID mouse bearing FAP-positive U87 (red) and FAP-negative PC3 (blue) tumor xenografts was injected with 7.4 MBq [<sup>111</sup>In]<b>QCP02</b><i>via</i> the tail vein, followed by serial SPECT-CT imaging. Representative three-dimensional SPECT-CT images  at various time points after injection (1, 3, 6, 10, and 28 h) are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">FAP provides a distinct marker of activated fibroblasts and is a key regulator and driver of the TME. Activated fibroblasts, also known as CAFs, are one of the largest components of the TME in many cancers. They promote tumorigenesis by secreting pro-inflammatory cytokines and growth factors, including the vascular endothelial growth factor, as well as by remodeling the ECM to enhance tumor cell invasion.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Additionally, FAP expression is not limited to fibroblasts but can also be seen on tumor epithelial cells,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> which can then support and accelerate tumorigenesis. This phenomenon has been demonstrated clinically, where FAP expression levels have been linked to poor outcomes.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18â20)</a> Mounting evidence for the role of FAP in cancer explains the rapid adoption of small-molecule agents that target FAP into clinical studies.</div><div class="NLM_p">The rapidity with which preclinical studies progressed to the clinic may suggest that limited medicinal chemistry was undertaken to optimize the agents that are being utilized in patients. Indeed, a number of new agents have been developed and studied preclinically, which may have superior characteristics to the most commonly used clinical compound.<a onclick="showRef(event, 'ref31 ref38'); return false;" href="javascript:void(0);" class="ref ref31 ref38">(31,38)</a> First, we provided a comprehensive summary of FAP-expressing cells and tissues from the CCLE and TCGA and chose six lines to test our compounds.</div><div class="NLM_p">Here, we report the syntheses, FAP binding affinities and specificities, and <i>in vivo</i> uptake of two new imaging agents targeting FAP in an experimental model. Novel aspects of this work include our co-development of an optical agent, <b>QCP01</b>, to examine the dynamics of FAP binding by this compound both <i>in vitro</i> and <i>in vivo</i>. Despite introduction of the bulky optical moiety to the (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold, <b>QCP01</b> retained FAP inhibitory capacity. The SPECT-CT imaging agent, [<sup>111</sup>In]<b>QCP02</b>, enabled us to investigate FAP expression and target selectivity in mice quantitatively. The use of a common FAP-binding intermediate having a reactive amine moiety permits the ready conjugation of any number of amine reactive optical dyes, metal chelating groups, or radiolabeled prosthetic groups for SPECT/PET imaging and theranostic applications.</div><div class="NLM_p">Using <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b>, we demonstrated the ability of our agents to target FAP on the surface of known FAP-positive cancer cells <i>in vitro</i> with minimal non-specific binding in FAP-negative cancer cells. Even within FAP-positive cell lines, we saw distinct differences in binding of FAP (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), further illustrating the heterogeneity of FAP expression within highly expressing cells and the sensitivity of our compounds for detecting these differences. To explore further the dynamics of FAP in cancer, we employed a tumor xenograft model with two cancer cell lines, FAP-positive U87 and FAP-negative PC3, in NOD/SCID mice. When we expanded these studies to <i>in vivo</i> imaging and biodistribution, we saw that the agents behaved similarly with favorable biodistribution and retained uptake in the FAP-positive xenograft at various imaging time points.</div><div class="NLM_p">Since FAP shares over 50 and 70% similarity in the sequence and catalytic region, respectively, with DPP-IV, most inhibitors of FAP also bind to DPP-IV.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Due to the ubiquitous expression of DPP-IV in normal human tissues,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> it was important to establish the specificity of imaging compounds of this class for FAP over DPP-IV. The specific binding of <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b> for FAP was verified in cellular studies of various cell lines with differing FAP expression. <i>In vitro</i> blocking studies also showed the specificity of <b>QCP01</b> for FAP over DPP-IV. In blocking studies, there was no change in binding of <b>QCP01</b> when only DPP-IV binding was inhibited. In contrast, binding of <b>QCP01</b> was blocked when DPP-IV and FAP were both inhibited. This was further supported in the biodistribution study for [<sup>111</sup>In]<b>QCP02</b>. This study showed that when a blocking dose was administered, no binding was observed in the FAP-positive xenograft, ruling out a substantial role for flow-mediated phenomena accounting for the observed activity within FAP-expressing tumors.</div><div class="NLM_p">Although both <b>QCP01</b> and [<sup>113/115</sup>In]<b>QCP02</b> have low-nanomolar inhibition, they differ by about 1 order of magnitude, with the former demonstrating greater inhibitory capacity. There were distinct differences between <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b><i>in vivo</i>. While both compounds demonstrated uptake in the FAP-positive U87 xenograft at early time points and clearance through the gastrointestinal tract, <b>QCP01</b> showed more non-specific uptake than [<sup>111</sup>In]<b>QCP02</b>. These differences in uptake could be attributed to factors besides binding affinity, such as molecular weight and lipophilicity.</div><div class="NLM_p">In comparison to other FAP-targeted imaging agents, [<sup>111</sup>In]<b>QCP02</b> demonstrated both higher tumor  and  normal organ uptake relative to <b>FAPI-02</b> and <b>FAPI-04</b>, which were evaluated in stably transfected FAP cell lines.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> [<sup>111</sup>In]<b>QCP02</b> also appears to have significantly higher uptake in the tumor and lower uptake in the kidney than another recently reported small-molecule agent, although again in different cell line xenografts.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The optimum imaging time for [<sup>111</sup>In]<b>QCP02</b> to make the best use of its high tumor uptake would appear to be â¼30 min post-injection in our mouse xenograft models, with relatively decreased tumor-to-normal-organ uptake after 3 h.</div><div class="NLM_p last">Because of an improved understanding of the TME in tumor progression and resistance to therapy,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> there has been a paradigm shift in cancer treatment to focus on targeting the tumor stroma and other aspects of the TME in addition to the cancer cells themselves.<a onclick="showRef(event, 'ref13 ref40'); return false;" href="javascript:void(0);" class="ref ref13 ref40">(13,40)</a> FAP can promote generation of regulatory T-cells and tumor-associated macrophages, contributing to the immunosuppressive tumor environment.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Active monitoring of targeted treatments with FAP imaging agents may promote optimal cancer management strategies.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We prepared two high-affinity FAP-targeted agents, <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b>, and demonstrated their specificity for FAP <i>in vitro</i> and <i>in vivo</i>. We initially tested them <i>in cellulo</i> based on the variable expression of FAP noted in a variety of cell lines and tissues according to the CCLE and TCGA. In mouse xenograft models with variable FAP expressions, both agents exhibited significant retention in FAP-positive tumors. The favorable pharmacokinetics and biodistribution observed with these agents provided FAP-specific images by 30 min after injection and also allow for imaging at later time points. The results provide impetus for pursuit of <b>QCP01</b>, [<sup>111</sup>In]<b>QCP02</b>, and analogues for clinical use.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22621" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22621" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> General Procedures</h3><div class="NLM_p">Reagents and solvents were purchased from commercial sources and were of analytical or HPLC grade, which were used as received. 6-Hydroxyquinoline-4-carboxylic acid was purchased from Sigma-Aldrich (St. Louis, MO). Methyl glycinate hydrochloride, 2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 1-hydroxylbenzotriazole monohydrate (HOBt), and diisopropylethylamine were purchased from Chem Impex International Inc. (Wood Dale, IL). 3-(Boc-amino) propyl bromide and (<i>S</i>)-pyrrolidine-2-carbonitrile hydrochloride were purchased from Combi-Blocks (San Diego, CA). 2-[1,4,7,10-Tetraazacyclododecane-4,7,10-tris(<i>t</i>-butyl acetate)]-pentanedioic acid-1-<i>tert</i>-butyl ester [DOTAGA-tetra(<i>tert</i>-Bu ester); DOTA-GA] was purchased from Macrocyclics (Dallas, TX). IRDye 800CW NHS ester was purchased from LI-COR Biosciences (Lincoln, NE). Reaction progress was monitored by analytical thin-layer chromatography and was performed on Analtech Uniplate 0.25 mm silica gel 60 F254 plates. Visualization was accomplished with ultraviolet (UV) light. Purification of reaction products was carried out by reverse-phase chromatography using a C18 cartridge (Silicycle, Canada) on a Biotage IsoleraOne flash purification system. HPLC purification was performed using a Phenomenex C18 Luna 10 Ã 250 mm<sup>2</sup> column on an Agilent Technologies 1260 Infinity semi-preparative HPLC System (Wilmington, DE). HPLC purification of the <sup>111</sup>In-labeled compound was performed on an Agilent PrepStar system (Santa Clara, CA), equipped with an Agilent ProStar 325 UVâvis variable wavelength detector and a Bioscan Flow-count in-line radioactivity detector (Washington, DC), with all controlled by OpenLAB software. Proton nuclear magnetic resonance spectra (<sup>1</sup>H NMR) were recorded on a Bruker UltraShield 400 MHz instrument and are reported in ppm using the solvent as an internal standard (CDCl<sub>3</sub> at 7.26 ppm and CD<sub>3</sub>OD at 3.31 ppm). Data are reported as app = apparent, br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and comp = complex, and coupling constant(s) are reported in Hz. Proton-decoupled carbon nuclear magnetic resonance spectra (<sup>13</sup>C NMR) were recorded on a Bruker UltraShield 400 MHz instrument and are reported in ppm using the solvent as an internal standard (CDCl<sub>3</sub> at 77.0 ppm and CD<sub>3</sub>OD at 49.00 ppm). Low-resolution electrospray ionization-mass spectrometry (ESI-MS) data were obtained using an Agilent Technologies 1260 series LCMS Single Quad System connected to a variable wavelength detector. High-resolution mass spectra were recorded at the University of Notre Dame Mass Spectrometry and Proteomics Facility (Notre Dame, IN) using ESI by direct infusion on a Bruker microTOF-II.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Methyl (6-Hydroxyquinoline-4-carbonyl)glycinate (<b>4</b>)</h4><div class="NLM_p last">6-Hydroxyquinoline-4-carboxylic acid (<b>3</b>) (210 mg, 1.1 mmol), methyl glycinate HCl salt (143 mg, 1.1 mmol), HBTU (420 mg, 1.1 mmol), and HOBt (170 mg, 1.1 mmol) were dissolved in 12 mL of dry dimethylformamide (DMF). To the solution, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) (0.77 mL, 4.4 mmol) was added. The reaction mixture was stirred at room temperature (RT) for 6 h. After the solvent was removed under vacuum, the mixture was loaded onto a 25 g C18 cartridge and the product was purified with a MeCN/water/trifluoroacetic acid (TFA) gradient (0/100/0.1 to 90/10/0.1). After lyophilization, product <b>4</b> was obtained as a yellow powder in a 76% yield (290 mg). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): Î´ 8.69 (s, 1H), 7.94 (d, <i>J</i> = 7.92 Hz, 1H), 7.57â7.51 (m, 3H), 7.42â7.37 (m, 1H), 4.21 (s, 2H), 3.81 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): Î´ 172.4, 160.9, 145.1, 143.7, 129.7, 129.4, 128.3, 121.8, 119.6, 112.4, 109.1, 56.8, 44.8. ESI-MS <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 261.3; found, 261.1.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Methyl (6-(3-((<i>tert</i>-Butoxycarbonyl)amino)propoxy)quinoline-4-carbonyl)glycinate (<b>5</b>)</h4><div class="NLM_p last">Methyl (6-hydroxyquinoline-4-carbonyl)glycinate (<b>3</b>) (360 mg, 1.0 mmol) and 3-(Boc-amino) propyl bromide (<b>4</b>) (500 mg, 2.1 mmol) were dissolved in 20 mL of DMF. Cs<sub>2</sub>CO<sub>3</sub> (1 g, 3.0 mmol) was added to the solution, and the reaction mixture was stirred at RT overnight. After filtration, the solvent was removed under vacuum and the remaining mixture was loaded onto a 25 g C18 cartridge. The product was purified with a MeCN/water/TFA gradient (0/100/0.1 to 90/10/0.1). After lyophilization, 270 mg of product <b>5</b> was obtained in a 54% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 8.68â8.37 (m, 2H), 8.02 (d, <i>J</i> = 9.1 Hz, 1H), 7.80 (s, 1H), 7.72â7.64 (m, 1H), 7.40 (d, <i>J</i> = 9.1 Hz, 1H), 4.94 (br s, 1H), 4.41â4.31 (m, 2H), 4.27â4.18 (m, 2H), 3.85 (s, 3H), 3.44â3.30 (m, 2H), 2.13â2.00 (m, 2H), 1.43 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 170.1, 167.2, 158.4, 144.7, 142.3, 128.4, 126.1, 124.7, 119.1, 103.7, 79.5, 60.4, 52.5, 41.4, 37.7, 29.3, 28.4. ESI-MS <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 418.5; found, 418.3.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> <i>tert</i>-Butyl(<i>S</i>)-(3-((4-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)carbamate (<b>7</b>)</h4><div class="NLM_p last">Compound <b>5</b> (110 mg, 0.21 mmol) and LiOH (30 mg, 1.2 mmol) were stirred in 4 mL of H<sub>2</sub>O/THF (1/1) for 6 h. After most of the THF was removed under vacuum, the mixture was loaded onto a 25 g C18 cartridge and eluted with a MeCN/water/TFA gradient (0/100/0.1 to 90/10/0.1) to remove the salts. After removal of the solvent and drying, product <b>6</b> was obtained and mixed with (<i>S</i>)-pyrrolidine-2-carbonitrile (53 mg, 0.4 mmol), HOBt (68 mg, 0.4 mmol), HBTU (152 mg, 0.4 mmol), and DIPEA (0.56 mL, 1.6 mmol) in dry DMF (10 mL). After 6 h, the solvent was removed under vacuum and the crude mixture was loaded onto a 25 g C18 cartridge (Silicycle, Canada). The product was purified with a MeCN/water/TFA gradient (0/100/0.1 to 90/10/0.1). After lyophilization, 99 mg of <b>7</b> was obtained in an 80% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 8.73 (s, 1H), 7.95 (d, <i>J</i> = 10.2 Hz, 1H), 7.68 (br s, 1H), 7.63â7.56 (m, 1H), 7.56â7.48 (m, 1H), 7.38â7.29 (m, 1H), 5.27 (br s, 1H), 4.84â4.72 (m, 1H), 4.46â4.35 (m, 1H), 4.33â4.20 (m, 1H), 4.17â4.09 (m, 2H), 3.78â3.64 (m, 1H), 3.59â3.46 (m, 1H), 3.36 (s, 2H), 2.38â2.17 (m, 4H), 1.42 (s, 9H), 1.35â1.27 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 167.6, 167.5, 157.9, 156.2, 146.3, 130.2, 125.7, 123.7, 119.3, 118.0, 103.3, 79.0, 65.9, 46.8, 45.7, 42.2, 37.6, 29.8, 29.3, 28.4, 25.1. ESI-MS <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>32</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 482.6; found, 482.3.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 1-(6-((3-((4-((2-((<i>S</i>)-2-Cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)amino)-6-oxohexyl)-2-((<i>E</i>)-2-((<i>E</i>)-3-(2-((<i>E</i>)-3,3-dimethyl-5-(trioxidaneylthio)-1-(4-(trioxidaneylthio)butyl)indolin-2-ylidene)ethylidene)-2-(4-(trioxidaneylthio)phenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-3<i>H</i>-indol-1-ium-5-sulfonate (<b>QCP01</b>)</h4><div class="NLM_p last">Compound <b>7</b> (1 mg, 1.7 Î¼mol) was treated with a 1 mL solution of TFA/methylene chloride (1/1) for 2 h. The solvent was removed under vacuum, and the remaining material was redissolved in 0.5 mL of DMF. To the solution, LI-COR IRdye 800CW-NHS ester (0.5 mg, 0.43 Î¼mol) and DIPEA (10 Î¼L) were added. After 2 h at ambient temperature, the solvent was removed and the product was purified by semi-preparative HPLC. 0.5 mg of the product was obtained in an 81% yield. HPLC conditions: Phenomenex, C18 Luna, 10Î¼, 10 mm Ã 250 mm column; gradient 90/10/0.1 to 80/20/0.1 water/acetonitrile/TFA over 15 min at a flow of 3 mL/min. The product was eluted at 10.1 min. ESI-MS <i>m</i>/<i>z</i>: calcd for C<sub>66</sub>H<sub>76</sub>N<sub>7</sub>O<sub>17</sub>S<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup>, 1366.4; found, 1366.8.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 2,2â²,2â³-(10-(1-Carboxy-4-((3-((4-((2-((<i>S</i>)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic Acid (<b>QCP02</b>)</h4><div class="NLM_p last">Compound <b>7</b> (15 mg, 31.3 Î¼mol) was treated with a 1 mL solution of TFA/methylene chloride (1/1) for 1 h. The solvent was removed under vacuum, and the remaining material was re-dissolved in 0.5 mL of DMF. To the solution, DIPEA (27 Î¼L, 156.5 Î¼mol) was added, followed by dropwise addition of a solution of DOTA-GA(<i>t</i>-Bu)<sub>4</sub>-NHS (25 mg, 31.3 Î¼L) in 0.5 mL of DMF. The reaction mixture was stirred for 4 h at ambient temperature and then concentrated under vacuum. The <i>tert</i>-Bu-protected intermediate was deprotected <i>in situ</i> without further purification using a 1 mL mixture of TFA, H<sub>2</sub>O, and triethylsilane (TES) (95:2.5:2.5). The reaction mixture was then concentrated and purified by semi-preparative HPLC to afford the product as a white solid (8.5 mg, 33% yield). HPLC conditions: Phenomenex, C18 Luna, 10Î¼, 10 mm Ã 250 mm column; mobile phase 95/5/0.1 to 75/25/0.1% water/acetonitrile/TFA over 20 min; flow 5 mL/min. <b>QCP02</b> was eluted at 11.8 min. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>39</sub>H<sub>54</sub>N<sub>9</sub>O<sub>12</sub> [M + H]<sup>+</sup>, 840.3892; found, 840.3885.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <sup>113/115</sup>Indium(III) 2,2â²,2â³-(10-(1-Carboxy-4-((3-((4-((2-((<i>S</i>)-2-cyanopyrrolidin-1-yl)-2-oxoethyl) carbamoyl)quinolin-6-yl)oxy)propyl) amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) Triacetate ([In]<b>QCP02</b>)</h4><div class="NLM_p last">To a solution of 2 mg (2.4 Î¼mol) of <b>QCP02</b> in 1 mL of aqueous 0.2 M sodium acetate, a solution of In(NO<sub>3</sub>)<sub>3</sub> (1.4 mg, 4.6 Î¼mol) in 0.5 mL of water was added and warmed in a 60 Â°C bath for 30 min. After cooling to ambient temperature, the mixture was purified by semi-preparative HPLC. The product was obtained as a white solid (1.8 mg, 79% yield). ESI-MS <i>m</i>/<i>z</i>: calcd for C<sub>39</sub>H<sub>51</sub>N<sub>9</sub>O<sub>12</sub>In [M + H]<sup>+</sup>, 952.7; found, 952.5. HPLC conditions: Phenomenex, C18 Luna, 10Î¼, 10 mm Ã 250 mm column; mobile phase 95/5/0.1 to 75/25/0.1 water/acetonitrile/TFA over 20 min; flow 5 mL/min. [In]<b>QCP02</b> was eluted at 14.0 min.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> [<sup>111</sup>In]2,2â²,2â³-(10-(1-Carboxy-4-((3-((4-((2-((<i>S</i>)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl) quinolin-6-yl)oxy)propyl) amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate ([<sup>111</sup>In]<b>QCP02</b>)</h4><div class="NLM_p last">Briefly, a 20 Î¼g <b>QCP02</b> solution in 20 Î¼L of 0.2 M NaOAc was added to 10 Î¼L of 170.2 MBq <sup>111</sup>InCl<sub>3</sub> solution in 0.05 N HCl and adjusted to a final pH of 5.5â6. The mixture was heated in a water bath at 70 Â°C for 30 min and then diluted with 200 Î¼L of water for HPLC purification. The solution was purified using a Phenomenex, C18 Luna, 5Î¼, 4.6 mm Ã 250 mm column (Torrance, CA) with a flow rate of 0.6 mL/min with water (0.1% TFA) (A) and MeCN (0.1% TFA) (B) as the eluting solvents. An isocratic solution of 88% A and 12% B was utilized for purification, resulting in [<sup>111</sup>In]<b>QCP02</b>, eluting at 19.3 min, followed by <b>QCP02</b> at 21.3 min. 118.4 MBq of the labeled compound was obtained in yields between 69 and 74%. The radiochemical purity was >95% as measured by HPLC. The obtained radioactivity was diluted with 20 mL of water and loaded onto activated Sep-Pak (WAT020515, Waters, Milford, MA). After the Sep-Pak was washed with 10 mL of water, [<sup>111</sup>In]<b>QCP02</b> was eluted with 1.5 mL of ethanol. The ethanol was evaporated under a gentle stream of nitrogen (to a total volume of <50 Î¼L) and diluted with saline to reduce the ethanol percentage to <10% for imaging and biodistribution studies.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> FAP Inhibition Assay</h3><div class="NLM_p last">The inhibitory activities of <b>QCP01</b> and [<sup>113/115</sup>In]<b>QCP02</b> were determined using a fluorogenic FAP Assay Kit (BPS Bioscience, San Diego, CA). Briefly, the test compound (<b>QCP01</b>: 50â0.39 nM, [<sup>113/115</sup>In]<b>QCP02</b>: 500â0.23 nM), the reactive substrate, and human recombinant FAP were loaded into a 96-well plate to initiate the enzymatic reaction. The reaction was left for 10 min at RT before the fluorescence was measured for 0.1 s per well with a VICTOR3 V multilabel plate reader (PerkinElmer Inc., Waltham, MA) at an excitation wavelength of 355 nm and an emission wavelength of 460 nm. Data were normalized, and semi-log inhibition curves were generated in order to determine the half-maximal inhibitory concentrations (IC<sub>50</sub> values) and subsequent enzyme inhibition constants (<i>K</i><sub>i</sub>) using the ChengâPrusoff conversion.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Generation of semi-log inhibition curves and IC<sub>50</sub> values was performed using GraphPad (Prism, San Diego, CA).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Analysis of the CCLE Database and TCGA Data</h3><div class="NLM_p last">Messenger RNA (mRNA) expression data of FAP in human cell lines, generated by RNAseq analysis, were downloaded (9/17/19) from the CCLE database<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and sorted by cell line âtypeâ. All samples with no type or FAP measurement were excluded. <i>Z</i>-Scores were calculated using all cell lines as a reference, and samples were grouped by cancer cell type for visualization. To evaluate FAP expression in normal tissues and human tumors, pan-cancer normalized FAP RNAseq (Illumina HiSeq) gene expressions in normal tissues and primary tumors (downloaded 9/20/19) were downloaded (10/22/19) for 18 TCGA cohorts and 32 TCGA cohorts, respectively, using the UCSC Xena platform.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Cell Lines</h3><div class="NLM_p">U87, SKMEL24, and NCIH2228 cell lines were identified from the CCLE as having high levels of FAP expression [FAP-positive (+)], whereas PC3, NCIH226, and HCT116 cells expressed very low levels of FAP [FAP-negative (â)]. FAP expression was further confirmed by flow cytometry with 10 Î¼L of an allophycocyanin-conjugated anti-FAP antibody (Clone #427819, R&D Systems, Minneapolis, MN) and quantitative real-time polymerase chain reaction. All cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA).</div><div class="NLM_p">Binding of imaging agents to FAP was assessed in six human cancer cell lines of different cancer types: glioblastoma (U87), melanoma (SKMEL24), prostate (PC3), NSCLC (NCIH2228), colorectal carcinoma (HCT116), and lung squamous cell carcinoma (NCIH226).</div><div class="NLM_p last">U87 cells were maintained in the <i>m</i><i>inimum</i><i>e</i><i>ssential</i><i>m</i><i>edium</i> (MEM) (Corning Cellgro, Manassas, VA), containing 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO) and 1% penicillinâstreptomycin (Corning Cellgro), supplemented with sodium bicarbonate (Corning Cellgro), sodium pyruvate (Gibco, Gaithersburg, MD), and MEM non-essential amino acids (Gibco). SKMEL24 cells were maintained in MEM, containing 15% FBS and 1% penicillinâstreptomycin, supplemented with sodium bicarbonate, sodium pyruvate, and MEM non-essential amino acids. PC3 cells were grown in Hamâs F-12K medium (Corning Cellgro), supplemented with 10% FBS and 1% penicillinâstreptomycin. NCIH2228, NCIH226, and HCT116 cells were cultured in the RPMI 1640 medium (Corning Cellgro), supplemented with 10% FBS and 1% penicillinâstreptomycin. Cell cultures were maintained at 37 Â°C and 5% carbon dioxide (CO<sub>2</sub>) in a humidified incubator.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Cellular Uptake Studies</h3><div class="NLM_p">For <i>in vitro</i> studies, cells were detached using 0.05% trypsin (Corning), re-suspended in 1 million cell aliquots in the binding buffer (1Ã PBS with 2 mM EDTA and 0.5% FBS), and incubated with various concentrations (range: 50â0.78 nM) of <b>QCP01</b> for 1 h in the incubator. To assess specific uptake of <b>QCP01</b>, cells were preblocked with an FAP- and DPP-IV-specific inhibitor, Val-boroPro (Millipore Sigma, Burlington, MA), or a DPP-IV-specific inhibitor, sitagliptin (Santa Cruz Biotechnology, Inc., Dallas, TX), at various concentrations (range: 10<sup>â10</sup> to 10<sup>â4</sup> M). This was followed by incubation with 25 nM <b>QCP01</b> in the binding buffer for 1 h at 37 Â°C, and cellular uptake was terminated by washing cells with ice cold PBS (1Ã) three times. Cells were re-suspended in the binding buffer and transferred to a 96-well plate for imaging. Images were obtained on the LI-COR Pearl Impulse Imager (Lincoln, NE) using an excitation wavelength of 785 nm and detection of the emission wavelength at 800 nm. Images were analyzed using LI-COR Pearl Impulse Software (Version 2.0), and the fluorescence intensity was corrected for the background signal and normalized to the well area.</div><div class="NLM_p last">Cellular uptake of [<sup>111</sup>In]<b>QCP02</b> was assessed by incubating cell aliquots (1 million) with 0.037 MBq [<sup>111</sup>In]<b>QCP02</b> in saline for 30 min at 37 Â°C. Cells were washed three times with cold PBS (1Ã), and the radioactivity of the cell pellets was measured with a 1282 CompuGamma CS gamma well counter (Pharmacia/LKB Nuclear, Inc., Gaithersberg, MD). The cellular uptake is presented as a percent of incubated activity measured using sample aliquots. All cellular uptake and binding studies were performed in triplicate and repeated three times.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Mouse Xenograft Models</h3><div class="NLM_p last">Animal studies were performed according to protocols approved by the Johns Hopkins University Animal Use and Care Committee. Male NOD/SCID mice, 6â8 weeks old, were purchased from the Johns Hopkins Immune Compromised Animal Core (Baltimore, MD). NOD/SCID mice were subcutaneously inoculated in the upper left and right flanks with 1 million FAP-positive U87 and FAP-negative PC3 cells in Hankâs balanced salt solution (HBSS), respectively. Mice were monitored for tumor size and used for imaging or biodistribution when the size of the tumors reached 100â300 mm<sup>3</sup>.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Small-Animal NIRF Imaging</h3><div class="NLM_p last">NIRF images were obtained on the LI-COR Pearl Impulse Imager using an excitation wavelength of 785 nm and a detection wavelength of 800 nm. Mice utilized for imaging studies were anesthetized with 3% isoflurane (v/v) and maintained at 1.5% isoflurane for the imaging procedure. NOD/SCID mice bearing U87 and PC3 tumor xenografts were injected with 5 nmol of <b>QCP01</b><i>via</i> the tail vein, and images were obtained at 0.5, 1.5, 2.5, 5, 24, and 48 h post injection. Mice were sacrificed at various time points, and whole body images were obtained. Following this, organs of interest were harvested and imaged <i>ex vivo</i> on a Petri dish. Data were displayed and analyzed using LI-COR Pearl Impulse Software (Version 2.0).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Small-Animal SPECT-CT Imaging</h3><div class="NLM_p last">For imaging studies, mice were induced with 3% isoflurane anesthesia and maintained at 1.5%. After mice were injected with 7.4 MBq [<sup>111</sup>In]<b>QCP02</b> in 200 Î¼L of saline, SPECT-CT imaging was carried out using a CT-equipped Gamma Medica-Ideas SPECT scanner (Northridge, CA) at the designated time points (1, 3, 6, 10, and 28 h) after [<sup>111</sup>In]<b>QCP02</b> injection. A CT scan was performed at the end of each SPECT scan for anatomic co-registration. Obtained data sets were reconstructed using the provided Gamma Medica-Ideas software for final data visualization. Volume-rendered images were prepared using Amira 5.3.3 software (Visage Imaging, Inc., San Diego, CA).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Biodistribution</h3><div class="NLM_p last">NOD/SCID mice bearing U87 and PC3 tumor xenografts were injected <i>via</i> the tail vein with 0.37 MBq [<sup>111</sup>In]<b>QCP02</b> in 200 Î¼L of saline. At 5 min, 30 min, 1 h, 3 h, 6 h, 10 h, and 28 h post injection, mice (<i>n</i> = 4) were sacrificed by CO<sub>2</sub> asphyxiation and blood was immediately collected by cardiac puncture. Additionally, the heart, lungs, liver, stomach, pancreas, spleen, fat, kidney, small intestine, large intestine, bladder, muscle, femur, and U87 and PC3 xenografts were collected for analysis. Each tissue was weighed, and the radioactivity was measured using an automated gamma counter. Radioactivity measurements were corrected for decay and compared with samples of a standard dilution of the initial dose to calculate the percentage injected dose per gram of tissue (% ID/g). For blocking studies, mice (<i>n</i> = 4) were co-injected with non-radiolabeled <b>QCP02</b> (50 Î¼g per mouse) and 0.37 MBq [<sup>111</sup>In]<b>QCP02</b> in 200 Î¼L of saline <i>via</i> the tail vein. At 6 h post injection, mice were sacrificed, tissues were collected, and the radioactivity was measured with the gamma counter.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Data Analysis</h3><div class="NLM_p last">Data are expressed as mean Â± standard deviation. Prism software (GraphPAD, San Diego, CA) was used for analysis, and the statistical significance was calculated using a two-tailed Studentâs <i>t</i>-test. A <i>P</i>-value <0.05 was considered significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02171" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30015" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30015" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02171?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02171</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chromatography of [<sup>113/115</sup>In]<b>QCP02</b> and [<sup>111</sup>In]<b>QCP02</b> and [<sup>113/115</sup>In]<b>QCP02</b>, inhibitory potency, FAP surface expression of cell lines used, and serial NIRF imaging of <b>QPC01</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf">jm0c02171_si_001.pdf (555.18 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02171" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36161" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36161" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sridhar Nimmagadda</span> - <span class="hlFld-Affiliation affiliation">The
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Sidney
Kimmel Comprehensive Cancer Center, Johns
Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6413-7191" title="Orcid link">http://orcid.org/0000-0002-6413-7191</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#04776a6d6969656335446e6c696d2a616071"><span class="__cf_email__" data-cfemail="ea99848387878b8ddbaa80828783c48f8e9f">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xing Yang</span> - <span class="hlFld-Affiliation affiliation">The
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span>;Â 
    <span>Present Address:
                        Department of Nuclear Medicine, Peking University First Hospital, Beijing, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5186-4990" title="Orcid link">http://orcid.org/0000-0001-5186-4990</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fa839b949d8293949dc8cacbcdba9890978fd49f9e8fd49994"><span class="__cf_email__" data-cfemail="aed7cfc0c9d6c7c0c99c9e9f99eeccc4c3db80cbcadb80cdc0">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin G. Pomper</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical Engineering, Johns Hopkins
University School of Medicine, Baltimore, Maryland 21287, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">The
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Sidney
Kimmel Comprehensive Cancer Center, Johns
Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6753-3010" title="Orcid link">http://orcid.org/0000-0001-6753-3010</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e588958a88958097a58f8d888ccb808190"><span class="__cf_email__" data-cfemail="5f322f30322f3a2d1f35373236713a3b2a">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephanie L. Slania</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical Engineering, Johns Hopkins
University School of Medicine, Baltimore, Maryland 21287, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepankar Das</span> - <span class="hlFld-Affiliation affiliation">The
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ala Lisok</span> - <span class="hlFld-Affiliation affiliation">The
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Du</span> - <span class="hlFld-Affiliation affiliation">The
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zirui Jiang</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical Engineering, Johns Hopkins
University School of Medicine, Baltimore, Maryland 21287, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ronnie C. Mease</span> - <span class="hlFld-Affiliation affiliation">The
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven P. Rowe</span> - <span class="hlFld-Affiliation affiliation">The
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Sidney
Kimmel Comprehensive Cancer Center, Johns
Hopkins University School of Medicine, Baltimore, Maryland 21287, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>Funding Sources: EB024495, National Natural Science Foundation of China (92059101, 21877004)</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): S.L.S., X.Y., S.P.R., S.N. and M.G.P. are co-inventors on a patent application covering FAP inhibitors and as such may be entitled to a portion of any licensing fees and royalties generated by this technology (WO 2019/083990 A2). That arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. S.P.R., S.N. and M.G.P. own equity in, serve as consult-ants to, and receive research funding from Precision Molecular, Inc., the licensee of the patent that covers QCP01/QCP02. X.Y. serves as a consultant to Precision Molecular, Inc.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Il Minn and Vanessa Merino for guidance on <i>in vitro</i> studies and the MRB Molecular Imaging Service Center for assistance in conducting the imaging studies.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">CAFs</td><td class="NLM_def"><p class="first last">cancer-associated fibroblasts</p></td></tr><tr><td class="NLM_term">CCLE</td><td class="NLM_def"><p class="first last">Cancer Cell Line Encyclopedia</p></td></tr><tr><td class="NLM_term">CI</td><td class="NLM_def"><p class="first last">confidence interval</p></td></tr><tr><td class="NLM_term">d</td><td class="NLM_def"><p class="first last">days</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DOTAGA</td><td class="NLM_def"><p class="first last">2-[1,4,7,10-tetraazacyclododecane-4,7,10-tris(<i>tert</i>-butyl acetate)]-pentanedioic acid-1-<i>tert</i>-butyl ester</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DPP</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">FAP</td><td class="NLM_def"><p class="first last">fibroblast activation protein</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hours</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hankâs balanced salt solution</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last">2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HOBT</td><td class="NLM_def"><p class="first last">1-hydroxylbenzotriazole monohydrate</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term"><sup><i>i</i></sup>Pr</td><td class="NLM_def"><p class="first last">isopropyl</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibitory constant</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MBq</td><td class="NLM_def"><p class="first last">megabequerels</p></td></tr><tr><td class="NLM_term">Î¼L</td><td class="NLM_def"><p class="first last">microliter</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minutes</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">molar</p></td></tr><tr><td class="NLM_term">NHS</td><td class="NLM_def"><p class="first last"><i>N</i>-hydroxysuccinimide</p></td></tr><tr><td class="NLM_term">NIRF</td><td class="NLM_def"><p class="first last">near-infrared fluorescence</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">% ID/g</td><td class="NLM_def"><p class="first last">percentage of injected dose per gram</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term"><b>QCP01</b></td><td class="NLM_def"><p class="first last">1-(6-((3-((4-((2-((<i>S</i>)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)amino)-6-oxohexyl)-2-((<i>E</i>)-2-((<i>E</i>)-3-(2-((<i>E</i>)-3,3-dimethyl-5-(trioxidaneylthio)-1-(4-(trioxidaneylthio)butyl)indolin-2-ylidene)ethylidene)-2-(4-(trioxidaneylthio)phenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-3<i>H</i>-indol-1-ium-5-sulfonate</p></td></tr><tr><td class="NLM_term"><b>QCP02</b></td><td class="NLM_def"><p class="first last">2,2â²,2â³-(10-(1-carboxy-4-((3-((4-((2-((<i>S</i>)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">s</td><td class="NLM_def"><p class="first last">seconds</p></td></tr><tr><td class="NLM_term">SPECT</td><td class="NLM_def"><p class="first last">single-photon emission computed tomography</p></td></tr><tr><td class="NLM_term"><sup><i>t</i></sup>Bu</td><td class="NLM_def"><p class="first last">tertiary butyl</p></td></tr><tr><td class="NLM_term">TCGA</td><td class="NLM_def"><p class="first last">The Cancer Genome Atlas</p></td></tr><tr><td class="NLM_term">TES</td><td class="NLM_def"><p class="first last">triethylsilane</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TOF</td><td class="NLM_def"><p class="first last">time of flight</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36844" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36844" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pure, E.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein in remodeling tissues</span>. <i>Curr. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1220</span>â <span class="NLM_lpage">1243</span>, <span class="refDoi">Â DOI: 10.2174/156652412803833607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2174%2F156652412803833607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22834826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVSltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1220-1243&author=M.+Jacobauthor=L.+Changauthor=E.+Pure&title=Fibroblast+activation+protein+in+remodeling+tissues&doi=10.2174%2F156652412803833607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein in remodeling tissues</span></div><div class="casAuthors">Jacob, M.; Chang, L.; Pure, E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1220-1243</span>CODEN:
                <span class="NLM_cas:coden">CMMUBP</span>;
        ISSN:<span class="NLM_cas:issn">1566-5240</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tissue remodeling is crit. during development and wound healing.  It also characterizes a no. of pathol. conditions, including chronic inflammation, fibrosis and cancer.  It is well appreciated that reactive stromal cells play crit. roles in these settings.  However, understanding of the mechanisms involved in the differentiation of reactive stromal cells and their biol. activities has been hampered by the fact that they are generated from diverse progenitors, and by their phenotypic and function heterogeneity.  Furthermore, mol. markers that are expressed by all reactive stromal cells and that distinguish them from all other cell types have been lacking.  Fibroblast activation protein (FAP) is a serine protease that was originally discovered as a cell surface protein expressed on astrocytomas and sarcomas.  Over the last two decades, FAP has attracted increasing attention as a selective marker of carcinoma-assocd. fibroblasts (CAFs) and more broadly, of activated fibroblasts in tissues undergoing remodeling of their extracellular matrix (ECM) due to chronic inflammation, fibrosis or wound healing.  Herein we review the evidence that FAP is indeed a robust and selective marker for reactive mesenchymal stromal cells assocd. with pathophysiol. tissue remodeling.  We also review recent insights obtained using FAP as a tool to define the relationship between subpopulations of reactive stromal cells in various settings of tissue remodeling.  Furthermore, we review recent genetic and pharmacol. data indicating that FAP and FAP-expressing cells play important roles in such conditions.  Finally, we discuss the potential risks and therapeutic benefits of targeting FAP and FAP-expressing cells, as well as approaches to do so.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW5D-MzwCIN7Vg90H21EOLACvtfcHk0lh5JPdFe4Z97A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVSltg%253D%253D&md5=edb22a8c889e95e97b9e023530274a43</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F156652412803833607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156652412803833607%26sid%3Dliteratum%253Aachs%26aulast%3DJacob%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DPure%26aufirst%3DE.%26atitle%3DFibroblast%2520activation%2520protein%2520in%2520remodeling%2520tissues%26jtitle%3DCurr.%2520Mol.%2520Med.%26date%3D2012%26volume%3D12%26spage%3D1220%26epage%3D1243%26doi%3D10.2174%2F156652412803833607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PurÃ©, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomberg, R.</span></span> <span> </span><span class="NLM_article-title">Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4343</span>â <span class="NLM_lpage">4357</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0275-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fs41388-018-0275-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29720723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVCqtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=4343-4357&author=E.+Pur%C3%A9author=R.+Blomberg&title=Pro-tumorigenic+roles+of+fibroblast+activation+protein+in+cancer%3A+back+to+the+basics&doi=10.1038%2Fs41388-018-0275-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics</span></div><div class="casAuthors">Pure, Ellen; Blomberg, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4343-4357</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components.  FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma.  It has also been proposed as a mol. target of cancer therapies, and, esp. in recent years, a great deal of research has gone into design and testing of diverse FAP-targeted treatments.  Yet despite this growing field of research, our knowledge of FAP's basic biol. and functional roles in various cancers has lagged behind its use as a tumor-stromal marker.  In this review, we summarize and analyze recent advances in understanding the functions of FAP in cancer, most notably its prognostic value in various tumor types, cellular effects on various cell types, and potential as a therapeutic target.  We highlight outstanding questions in the field, the answers to which could shape preclin. and clin. studies of FAP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-SoG71uv287Vg90H21EOLACvtfcHk0ljvV1vNTvvimg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVCqtLg%253D&md5=840fdb5e306b61906acb0c24755f5a2d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0275-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0275-3%26sid%3Dliteratum%253Aachs%26aulast%3DPur%25C3%25A9%26aufirst%3DE.%26aulast%3DBlomberg%26aufirst%3DR.%26atitle%3DPro-tumorigenic%2520roles%2520of%2520fibroblast%2520activation%2520protein%2520in%2520cancer%253A%2520back%2520to%2520the%2520basics%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D4343%26epage%3D4357%26doi%3D10.1038%2Fs41388-018-0275-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiraja, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, K.</span></span> <span> </span><span class="NLM_article-title">Near-Infrared Fluorescent Molecular Probe for Sensitive Imaging of Keloid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1256</span>â <span class="NLM_lpage">1260</span>, <span class="refDoi">Â DOI: 10.1002/anie.201710727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1002%2Fanie.201710727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1ersw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1256-1260&author=Q.+Miaoauthor=D.+C.+Yeoauthor=C.+Wirajaauthor=J.+Zhangauthor=X.+Ningauthor=C.+Xuauthor=K.+Pu&title=Near-Infrared+Fluorescent+Molecular+Probe+for+Sensitive+Imaging+of+Keloid&doi=10.1002%2Fanie.201710727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Near-Infrared Fluorescent Molecular Probe for Sensitive Imaging of Keloid</span></div><div class="casAuthors">Miao, Qingqing; Yeo, David C.; Wiraja, Christian; Zhang, Jianjian; Ning, Xiaoyu; Xu, Chenjie; Pu, Kanyi</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1256-1260</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Early detection of skin diseases is imperative for their effective treatment.  However, fluorescence mol. probes that allow this are rare.  The first activatable near-IR (NIR) fluorescent mol. probe is reported for sensitive imaging of keloid cells, skin cells from abnormal scar fibrous lesions.  As keloid cells have high expression levels of fibroblast activation protein-alpha (FAPÎ±), the probe (FNP1) is designed to have a caged NIR dye and a FAPÎ±-cleavable peptide substrate linked by a self-immolative segment.  FNP1 can quickly and specifically turn on its fluorescence at 710 nm by 45-fold in the presence of FAPÎ±, allowing it to effectively recognize keloid cells from normal skin cells.  Integration of FNP1 with a simple microneedle-assisted topical application enables sensitive detection of keloid cells in metabolically-active human skin tissue with a theor. limit of detection down to 20 000 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAYD4nFFZGgLVg90H21EOLACvtfcHk0ljvV1vNTvvimg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1ersw%253D%253D&md5=55b46295ecd424d14123d5ab5939a0e0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710727%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DQ.%26aulast%3DYeo%26aufirst%3DD.%2BC.%26aulast%3DWiraja%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DPu%26aufirst%3DK.%26atitle%3DNear-Infrared%2520Fluorescent%2520Molecular%2520Probe%2520for%2520Sensitive%2520Imaging%2520of%2520Keloid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D1256%26epage%3D1260%26doi%3D10.1002%2Fanie.201710727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Geest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeleveld, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgreen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helsen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metselaar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berg, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Kraan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laverman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerman, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenders, M. I.</span></span> <span> </span><span class="NLM_article-title">Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">737</span>â <span class="NLM_lpage">747</span>, <span class="refDoi">Â DOI: 10.1093/rheumatology/kex456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1093%2Frheumatology%2Fkex456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29361119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpslyis7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=737-747&author=T.+van%0Ader+Geestauthor=D.+M.+Roeleveldauthor=B.+Walgreenauthor=M.+M.+Helsenauthor=T.+K.+Nayakauthor=C.+Kleinauthor=M.+Hegenauthor=G.+Stormauthor=J.+M.+Metselaarauthor=W.+B.+van+den+Bergauthor=P.+M.+van+der+Kraanauthor=P.+Lavermanauthor=O.+C.+Boermanauthor=M.+I.+Koenders&title=Imaging+fibroblast+activation+protein+to+monitor+therapeutic+effects+of+neutralizing+interleukin-22+in+collagen-induced+arthritis&doi=10.1093%2Frheumatology%2Fkex456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis</span></div><div class="casAuthors">van der Geest, Tessa; Roeleveld, Debbie M.; Walgreen, Birgitte; Helsen, Monique M.; Nayak, Tapan K.; Klein, Christian; Hegen, Martin; Storm, Gert; Metselaar, Josbert M.; van den Berg, Wim B.; van den Kraan, Peter M.; Laverman, Peter; Boerman, Otto C.; Koenders, Marije I.</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">737-747</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0332</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: RA is a chronic autoimmune disease leading to progressive destruction of cartilage and bone.  RA patients show elevated IL-22 levels and the amt. of IL-22-producing Th cells pos. correlates with the extent of erosive disease, suggesting a role for this cytokine in RA pathogenesis.  The purpose of this study was to det. the feasibility of SPECT/CT imaging with 111In-labeled anti-fibroblast activation protein antibody (28H1) to monitor the therapeutic effect of neutralizing IL-22 in exptl. arthritis.  Methods: Mice (six mice/group) with CIA received anti-IL-22 or isotype control antibodies.  To monitor therapeutic effects after treatment, SPECT/CT images were acquired 24 h after injection of 111In-28H1.  Imaging results were compared with macroscopic, histol. and radiog. arthritis scores.  Results: Neutralizing IL-22 before CIA onset effectively prevented arthritis development, reaching a disease incidence of only 50%, vs 100% in the control group.  SPECT imaging showed significantly lower joint tracer uptake in mice treated early with anti-IL-22 antibodies compared with the control-treated group.  Redn. of disease activity in those mice was confirmed by macroscopic, histol. and radiog. pathol. scores.  However, when treatment was initiated in a later phase of CIA, progression of joint pathol. could not be prevented.  Conclusions: These findings suggest that IL-22 plays an important role in CIA development, and neutralizing this cytokine seems an attractive new strategy in RA treatment.  Most importantly, SPECT/CT imaging with 111In-28H1 can be used to specifically monitor therapy responses, and is potentially more sensitive in disease monitoring than the gold std. method of macroscopic arthritis scoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYJDeedA0jlbVg90H21EOLACvtfcHk0ljvV1vNTvvimg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpslyis7g%253D&md5=969ce3d26f81ba3b58225f0386d484a2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkex456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkex456%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BGeest%26aufirst%3DT.%26aulast%3DRoeleveld%26aufirst%3DD.%2BM.%26aulast%3DWalgreen%26aufirst%3DB.%26aulast%3DHelsen%26aufirst%3DM.%2BM.%26aulast%3DNayak%26aufirst%3DT.%2BK.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DStorm%26aufirst%3DG.%26aulast%3DMetselaar%26aufirst%3DJ.%2BM.%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DW.%2BB.%26aulast%3Dvan%2Bder%2BKraan%26aufirst%3DP.%2BM.%26aulast%3DLaverman%26aufirst%3DP.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26aulast%3DKoenders%26aufirst%3DM.%2BI.%26atitle%3DImaging%2520fibroblast%2520activation%2520protein%2520to%2520monitor%2520therapeutic%2520effects%2520of%2520neutralizing%2520interleukin-22%2520in%2520collagen-induced%2520arthritis%26jtitle%3DRheumatology%26date%3D2018%26volume%3D57%26spage%3D737%26epage%3D747%26doi%3D10.1093%2Frheumatology%2Fkex456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadvi, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaughan, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrell, M. D.</span></span> <span> </span><span class="NLM_article-title">The dipeptidyl peptidase IV family in cancer and cell biology</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">1126</span>â <span class="NLM_lpage">1144</span>, <span class="refDoi">Â DOI: 10.1111/j.1742-4658.2009.07526.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1111%2Fj.1742-4658.2009.07526.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=20074209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVSmtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2010&pages=1126-1144&author=D.+M.+T.+Yuauthor=T.-W.+Yaoauthor=S.+Chowdhuryauthor=N.+A.+Nadviauthor=B.+Osborneauthor=W.+B.+Churchauthor=G.+W.+McCaughanauthor=M.+D.+Gorrell&title=The+dipeptidyl+peptidase+IV+family+in+cancer+and+cell+biology&doi=10.1111%2Fj.1742-4658.2009.07526.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The dipeptidyl peptidase IV family in cancer and cell biology</span></div><div class="casAuthors">Yu, Denise M. T.; Yao, Tsun-Wen; Chowdhury, Sumaiya; Nadvi, Naveed A.; Osborne, Brenna; Church, W. Bret; McCaughan, Geoffrey W.; Gorrell, Mark D.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1126-1144</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Of the 600+ known proteases identified to date in mammals, a significant percentage is involved or implicated in pathogenic and cancer processes.  The dipeptidyl peptidase IV (DPIV) gene family, comprising 4 enzyme members [DPIV (EC 3.4.14.5), fibroblast activation protein, DP8 and DP9] and 2 non-enzyme members [DP6 (DPL1) and DP10 (DPL2)], are interesting in this regard because of their multiple diverse functions, varying patterns of distribution/localization and subtle, but significant, differences in structure/substrate recognition.  In addn., their engagement in cell biol. processes involves both enzymic and nonenzymic capabilities.  Here, the authors examine, in detail, the current understanding of the biol. involvement of this unique enzyme family and their overall potential as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEodr7pwXK6LVg90H21EOLACvtfcHk0ljkcriu9i0aXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVSmtr8%253D&md5=4c1423e97c4688e223982737ebe76d2d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2009.07526.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2009.07526.x%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DD.%2BM.%2BT.%26aulast%3DYao%26aufirst%3DT.-W.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DNadvi%26aufirst%3DN.%2BA.%26aulast%3DOsborne%26aufirst%3DB.%26aulast%3DChurch%26aufirst%3DW.%2BB.%26aulast%3DMcCaughan%26aufirst%3DG.%2BW.%26aulast%3DGorrell%26aufirst%3DM.%2BD.%26atitle%3DThe%2520dipeptidyl%2520peptidase%2520IV%2520family%2520in%2520cancer%2520and%2520cell%2520biology%26jtitle%3DFEBS%2520J.%26date%3D2010%26volume%3D277%26spage%3D1126%26epage%3D1144%26doi%3D10.1111%2Fj.1742-4658.2009.07526.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brennen, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denmeade, S. R.</span></span> <span> </span><span class="NLM_article-title">Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">257</span>â <span class="NLM_lpage">266</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-11-0340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1158%2F1535-7163.MCT-11-0340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22323494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWlt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=257-266&author=W.+N.+Brennenauthor=J.+T.+Isaacsauthor=S.+R.+Denmeade&title=Rationale+behind+targeting+fibroblast+activation+protein-expressing+carcinoma-associated+fibroblasts+as+a+novel+chemotherapeutic+strategy&doi=10.1158%2F1535-7163.mct-11-0340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale Behind Targeting Fibroblast Activation Protein-Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy</span></div><div class="casAuthors">Brennen, W. Nathaniel; Isaacs, John T.; Denmeade, Samuel R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-266</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The tumor microenvironment has emerged as a novel chemotherapeutic strategy in the treatment of cancer.  This is most clearly exemplified by the antiangiogenesis class of compds.  Therapeutic strategies that target fibroblasts within the tumor stroma offer another treatment option.  However, despite promising data obtained in preclin. models, such strategies have not been widely used in the clin. setting, largely due to a lack of effective treatments that specifically target this population of cells.  The identification of fibroblast activation protein Î± (FAP) as a target selectively expressed on fibroblasts within the tumor stroma or on carcinoma-assocd. fibroblasts led to intensive efforts to exploit this novel cellular target for clin. benefit.  FAP is a membrane-bound serine protease of the prolyl oligopeptidase family with unique post-prolyl endopeptidase activity.  Until recently, the majority of FAP-based therapeutic approaches focused on the development of small-mol. inhibitors of enzymic activity.  Evidence suggests, however, that FAP's pathophysiol. role in carcinogenesis may be highly contextual, depending on both the exact nature of the tumor microenvironment present and the cancer type in question to det. its tumor-promoting or tumor-suppressing phenotype.  As an alternative strategy, we are taking advantage of FAP's restricted expression and unique substrate preferences to develop a FAP-activated prodrug to target the activation of a cytotoxic compd. within the tumor stroma.  Of note, this strategy would be effective independently of FAP's role in tumor progression because its therapeutic benefit would rely on FAP's localization and activity within the tumor microenvironment rather than strictly on inhibition of its function.  Mol Cancer Ther; 11(2); 257-66.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIsKiWvE8RALVg90H21EOLACvtfcHk0ljkcriu9i0aXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWlt7o%253D&md5=3eaf9c277128da6a1b0d042033da92ab</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0340%26sid%3Dliteratum%253Aachs%26aulast%3DBrennen%26aufirst%3DW.%2BN.%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26aulast%3DDenmeade%26aufirst%3DS.%2BR.%26atitle%3DRationale%2520behind%2520targeting%2520fibroblast%2520activation%2520protein-expressing%2520carcinoma-associated%2520fibroblasts%2520as%2520a%2520novel%2520chemotherapeutic%2520strategy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D257%26epage%3D266%26doi%3D10.1158%2F1535-7163.mct-11-0340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waumans, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baerts, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehoe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span> <span> </span><span class="NLM_article-title">The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">387</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2015.00387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.3389%2Ffimmu.2015.00387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=26300881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=387&author=Y.+Waumansauthor=L.+Baertsauthor=K.+Kehoeauthor=A.+M.+Lambeirauthor=I.+De+Meester&title=The+Dipeptidyl+Peptidase+Family%2C+Prolyl+Oligopeptidase%2C+and+Prolyl+Carboxypeptidase+in+the+Immune+System+and+Inflammatory+Disease%2C+Including+Atherosclerosis&doi=10.3389%2Ffimmu.2015.00387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis</span></div><div class="casAuthors">Waumans, Yannick; Baerts, Lesley; Kehoe, Kaat; Lambeir, Anne-Marie; De Meester, Ingrid</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">387/1-387/18</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Research from over the past 20 years has implicated dipeptidyl peptidase (DPP) IV and its family members in many processes and different pathologies of the immune system.  Most research has been focused on either DPPIV or just a few of its family members.  It is, however, essential to consider the entire DPP family when discussing any one of its members.  There is a substantial overlap between family members in their substrate specificity, inhibitors, and functions.  In this review, we provide a comprehensive discussion on the role of prolyl-specific peptidases DPPIV, FAP, DPP8, DPP9, dipeptidyl peptidase II, prolyl carboxypeptidase, and prolyl oligopeptidase in the immune system and its diseases.  We highlight possible therapeutic targets for the prevention and treatment of atherosclerosis, a condition that lies at the frontier between inflammation and cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB98L7gAzAqrVg90H21EOLACvtfcHk0lisjeOsW_6I6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurjN&md5=6bb76e8a88d4cd20fec0e7707bd7865d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2015.00387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2015.00387%26sid%3Dliteratum%253Aachs%26aulast%3DWaumans%26aufirst%3DY.%26aulast%3DBaerts%26aufirst%3DL.%26aulast%3DKehoe%26aufirst%3DK.%26aulast%3DLambeir%26aufirst%3DA.%2BM.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26atitle%3DThe%2520Dipeptidyl%2520Peptidase%2520Family%252C%2520Prolyl%2520Oligopeptidase%252C%2520and%2520Prolyl%2520Carboxypeptidase%2520in%2520the%2520Immune%2520System%2520and%2520Inflammatory%2520Disease%252C%2520Including%2520Atherosclerosis%26jtitle%3DFront.%2520Immunol.%26date%3D2015%26volume%3D6%26spage%3D387%26doi%3D10.3389%2Ffimmu.2015.00387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span> <span> </span><span class="NLM_article-title">Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1447</span>â <span class="NLM_lpage">1463</span>, <span class="refDoi">Â DOI: 10.2174/156802611795860933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2174%2F156802611795860933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=21510839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOrtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1447-1463&author=S.-J.+Chenauthor=W.-T.+Jiaang&title=Current+advances+and+therapeutic+potential+of+agents+targeting+dipeptidyl+peptidases-IV%2C+-II%2C+8%2F9+and+fibroblast+activation+protein&doi=10.2174%2F156802611795860933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein</span></div><div class="casAuthors">Chen, Shu-Jen; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1447-1463</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Dipeptidyl peptidase-IV (DPP-IV), a serine protease that specifically cleaves the N-terminal dipeptide with a preference for L-proline or L-alanine at the penultimate position, is involved in the degrdn. of incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).  GLP-1 regulates glucose homeostasis by stimulating insulin secretion, inhibiting glucagon release, and delaying gastric emptying.  I.v. GLP-1 has been shown to increase insulin secretion in response to elevated glucose levels and offers therapeutic benefit for patients with type 2 diabetes.  However, the therapeutic application of GLP-1 is severely compromised by its lack of oral activity and its rapid degrdn. by plasma DPP-IV.  Consequently, small-mol. DPP-IV inhibitors that could extend the duration of action of GLP-1 and prolong its beneficial effects were investigated as promising therapeutics for type 2 diabetes.  This review summarizes important structural classes of DPP-IV inhibitors, focusing mainly on their inhibitory potency and selectivity for DPP-IV over other related peptidases such as DPP-II, DPP8, DPP9, and FAP.  Because inhibition of DPP8 and/or DPP9 has been shown to cause severe toxicity in preclin. species, high selectivity is an important criterion in selecting DPP-IV inhibitors for clin. development.  As of today, several DPP-IV inhibitors have completed phase III clin. studies for the treatment of type 2 diabetes.  A brief overview of clin. efficacy data on these inhibitor drugs is provided here.  In addn., biol. activities of other related dipeptidyl peptidases (DPP-II, DPP8, DPP9, and FAP) will be summarized.  Selective inhibitors for these peptidases and their therapeutic potential will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ5h8U-FUCG7Vg90H21EOLACvtfcHk0lisjeOsW_6I6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOrtbs%253D&md5=45b5edc768d45d2e62e6588c334bdcdb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F156802611795860933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795860933%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DJiaang%26aufirst%3DW.-T.%26atitle%3DCurrent%2520advances%2520and%2520therapeutic%2520potential%2520of%2520agents%2520targeting%2520dipeptidyl%2520peptidases-IV%252C%2520-II%252C%25208%252F9%2520and%2520fibroblast%2520activation%2520protein%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1447%26epage%3D1463%26doi%3D10.2174%2F156802611795860933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafelmeyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein-alpha in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">977</span>â <span class="NLM_lpage">991</span>, <span class="refDoi">Â DOI: 10.1080/14728222.2017.1370455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1080%2F14728222.2017.1370455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28829211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVarsLvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=977-991&author=L.+Juillerat-Jeanneretauthor=P.+Tafelmeyerauthor=D.+Golshayan&title=Fibroblast+activation+protein-alpha+in+fibrogenic+disorders+and+cancer%3A+more+than+a+prolyl-specific+peptidase%3F&doi=10.1080%2F14728222.2017.1370455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein-Î± in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne; Tafelmeyer, Petra; Golshayan, Dela</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">977-991</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Fibroblast activation protein-Î± (FAP-Î±) belongs to the family of prolyl-specific serine proteases.  FAP-Î± displays both exopeptidase and endopeptidase/gelatinase/collagenase activities.  FAP-Î± protein and/or activity have been assocd. with fibrosis, inflammation and cancer, but the protein is undetectable in most normal tissues.  FAP-Î± is selectively expressed at sites of tissue remodeling and repair and enhances tumor progression, suggesting that this protease may be a therapeutic target to treat human disorders assocd. with fibrotic dysregulation.  In this review, we summarize the mechanisms driving tissue fibrosis and describe some of the enzymes involved in fibrosis, concg. on FAP-Î±.  We describe its enzymic properties, discuss the tools developed to control its activity and the problem of selectivity toward the other proteases of the family and outline its potential biol. substrates.  We also consider non-enzymic functions of this protein and suggest that repression of FAP-Î± expression may represent therapeutic options.  Questions remain regarding the biol. functions of FAP-Î±, either dependent or independent of its enzyme activity.  However, as progress is underway to develop FAP-Î±-specific inhibitors and therapeutic antibodies, its role in diseases assocd. with fibrosis is starting to emerge, ultimately leading to novel therapeutic options for inflammatory and oncol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcbPSAqAMjn7Vg90H21EOLACvtfcHk0lisjeOsW_6I6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVarsLvJ&md5=596669985733b4eb79e68a66031f7e7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1080%2F14728222.2017.1370455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2017.1370455%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DTafelmeyer%26aufirst%3DP.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DFibroblast%2520activation%2520protein-alpha%2520in%2520fibrogenic%2520disorders%2520and%2520cancer%253A%2520more%2520than%2520a%2520prolyl-specific%2520peptidase%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2017%26volume%3D21%26spage%3D977%26epage%3D991%26doi%3D10.1080%2F14728222.2017.1370455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yazbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenisch, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, C. A.</span></span> <span> </span><span class="NLM_article-title">Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein</span>. <i>Protoplasma</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">375</span>â <span class="NLM_lpage">386</span>, <span class="refDoi">Â DOI: 10.1007/s00709-017-1129-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1007%2Fs00709-017-1129-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28620698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjs7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2018&pages=375-386&author=R.+Yazbeckauthor=S.+E.+Jaenischauthor=C.+A.+Abbott&title=Potential+disease+biomarkers%3A+dipeptidyl+peptidase+4+and+fibroblast+activation+protein&doi=10.1007%2Fs00709-017-1129-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein</span></div><div class="casAuthors">Yazbeck, Roger; Jaenisch, Simone E.; Abbott, Catherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Protoplasma</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">375-386</span>CODEN:
                <span class="NLM_cas:coden">PROTA5</span>;
        ISSN:<span class="NLM_cas:issn">0033-183X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">The importance of the dipeptidyl peptidase 4 (DPP4) gene family in regulating crit. biochem. pathways continues to emerge.  The two most well-studied members of the family, DPP4 and fibroblast activation protein (FAP), have been investigated both as therapeutic targets for disease and as diagnostic biomarkers.  The interest in DPP4 and FAP as potential disease biomarkers has been driven primarily by observations of altered expression profiles in inflammatory diseases and cancer.  Furthermore, the stability and persistence of sol. DPP4 and FAP in the serum make them attractive candidate serol. markers.  This review summarizes investigations into DPP4 and FAP as biomarkers of autoimmune disease, gut inflammation, psychosomatic disorders and malignancy and discusses their potential likelihood as clin. useful tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4SrnDaedoG7Vg90H21EOLACvtfcHk0lisjeOsW_6I6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjs7zI&md5=f931d730985cc3b3e889c692d9fa5bda</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00709-017-1129-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00709-017-1129-5%26sid%3Dliteratum%253Aachs%26aulast%3DYazbeck%26aufirst%3DR.%26aulast%3DJaenisch%26aufirst%3DS.%2BE.%26aulast%3DAbbott%26aufirst%3DC.%2BA.%26atitle%3DPotential%2520disease%2520biomarkers%253A%2520dipeptidyl%2520peptidase%25204%2520and%2520fibroblast%2520activation%2520protein%26jtitle%3DProtoplasma%26date%3D2018%26volume%3D255%26spage%3D375%26epage%3D386%26doi%3D10.1007%2Fs00709-017-1129-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, A.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein-alpha: a key modulator of the microenvironment in multiple pathologies</span>. <i>Int. Rev. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">83</span>â <span class="NLM_lpage">116</span>, <span class="refDoi">Â DOI: 10.1016/b978-0-12-394308-8.00003-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2FB978-0-12-394308-8.00003-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22608558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKgtbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2012&pages=83-116&author=T.+Kellyauthor=Y.+Huangauthor=A.+E.+Simmsauthor=A.+Mazur&title=Fibroblast+activation+protein-alpha%3A+a+key+modulator+of+the+microenvironment+in+multiple+pathologies&doi=10.1016%2Fb978-0-12-394308-8.00003-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein-Î±: a key modulator of the microenvironment in multiple pathologies</span></div><div class="casAuthors">Kelly, Thomas; Huang, Yan; Simms, Avis E.; Mazur, Anna</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-116</span>CODEN:
                <span class="NLM_cas:coden">IRCMAH</span>;
        ISSN:<span class="NLM_cas:issn">1937-6448</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Fibroblast activation protein-Î± (FAP) is a serine protease that can provide target specificity to therapeutic agents because in adults its expression is restricted to pathol. sites, including cancer, fibrosis, arthritis, wounding, or inflammation.  It is not expressed in most normal tissues.  The majority of FAP is expressed by activated fibroblasts responding to the pathol. situations.  FAP is typically found as a type II transmembrane protein phys. attached to cells and with the bulk of the protein, including the catalytic domain, exposed to the extracellular space and accessible to small mols.  In this chapter, we review the structure, substrate specificities, signaling functions, and current design of FAP inhibitors.  Evidence indicating the presence of FAP in multiple cancers, arthritis, fibrosis, keloids, and other pathologies is described and indicates possible roles for FAP in facilitating cell invasion and growth.  Sep. sections are devoted to the role of FAP in coordinating the stromal response to cancer, including a role in angiogenesis and a potential role in modulation of the antitumor immune response.  Finally studies attempting to demonstrate the clin. potential of FAP are discussed, as well as some novel applications employing FAP in therapy or diagnosis.  Throughout this review, effort is made to highlight areas where information is lacking and to highlight important questions that require further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl6m1rj-1CzLVg90H21EOLACvtfcHk0lj-TtGHrahzhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKgtbjL&md5=e21de80d77e6b473d8c6fc3d17156a36</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-394308-8.00003-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-394308-8.00003-0%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DSimms%26aufirst%3DA.%2BE.%26aulast%3DMazur%26aufirst%3DA.%26atitle%3DFibroblast%2520activation%2520protein-alpha%253A%2520a%2520key%2520modulator%2520of%2520the%2520microenvironment%2520in%2520multiple%2520pathologies%26jtitle%3DInt.%2520Rev.%2520Cell%2520Mol.%2520Biol.%26date%3D2012%26volume%3D297%26spage%3D83%26epage%3D116%26doi%3D10.1016%2Fb978-0-12-394308-8.00003-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, E.</span></span> <span> </span><span class="NLM_article-title">Turning foes to friends: targeting cancer-associated fibroblasts</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">99</span>â <span class="NLM_lpage">115</span>, <span class="refDoi">Â DOI: 10.1038/s41573-018-0004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fs41573-018-0004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30470818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlClsL7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=99-115&author=X.+Chenauthor=E.+Song&title=Turning+foes+to+friends%3A+targeting+cancer-associated+fibroblasts&doi=10.1038%2Fs41573-018-0004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Turning foes to friends: targeting cancer-associated fibroblasts</span></div><div class="casAuthors">Chen, Xueman; Song, Erwei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-115</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Current paradigms of cancer-centric therapeutics are usually not sufficient to eradicate the malignancy, as the cancer stroma may prompt tumor relapse and therapeutic resistance.  Among all the stromal cells that populate the tumor microenvironment, cancer-assocd. fibroblasts (CAFs) are the most abundant and are critically involved in cancer progression.  CAFs regulate the biol. of tumor cells and other stromal cells via cell-cell contact, releasing numerous regulatory factors and synthesizing and remodelling the extracellular matrix, and thus these cells affect cancer initiation and development.  The recent characterization of CAFs based on specific cell surface markers not only deepens our insight into their phenotypic heterogeneity and functional diversity but also brings CAF-targeting therapies for cancer treatment onto the agenda.  In this Review, we discuss the current knowledge of biol. hallmarks, cellular origins, phenotypical plasticity and functional heterogeneity of CAFs and underscore their contribution to cancer progression.  Moreover, we highlight relevant translational advances and potential therapeutic strategies that target CAFs for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt_XifgrPYT7Vg90H21EOLACvtfcHk0lj-TtGHrahzhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlClsL7J&md5=468c018a319141be0e27f9166132facc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41573-018-0004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-018-0004-1%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DE.%26atitle%3DTurning%2520foes%2520to%2520friends%253A%2520targeting%2520cancer-associated%2520fibroblasts%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2019%26volume%3D18%26spage%3D99%26epage%3D115%26doi%3D10.1038%2Fs41573-018-0004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quail, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span> <span> </span><span class="NLM_article-title">Microenvironmental regulation of tumor progression and metastasis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1423</span>â <span class="NLM_lpage">1437</span>, <span class="refDoi">Â DOI: 10.1038/nm.3394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fnm.3394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=24202395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCmsrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1423-1437&author=D.+F.+Quailauthor=J.+A.+Joyce&title=Microenvironmental+regulation+of+tumor+progression+and+metastasis&doi=10.1038%2Fnm.3394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Microenvironmental regulation of tumor progression and metastasis</span></div><div class="casAuthors">Quail, Daniela F.; Joyce, Johanna A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1423-1437</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis.  Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence.  However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis.  Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer.  Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3iXox3-NemLVg90H21EOLACvtfcHk0lj-TtGHrahzhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCmsrjL&md5=52d5ff0b56fb4749d0a42fedb3b83eb2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnm.3394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3394%26sid%3Dliteratum%253Aachs%26aulast%3DQuail%26aufirst%3DD.%2BF.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26atitle%3DMicroenvironmental%2520regulation%2520of%2520tumor%2520progression%2520and%2520metastasis%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1423%26epage%3D1437%26doi%3D10.1038%2Fnm.3394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. H.</span></span> <span> </span><span class="NLM_article-title">Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">840</span>â <span class="NLM_lpage">846</span>, <span class="refDoi">Â DOI: 10.3748/wjg.v18.i8.840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.3748%2Fwjg.v18.i8.840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22371645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XjslOlsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=840-846&author=M.+Shiauthor=D.+H.+Yuauthor=Y.+Chenauthor=C.+Y.+Zhaoauthor=J.+Zhangauthor=Q.+H.+Liuauthor=C.+R.+Niauthor=M.+H.+Zhu&title=Expression+of+fibroblast+activation+protein+in+human+pancreatic+adenocarcinoma+and+its+clinicopathological+significance&doi=10.3748%2Fwjg.v18.i8.840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance</span></div><div class="casAuthors">Shi, Min; Yu, Dang-Hui; Chen, Ying; Zhao, Chen-Yan; Zhang, Jing; Liu, Qing-Hua; Ni, Can-Rong; Zhu, Ming-Hua</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">840-846</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">Aim: To examine fibroblast activation protein (FAP) expression in pancreatic ductal adenocarcinoma (PDAC) and to analyze its relationship with the clinicopathol. of PDAC.  Methods: FAP expression was examd. in 134 PDAC specimens by immunohistochem. and in four pancreatic cancer cell lines (SW1990, Miapaca-2, AsPC-1 and BxPC-3) by Western blotting assay.  We also analyzed the assocn. between FAP expression in PDAC cells and the clinicopathol. of PDAC patients.  Results: The results showed that the FAP was expressed in both stromal fibroblast cells (98/134, 73.1%) and carcinoma cells (102/134, 76.1 %).  All 4 pancreatic cancer cell lines expressed FAP protein at different levels.  Protein bands corresponding to the proteolytically active 170-kDa seprase dimer and its 88-kDa seprase subunit were identified.  Higher FAP expression in carcinoma cells was assocd. with tumor size (P < 0.001), fibrotic focus (P = 0.003), perineural invasion (P = 0.009) and worse clin. outcome (P = 0.0085).  Conclusion: FAP is highly expressed in carcinoma cells and fibroblasts in PDAC tissues and its expression is assocd. with desmoplasia and worse prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxNJB6yGpISbVg90H21EOLACvtfcHk0lgQYLu7u79Emw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjslOlsr4%253D&md5=3e73023ef7a37f9d8eba9decdf4b72e6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v18.i8.840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v18.i8.840%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DD.%2BH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%2BH.%26aulast%3DNi%26aufirst%3DC.%2BR.%26aulast%3DZhu%26aufirst%3DM.%2BH.%26atitle%3DExpression%2520of%2520fibroblast%2520activation%2520protein%2520in%2520human%2520pancreatic%2520adenocarcinoma%2520and%2520its%2520clinicopathological%2520significance%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2012%26volume%3D18%26spage%3D840%26epage%3D846%26doi%3D10.3748%2Fwjg.v18.i8.840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein alpha in tumor microenvironment: recent progression and implications (review)</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3203</span>â <span class="NLM_lpage">3211</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2015.3197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.3892%2Fmmr.2015.3197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=25593080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVyqt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=3203-3211&author=F.+Ziauthor=J.+Heauthor=D.+Heauthor=Y.+Liauthor=L.+Yangauthor=Z.+Cai&title=Fibroblast+activation+protein+alpha+in+tumor+microenvironment%3A+recent+progression+and+implications+%28review%29&doi=10.3892%2Fmmr.2015.3197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein Î± in tumor microenvironment: recent progression and implications (Review)</span></div><div class="casAuthors">Zi, Fuming; He, Jingsong; He, Donghua; Li, Yi; Yang, Li; Cai, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3203-3211</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-2997</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Accumulated evidence has demonstrated that the microenvironment of a given tumor is important in detg. its drug resistance, tumorigenesis, progression and metastasis.  These microenvironments, like tumor cells, are vital targets for cancer therapy.  The cross-talk between tumor cells and cancer-assocd. fibroblasts (CAFs, alternatively termed activated fibroblasts) is crucial in regulating the drug resistance, tumorigenesis, neoplastic progression, angiogenesis, invasion and metastasis of a tumor.  Fibroblast activation protein Î± (FAPÎ±) is a transmembrane serine protease and is highly expressed on CAFs present in >90% of human epithelial neoplasms.  FAPÎ± activity, alongside that of gelatinase and type I collagenase, has become increasingly important in cancer therapy due to its effectiveness in modulating tumor behavior.  In this review, recent progression in the knowledge of the role of FAPÎ± in tumor microenvironments is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKNDxkdT7UU7Vg90H21EOLACvtfcHk0lgQYLu7u79Emw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVyqt7s%253D&md5=f81b4233a1aa58afe12bcc184c578c3c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2015.3197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2015.3197%26sid%3Dliteratum%253Aachs%26aulast%3DZi%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DCai%26aufirst%3DZ.%26atitle%3DFibroblast%2520activation%2520protein%2520alpha%2520in%2520tumor%2520microenvironment%253A%2520recent%2520progression%2520and%2520implications%2520%2528review%2529%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2015%26volume%3D11%26spage%3D3203%26epage%3D3211%26doi%3D10.3892%2Fmmr.2015.3197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandberg, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosting, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollenaar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sier, C. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesker, W. E.</span></span> <span> </span><span class="NLM_article-title">Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer</span>. <i>BMC Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">284</span>, <span class="refDoi">Â DOI: 10.1186/s12885-019-5462-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1186%2Fs12885-019-5462-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30922247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A280%3ADC%252BB3cbptF2rtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=284&author=T.+P.+Sandbergauthor=M.+Stuartauthor=J.+Oostingauthor=R.+Tollenaarauthor=C.+F.+M.+Sierauthor=W.+E.+Mesker&title=Increased+expression+of+cancer-associated+fibroblast+markers+at+the+invasive+front+and+its+association+with+tumor-stroma+ratio+in+colorectal+cancer&doi=10.1186%2Fs12885-019-5462-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer</span></div><div class="casAuthors">Sandberg Tessa P; Stuart Maaike P M E; Tollenaar Rob A E M; Sier Cornelis F M; Mesker Wilma E; Sandberg Tessa P; Oosting Jan</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">284</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The tumor microenvironment has a critical role in regulating cancer cell behavior.  Tumors with high stromal content are associated with poor patient outcome.  The tumor-stroma ratio (TSR) identifies colorectal cancers (CRC) with poor patient prognosis based on hematoxylin & eosin stained sections.  The desmoplastic reaction consists to a great extent of cancer-associated fibroblasts (CAFs) of which different subtypes are known.  The aim of this study is to investigate and quantify CAFs present in the tumor stroma of CRC stratified by the TSR to possibly add prognostic significance to the TSR.  METHODS:  The expression of established CAF markers was compared between stroma-low and stroma-high tumors using transcriptomic data of 71 stage I - III CRC.  Based on literature, fibroblast and stromal markers were selected to perform multiplex immunofluorescent staining on formalin fixed, paraffin-embedded tumor sections of patients diagnosed with stage III colon cancer.  Antibodies against the following markers were used: Î±SMA, PDGFR -Î², FAP, FSP1 and the stromal markers CD45 and CD31 as reference.  The markers were subsequently quantified in the stroma using the Vectra imaging microscope.  RESULTS:  The transcriptomic data showed that all CAF markers except one were higher expressed in stroma-high compared to stroma-low tumors.  Histologically, stroma-high tumors showed a decreased number of FSP1(+)/CD45(+) cells and a trend of an increased expression of FAP compared to stroma-low tumors.  FAP was higher expressed at the invasive part compared to the tumor center in both stroma-high and stroma-low tumors.  CONCLUSIONS:  The increased expression of FAP at the invasive part and in stroma-high tumors might contribute to the invasive behavior of cancer cells.  Future functional experiments should investigate the contribution of FAP to cancer cell invasion.  Combining the quantity of the stroma as defined by the TSR with the activity level of CAFs using the expression of FAP may result in an expanded stroma-based tool for patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7CRJaefcy5bxanA7vODO6fW6udTcc2eYNh9W8fx-RLrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbptF2rtg%253D%253D&md5=afd1ca01868243e7120ef8ca77a7eb2a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs12885-019-5462-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-019-5462-2%26sid%3Dliteratum%253Aachs%26aulast%3DSandberg%26aufirst%3DT.%2BP.%26aulast%3DStuart%26aufirst%3DM.%26aulast%3DOosting%26aufirst%3DJ.%26aulast%3DTollenaar%26aufirst%3DR.%26aulast%3DSier%26aufirst%3DC.%2BF.%2BM.%26aulast%3DMesker%26aufirst%3DW.%2BE.%26atitle%3DIncreased%2520expression%2520of%2520cancer-associated%2520fibroblast%2520markers%2520at%2520the%2520invasive%2520front%2520and%2520its%2520association%2520with%2520tumor-stroma%2520ratio%2520in%2520colorectal%2520cancer%26jtitle%3DBMC%2520Canc.%26date%3D2019%26volume%3D19%26spage%3D284%26doi%3D10.1186%2Fs12885-019-5462-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span> <span> </span><span class="NLM_article-title">FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">8</span>â <span class="NLM_lpage">14</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2017.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.bbrc.2017.03.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28302482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1alur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2017&pages=8-14&author=L.+Chenauthor=X.+Qiuauthor=X.+Wangauthor=J.+He&title=FAP+positive+fibroblasts+induce+immune+checkpoint+blockade+resistance+in+colorectal+cancer+via+promoting+immunosuppression&doi=10.1016%2Fj.bbrc.2017.03.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression</span></div><div class="casAuthors">Chen, Lingling; Qiu, Xiangting; Wang, Xinhua; He, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-14</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Immune checkpoint blockades that significantly prolonged survival of melanoma patients have been less effective on colorectal cancer (CRC) patients.  Growing evidence suggested that fibroblast activation protein-alpha (FAP) on cancer assoc. fibroblasts (CAFs) has crit. roles in regulating antitumor immune response by inducing tumor-promoting inflammation.  In this study, we explored the roles of FAP in regulating the tumor immunity and immune checkpoint blockades resistance in CRC exptl. systems.  We found that CAFs with high FAP expression could induce immune checkpoint blockade resistance in CRC mouse model.  Mechanistically, CAFs with high FAP expression promoted immunosuppression in the CRC tumor immune microenvironment by up-regulating CCL2 secretion, recruiting myeloid cells, and decreasing T-cell activity.  In human CRC samples, FAP expression was proportional to myeloid cells no., but inversely related to T-cell no.  High FAP expression also predicted poor survival of CRC patients.  Taken together, our study suggested that high FAP expression in CAFs is one reason leading to immune checkpoint blockades resistance in CRC patients and FAP is an optional target for reversing immune checkpoint blockades resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs1Gr9-py6brVg90H21EOLACvtfcHk0ljxJr3PQbn8BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1alur0%253D&md5=53fb3ef60d253b2a0e172e85fbaa23b6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DJ.%26atitle%3DFAP%2520positive%2520fibroblasts%2520induce%2520immune%2520checkpoint%2520blockade%2520resistance%2520in%2520colorectal%2520cancer%2520via%2520promoting%2520immunosuppression%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D487%26spage%3D8%26epage%3D14%26doi%3D10.1016%2Fj.bbrc.2017.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buza, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindaraju, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monslow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pure, E.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e92232</span> <span class="refDoi">Â DOI: 10.1172/jci.insight.92232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1172%2Fjci.insight.92232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28978805" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&author=A.+Loauthor=C.+P.+Liauthor=E.+L.+Buzaauthor=R.+Blombergauthor=P.+Govindarajuauthor=D.+Averyauthor=J.+Monslowauthor=M.+Hsiaoauthor=E.+Pure&title=Fibroblast+activation+protein+augments+progression+and+metastasis+of+pancreatic+ductal+adenocarcinoma&doi=10.1172%2Fjci.insight.92232"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.92232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.92232%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DC.%2BP.%26aulast%3DBuza%26aufirst%3DE.%2BL.%26aulast%3DBlomberg%26aufirst%3DR.%26aulast%3DGovindaraju%26aufirst%3DP.%26aulast%3DAvery%26aufirst%3DD.%26aulast%3DMonslow%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DM.%26aulast%3DPure%26aufirst%3DE.%26atitle%3DFibroblast%2520activation%2520protein%2520augments%2520progression%2520and%2520metastasis%2520of%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DJCI%2520Insight%26date%3D2017%26volume%3D2%26doi%3D10.1172%2Fjci.insight.92232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span> <span> </span><span class="NLM_article-title">Clinical implications of fibroblast activation protein-alpha in non-small cell lung cancer after curative resection: a new predictor for prognosis</span>. <i>J. Canc. Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1523</span>â <span class="NLM_lpage">1528</span>, <span class="refDoi">Â DOI: 10.1007/s00432-013-1471-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1007%2Fs00432-013-1471-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=23835897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlShsLzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2013&pages=1523-1528&author=Y.+Liaoauthor=Y.+Niauthor=R.+Heauthor=W.+Liuauthor=J.+Du&title=Clinical+implications+of+fibroblast+activation+protein-alpha+in+non-small+cell+lung+cancer+after+curative+resection%3A+a+new+predictor+for+prognosis&doi=10.1007%2Fs00432-013-1471-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical implications of fibroblast activation protein-Î± in non-small cell lung cancer after curative resection: a new predictor for prognosis</span></div><div class="casAuthors">Liao, Yida; Ni, Yang; He, Ren; Liu, Weidong; Du, Jiajun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1523-1528</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Fibroblast activation protein-Î± (FAP-Î±), which is a serine protease specially expressed on the surface of the cancer stromal cells, plays an important role in the progression and prognosis in diverse malignancies.  However, the role of FAP-Î± in non-small cell lung cancer (NSCLC) is still unknown.  Materials and methods: We enrolled 59 NSCLC patients who received complete resection.  Sections of paraffin-embedded primary NSCLC specimens of all the patients were stained with antibody directed against FAP-Î±.  Overall, percentage (Grade 0-3) and intensity (0-3+) of stromal FAP-Î± staining of the tumor were assessed.  Results: FAP-Î± was detected in >76 % of the specimens examd., and its high expression seemed to be correlated with poor tumor differentiation (P = 0.06).  Furthermore, both increased FAP-Î± staining percentage and intensity were assocd. with worse overall survival of the patients (percentage, P = 0.0087; intensity, P = 0.05).  Higher FAP-Î± staining percentage was obsd. in those patients with increased peripheral neutrophil and lymphocyte count ratio (P = 0.034).  Conclusions: FAP-Î± is highly expressed in cancer stroma and also a predictor of poor survival of NSCLC patients.  Elevated FAP-Î± expression may be assocd. with inflammation and suppressed lymphocyte-dependent immune response, which then result in the tumor progression.  Therefore, FAP-Î± plays an important role in the progression of NSCLC, and its high expression is a predictor of poor survival.  Targeting FAP-Î± may be a novel strategy for NSCLC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt_AndbnpT5rVg90H21EOLACvtfcHk0ljxJr3PQbn8BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlShsLzE&md5=97ca27f16944fc3a3497e26b1e8edf9c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00432-013-1471-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-013-1471-8%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26atitle%3DClinical%2520implications%2520of%2520fibroblast%2520activation%2520protein-alpha%2520in%2520non-small%2520cell%2520lung%2520cancer%2520after%2520curative%2520resection%253A%2520a%2520new%2520predictor%2520for%2520prognosis%26jtitle%3DJ.%2520Canc.%2520Res.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D139%26spage%3D1523%26epage%3D1528%26doi%3D10.1007%2Fs00432-013-1471-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein-Szanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span> <span> </span><span class="NLM_article-title">Clinical implications of fibroblast activation protein in patients with colon cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1736</span>â <span class="NLM_lpage">1741</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-06-1746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1158%2F1078-0432.CCR-06-1746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=17363526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2gt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1736-1741&author=L.+R.+Henryauthor=H.-O.+Leeauthor=J.+S.+Leeauthor=A.+Klein-Szantoauthor=P.+Wattsauthor=E.+A.+Rossauthor=W.-T.+Chenauthor=J.+D.+Cheng&title=Clinical+implications+of+fibroblast+activation+protein+in+patients+with+colon+cancer&doi=10.1158%2F1078-0432.ccr-06-1746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer</span></div><div class="casAuthors">Henry, Leonard R.; Lee, Hyung-Ok; Lee, John S.; Klein-Szanto, Andres; Watts, Perry; Ross, Eric A.; Chen, Wen-Tien; Cheng, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1736-1741</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Human fibroblast activation protein (FAP)/seprase is a 97-kDa surface glycoprotein expressed on tumor assocd. fibroblasts in the majority of epithelial cancers including colon adenocarcinomas.  FAP overexpression in human tumor cells has been shown to promote tumor growth in animal models, and clin. trials targeting FAP enzymic activity have been initiated.  The primary objective of this study was to evaluate the clin. significance of stromal FAP in human colon cancers by immunohistochemisty.  Exptl. Design: Sections of paraffin-embedded resected primary human colon cancer specimens from 1996 through 2001 within the Fox Chase Cancer Center tumor bank were stained with D8 antibody directed against FAP/seprase.  Xenotransplanted human colorectal tumors in mice were examd. similarly for stromal FAP in tumors of different sizes.  Overall percentage of stromal FAP staining of the primary tumor was assessed semiquant. (0, 1+, 2+, 3+) and staining intensity was also graded (none, weak, intermediate, strong).  Survival time and time to recurrence data were analyzed using Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models.  RESULTS: One hundred thirty-eight patients with resected specimens were available for study (mean follow-up, 1,050 days) with 6 (4%) stage I, 52 (38%) stage II, 43 (31%) stage III, and 37 (27%) stage IV patients. FAP was detected in >93% of specimens.  Semiquant. staining was scored as 1+ in 28 (20%), 2+ in 52 (38%), and 3+ in 49 (35%).  FAP staining intensity was graded as weak in 45 (33%), intermediate in 48 (35%), and dark in 36 (26%).  Stromal FAP was found to correlate inversely with tumor stage (semiquant., P = 0.01; intensity, P = 0.009) and with tumor size of the tumor xenograft model (correlation coeff., -0.61; P = 0.047), suggesting that stromal FAP may have a greater role in the early development of tumors.  Furthermore, greater stromal FAP for patients with known metastatic disease was assocd. with a decreased survival.  CONCLUSION: Our data indicate that patients whose colon tumors have high levels of stromal FAP are more likely to have aggressive disease progression and potential development of metastases or recurrence.  This study affirms the rationale for ongoing clin. investigations using FAP as a therapeutic target to disrupt FAP-driven tumor progression in patients with metastatic disease.  It also suggests that the effects of FAP inhibition should be investigated in earlier-stage tumors, given its high levels and potential effect earlier in the course of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgsCCFFALY2bVg90H21EOLACvtfcHk0ljxJr3PQbn8BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2gt7o%253D&md5=9521921702b2ab2100c05e79c8eb07cf</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1746%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DL.%2BR.%26aulast%3DLee%26aufirst%3DH.-O.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DWatts%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DW.-T.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26atitle%3DClinical%2520implications%2520of%2520fibroblast%2520activation%2520protein%2520in%2520patients%2520with%2520colon%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1736%26epage%3D1741%26doi%3D10.1158%2F1078-0432.ccr-06-1746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Welt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divgi, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carswell, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Old, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span> <span> </span><span class="NLM_article-title">Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1193</span>â <span class="NLM_lpage">1203</span>, <span class="refDoi">Â DOI: 10.1200/jco.1994.12.6.1193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1200%2FJCO.1994.12.6.1193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=8201382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A280%3ADyaK2c3mtValtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1994&pages=1193-1203&author=S.+Weltauthor=C.+R.+Divgiauthor=A.+M.+Scottauthor=P.+Garin-Chesaauthor=R.+D.+Finnauthor=M.+Grahamauthor=E.+A.+Carswellauthor=A.+Cohenauthor=S.+M.+Larsonauthor=L.+J.+Oldauthor=W.+J.+Rettig&title=Antibody+targeting+in+metastatic+colon+cancer%3A+a+phase+I+study+of+monoclonal+antibody+F19+against+a+cell-surface+protein+of+reactive+tumor+stromal+fibroblasts&doi=10.1200%2Fjco.1994.12.6.1193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts</span></div><div class="casAuthors">Welt S; Divgi C R; Scott A M; Garin-Chesa P; Finn R D; Graham M; Carswell E A; Cohen A; Larson S M; Old L J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1193-203</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  To define the toxicity, imaging, and biodistribution characteristics of iodine 131-labeled monoclonal antibody F19 (131I-mAbF19).  MAbF19 recognizes the fibroblast activation protein (FAP), a cell-surface glycoprotein not present in most normal tissues, but abundantly expressed by reactive stromal fibroblasts of epithelial cancers, including more than 95% of primary and metastatic colorectal carcinomas.  PATIENTS AND METHODS:  131I-mAbF19 was administered intravenously to 17 patients with hepatic metastases from colorectal carcinoma who were scheduled for resection of localized metastases or insertion of hepatic artery catheter for regional chemotherapy.  Seven to 8 days before surgery, patients received 131I-mAbF19 at three dose levels, with at least four patients entered at each level.  RESULTS:  No toxicity associated with intravenous 131I-mAbF19 administration was observed.  Tumor images were obtained on planar and single-photon emission tomography (SPECT) scans in 15 of 17 patients with hepatic metastases, tumor-infiltrated portal lymph nodes, and/or recurrent pelvic disease.  The smallest lesion visualized was 1 cm in diameter.  The optimal time for tumor imaging was 3 to 5 days after 131I-mAbF19 administration.  The use of image registration techniques allowed precise anatomic localization of 131I-mAbF19 accumulation.  Immunohistochemical analysis of biopsy tissues showed expression of FAP in the tumor stroma (but not in normal liver) in all patients studied and confirmed that the FAP-positive tumor stromal fibroblasts were interposed between the tumor capillaries and the malignant colon epithelial cells.  At the time of surgery, tumor-to-liver ratios up to 21:1 and tumor-to-serum ratios up to 9:1 were obtained.  The fraction of the injected 131I-mAbF19 dose per gram tumor (%ID/g tumor) localized to hepatic metastases at the time of surgery ranged from 0.001% to 0.016%.  CONCLUSION:  The FAP tumor fibroblast antigen is highly expressed in primary and metastatic colorectal carcinomas and shows limited expression in normal adult tissues.  This highly selective expression pattern allows imaging of colorectal carcinoma lesions as small as 1 cm in diameter on 131I-mAbF19 scans.  Because of the consistent presence of FAP in the stroma of epithelial cancers and the accessibility of FAP-positive tumor stromal fibroblasts to circulating monoclonal antibodies (mAbs), this study suggests possible diagnostic and therapeutic applications of humanized mAbF19 and mAbF19 constructs with novel immune and nonimmune effector functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUDgydeJD4dJQHPYJuLg8TfW6udTcc2ebVMWHukHiMSbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3mtValtA%253D%253D&md5=53dff2e4869797546a8c14c925bc5ef4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.1994.12.6.1193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1994.12.6.1193%26sid%3Dliteratum%253Aachs%26aulast%3DWelt%26aufirst%3DS.%26aulast%3DDivgi%26aufirst%3DC.%2BR.%26aulast%3DScott%26aufirst%3DA.%2BM.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DFinn%26aufirst%3DR.%2BD.%26aulast%3DGraham%26aufirst%3DM.%26aulast%3DCarswell%26aufirst%3DE.%2BA.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DAntibody%2520targeting%2520in%2520metastatic%2520colon%2520cancer%253A%2520a%2520phase%2520I%2520study%2520of%2520monoclonal%2520antibody%2520F19%2520against%2520a%2520cell-surface%2520protein%2520of%2520reactive%2520tumor%2520stromal%2520fibroblasts%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1994%26volume%3D12%26spage%3D1193%26epage%3D1203%26doi%3D10.1200%2Fjco.1994.12.6.1193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laverman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Geest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, S. Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerrits, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgreen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helsen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freimoser-Grundschober, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldhauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosse, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moessner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyen, W. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenders, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerman, O. C.</span></span> <span> </span><span class="NLM_article-title">Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">778</span>â <span class="NLM_lpage">783</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.114.152959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.114.152959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=25858044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFaktr3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=778-783&author=P.+Lavermanauthor=T.+van+der+Geestauthor=S.+Y.+A.+Terryauthor=D.+Gerritsauthor=B.+Walgreenauthor=M.+M.+Helsenauthor=T.+K.+Nayakauthor=A.+Freimoser-Grundschoberauthor=I.+Waldhauerauthor=R.+J.+Hosseauthor=E.+Moessnerauthor=P.+Umanaauthor=C.+Kleinauthor=W.+J.+G.+Oyenauthor=M.+I.+Koendersauthor=O.+C.+Boerman&title=Immuno-PET+and+Immuno-SPECT+of+Rheumatoid+Arthritis+with+Radiolabeled+Anti-Fibroblast+Activation+Protein+Antibody+Correlates+with+Severity+of+Arthritis&doi=10.2967%2Fjnumed.114.152959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis</span></div><div class="casAuthors">Laverman, Peter; van der Geest, Tessa; Terry, Samantha Y. A.; Gerrits, Danny; Walgreen, Birgitte; Helsen, Monique M.; Nayak, Tapan K.; Freimoser-Grundschober, Anne; Waldhauer, Inja; Hosse, Ralf J.; Moessner, Ekkerhard; Umana, Pablo; Klein, Christian; Oyen, Wim J. G.; Koenders, Marjie I.; Boerman, Otto C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">778-783</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">One of the most prominent cell populations playing a role in rheumatoid arthritis (RA) is activated fibroblast-like synoviocytes.  Among many other proteins, fibroblast-like synoviocytes dominantly express fibroblast activation protein (FAP).  Because of the high expression of FAP in arthritic joints, radioimmunoimaging of activated fibroblasts with anti-FAP antibodies might be an attractive noninvasive imaging tool in RA.  Methods: SPECT and PET with 111In- and 89Zr-labeled anti-FAP antibody 28H1 was performed in mice with CIA.  The radioactivity uptake in joints was quantified and correlated with arthritis score.  Results: Both 111In-28H1 and 89Zr-28H1 showed high uptake in inflamed joints, being 3-fold higher than that of the irrelevant isotype-matched control antibody DP47GS, clearly indicating specific accumulation of 28H1.  Uptake of 111In-28H1 ranged from 2.2 percentage injected dose per g (%ID/g) in noninflamed joints to 32.1 %ID/g in severely inflamed joints.  DP47GS accumulation ranged from 1.6 %ID/g in noninflamed tissue to 12.0 %ID/g in severely inflamed joints.  Uptake of 28H1 in inflamed joints correlated with arthritis score (Spearman Ï, 0.69; P < 0.0001) and increased with severity of arthritis.  Conclusion: SPECT/CT imaging with the anti-FAP antibody 111In-28H1 specifically visualized arthritic joints with high resoln., and tracer accumulation correlated with the severity of the inflammation in murine exptl. arthritis.  Background uptake of the radiolabeled antibody was low, resulting in excellent image quality. 89Zr-28H1 was less favorable for RA imaging because of an elevated bone uptake of 89Zr.  Future studies will focus on the potential role of 28H1 as a tool to monitor therapy response early on.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaYZGEf70NP7Vg90H21EOLACvtfcHk0lgVWKHz6IGGxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFaktr3O&md5=e19e343e750cc081e5d476a303d92997</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.114.152959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.114.152959%26sid%3Dliteratum%253Aachs%26aulast%3DLaverman%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BGeest%26aufirst%3DT.%26aulast%3DTerry%26aufirst%3DS.%2BY.%2BA.%26aulast%3DGerrits%26aufirst%3DD.%26aulast%3DWalgreen%26aufirst%3DB.%26aulast%3DHelsen%26aufirst%3DM.%2BM.%26aulast%3DNayak%26aufirst%3DT.%2BK.%26aulast%3DFreimoser-Grundschober%26aufirst%3DA.%26aulast%3DWaldhauer%26aufirst%3DI.%26aulast%3DHosse%26aufirst%3DR.%2BJ.%26aulast%3DMoessner%26aufirst%3DE.%26aulast%3DUmana%26aufirst%3DP.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26aulast%3DKoenders%26aufirst%3DM.%2BI.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26atitle%3DImmuno-PET%2520and%2520Immuno-SPECT%2520of%2520Rheumatoid%2520Arthritis%2520with%2520Radiolabeled%2520Anti-Fibroblast%2520Activation%2520Protein%2520Antibody%2520Correlates%2520with%2520Severity%2520of%2520Arthritis%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26spage%3D778%26epage%3D783%26doi%3D10.2967%2Fjnumed.114.152959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meletta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller Herde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiotellis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rancic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¤mer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2081</span>â <span class="NLM_lpage">2099</span>, <span class="refDoi">Â DOI: 10.3390/molecules20022081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.3390%2Fmolecules20022081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=25633335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitF2gs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=2081-2099&author=R.+Melettaauthor=A.+M%C3%BCller+Herdeauthor=A.+Chiotellisauthor=M.+Isaauthor=Z.+Rancicauthor=N.+Borelauthor=S.+Ametameyauthor=S.+Kr%C3%A4merauthor=R.+Schibli&title=Evaluation+of+the+radiolabeled+boronic+acid-based+FAP+inhibitor+MIP-1232+for+atherosclerotic+plaque+imaging&doi=10.3390%2Fmolecules20022081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging</span></div><div class="casAuthors">Meletta, Romana; Herde, Adrienne Muller; Chiotellis, Aristeidis; Isa, Malsor; Rancic, Zoran; Borel, Nicole; Ametamey, Simon M.; Kramer, Stefanie D.; Schibli, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2081-2099, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Research towards the non-invasive imaging of atherosclerotic plaques is of high clin. priority as early recognition of vulnerable plaques may reduce the incidence of cardiovascular events.  The fibroblast activation protein alpha (FAP) was recently proposed as inflammation-induced protease involved in the process of plaque vulnerability.  In this study, FAP mRNA and protein levels were investigated by quant. polymerase chain reaction and immunohistochem., resp., in human endarterectomized carotid plaques.  A published boronic-acid based FAP inhibitor, MIP-1232, was synthesized and radiolabeled with iodine-125.  The potential of this radiotracer to image plaques was evaluated by in vitro autoradiog. with human carotid plaques.  Specificity was assessed with a xenograft with high and one with low FAP level, grown in mice.  Target expression analyses revealed a moderately higher protein level in atherosclerotic plaques than normal arteries correlating with plaque vulnerability.  No difference in expression was detd. on mRNA level.  The radiotracer was successfully produced and accumulated strongly in the FAP-pos. SK-Mel-187 melanoma xenograft in vitro while accumulation was negligible in an NCI-H69 xenograft with low FAP levels.  Binding of the tracer to endarterectomized tissue was similar in plaques and normal arteries, hampering its use for atherosclerosis imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCElQwBPeOS7Vg90H21EOLACvtfcHk0ljIre39-KdtUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitF2gs7Y%253D&md5=5900591e2f9af2274b2e699be2cc8ee1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3390%2Fmolecules20022081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules20022081%26sid%3Dliteratum%253Aachs%26aulast%3DMeletta%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%2BHerde%26aufirst%3DA.%26aulast%3DChiotellis%26aufirst%3DA.%26aulast%3DIsa%26aufirst%3DM.%26aulast%3DRancic%26aufirst%3DZ.%26aulast%3DBorel%26aufirst%3DN.%26aulast%3DAmetamey%26aufirst%3DS.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DS.%26aulast%3DSchibli%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520the%2520radiolabeled%2520boronic%2520acid-based%2520FAP%2520inhibitor%2520MIP-1232%2520for%2520atherosclerotic%2520plaque%2520imaging%26jtitle%3DMolecules%26date%3D2015%26volume%3D20%26spage%3D2081%26epage%3D2099%26doi%3D10.3390%2Fmolecules20022081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D.</span></span> <span> </span><span class="NLM_article-title">On the edge of validation--cancer protease fibroblast activation protein</span>. <i>Mini Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">719</span>â <span class="NLM_lpage">727</span>, <span class="refDoi">Â DOI: 10.2174/138955708784567449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2174%2F138955708784567449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=18537727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnslWkurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=719-727&author=B.+Wolfauthor=C.+Quanauthor=T.+Tranauthor=C.+Wiesmannauthor=D.+Sutherlin&title=On+the+edge+of+validation%2D%2Dcancer+protease+fibroblast+activation+protein&doi=10.2174%2F138955708784567449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">On the edge of validation - cancer protease fibroblast activation protein</span></div><div class="casAuthors">Wolf, Beni B.; Quan, Clifford; Tran, Thuy; Wiesmann, Christian; Sutherlin, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">719-727</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Numerous studies implicate the prolyl peptidase, fibroblast activation protein (FAP) in tumorigenesis; however, FAP-selective inhibitors have not yet been developed to fully validate FAP as a therapeutic target.  Herein, we review recent efforts aimed at validating and inhibiting FAP for cancer therapy and highlight future directions for successful targeting of this prolyl peptidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraYmP1yHrDjrVg90H21EOLACvtfcHk0ljIre39-KdtUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnslWkurg%253D&md5=2f69de69d02154c3a8aa456eab8f05ed</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F138955708784567449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708784567449%26sid%3Dliteratum%253Aachs%26aulast%3DWolf%26aufirst%3DB.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DSutherlin%26aufirst%3DD.%26atitle%3DOn%2520the%2520edge%2520of%2520validation--cancer%2520protease%2520fibroblast%2520activation%2520protein%26jtitle%3DMini%2520Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D719%26epage%3D727%26doi%3D10.2174%2F138955708784567449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemayehu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenkrants, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minimo, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripka, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szardenings, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozarich, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreder, K. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4239</span>â <span class="NLM_lpage">4242</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2005.06.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.bmcl.2005.06.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=16085416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1Wns7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=4239-4242&author=Y.+Huauthor=L.+Maauthor=M.+Wuauthor=M.+S.+Wongauthor=B.+Liauthor=S.+Corralauthor=Z.+Yuauthor=T.+Nomanbhoyauthor=S.+Alemayehuauthor=S.+R.+Fullerauthor=J.+S.+Rosenblumauthor=N.+Rozenkrantsauthor=L.+C.+Minimoauthor=W.+C.+Ripkaauthor=A.+K.+Szardeningsauthor=J.+W.+Kozarichauthor=K.+R.+Shreder&title=Synthesis+and+structure-activity+relationship+of+N-alkyl+Gly-boro-Pro+inhibitors+of+DPP4%2C+FAP%2C+and+DPP7&doi=10.1016%2Fj.bmcl.2005.06.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7</span></div><div class="casAuthors">Hu, Yi; Ma, Lifu; Wu, Min; Wong, Melissa S.; Li, Bei; Corral, Sergio; Yu, Zhizhou; Nomanbhoy, Tyzoon; Alemayehu, Senaiet; Fuller, Stacy R.; Rosenblum, Jonathan S.; Rozenkrants, Natasha; Minimo, Lauro C.; Ripka, William C.; Szardenings, Anna K.; Kozarich, John W.; Shreder, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4239-4242</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity relationship of various N-alkyl Gly-boro-Pro derivs. against three dipeptidyl peptidases (DPPs) was studied.  In a series of N-cycloalkyl analogs, DPP4 and fibroblast activation protein-Î± (FAP) optimally preferred N-cycloheptyl whereas DPP7 tolerated even larger cycloalkyl rings.  Gly Î±-carbon derivatization of N-cyclohexyl or N-(2-adamantyl) Gly-boro-Pro resulted in a significant decrease in potency against all the three DPPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3KP4LcEmwSbVg90H21EOLACvtfcHk0ljIre39-KdtUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1Wns7g%253D&md5=a9393433dff6f834f9dd457a9c643a3f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.06.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.06.075%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DM.%2BS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCorral%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DAlemayehu%26aufirst%3DS.%26aulast%3DFuller%26aufirst%3DS.%2BR.%26aulast%3DRosenblum%26aufirst%3DJ.%2BS.%26aulast%3DRozenkrants%26aufirst%3DN.%26aulast%3DMinimo%26aufirst%3DL.%2BC.%26aulast%3DRipka%26aufirst%3DW.%2BC.%26aulast%3DSzardenings%26aufirst%3DA.%2BK.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26aulast%3DShreder%26aufirst%3DK.%2BR.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%2520N-alkyl%2520Gly-boro-Pro%2520inhibitors%2520of%2520DPP4%252C%2520FAP%252C%2520and%2520DPP7%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D4239%26epage%3D4242%26doi%3D10.1016%2Fj.bmcl.2005.06.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loktev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1415</span>â <span class="NLM_lpage">1422</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.210443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.118.210443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29626119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFWnu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1415-1422&author=T.+Lindnerauthor=A.+Loktevauthor=A.+Altmannauthor=F.+Gieselauthor=C.+Kratochwilauthor=J.+Debusauthor=D.+J%C3%A4gerauthor=W.+Mierauthor=U.+Haberkorn&title=Development+of+Quinoline-Based+Theranostic+Ligands+for+the+Targeting+of+Fibroblast+Activation+Protein&doi=10.2967%2Fjnumed.118.210443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein</span></div><div class="casAuthors">Lindner, Thomas; Loktev, Anastasia; Altmann, Annette; Giesel, Frederik; Kratochwil, Clemens; Debus, Juergen; Jaeger, Dirk; Mier, Walter; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1415-1423</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Fibroblast activation protein (FAP) is overexpressed in cancer assocd. fibroblasts and is involved in a variety of tumor-promoting activities such as matrix remodeling, angiogenesis, chemotherapy resistance, and immunosuppression.  Because FAP shows low expression in most normal organs, it presents an interesting target for imaging and endoradiotherapy.  In this investigation, FAP inhibitors (FAPIs) were modified and optimized for use as theranostic tracers.  FAPIs based on a quinoline structure were synthesized and characterized with respect to binding, internalization, and efflux in cells expressing human and murine FAP as well as CD26.  Preclin. pharmacokinetics were detd. in tumor-bearing animals with biodistribution expts. and smallanimal PET.  Finally, a proof-of-concept approach toward imaging and therapy was chosen for 2 patients with metastasized breast cancer.  Of 15 synthesized FAPIs, FAPI-04 was identified as the most promising tracer for clin. application.  Compared with the previously published ligand, FAPI-02, FAPI-04 showed excellent stability in human serum, higher affinity for FAP as opposed to CD26, and slower excretion in vitro.  In vivo, a higher SUV was reached in tumor-bearing animals, leading to larger areas under the curve as calcd. from biodistribution expts.  Finally, PET/CT scans with 68Ga-FAPI-04 in 2 patients withmetastasized breast cancer revealed high tracer uptake in metastases and a redn. in pain symptoms after therapy with a considerably low dose of 90Y-FAPI-04.  FAPI-04 represents a promising tracer for both diagnostic imaging and, possibly, targeted therapy of malignant tumors with a high content of activated fibroblasts, such as breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_tGKFNSoNl7Vg90H21EOLACvtfcHk0ljIre39-KdtUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFWnu74%253D&md5=8a47c1c15ec3d7e16462d7712865f94f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.210443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.210443%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DLoktev%26aufirst%3DA.%26aulast%3DAltmann%26aufirst%3DA.%26aulast%3DGiesel%26aufirst%3DF.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DD.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DDevelopment%2520of%2520Quinoline-Based%2520Theranostic%2520Ligands%2520for%2520the%2520Targeting%2520of%2520Fibroblast%2520Activation%2520Protein%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D1415%26epage%3D1422%26doi%3D10.2967%2Fjnumed.118.210443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heirbaut, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabtsova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">491</span>â <span class="NLM_lpage">496</span>, <span class="refDoi">Â DOI: 10.1021/ml300410d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300410d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKnsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=491-496&author=K.+Jansenauthor=L.+Heirbautauthor=J.+D.+Chengauthor=J.+Joossensauthor=O.+Ryabtsovaauthor=P.+Cosauthor=L.+Maesauthor=A.-M.+Lambeirauthor=I.+De+Meesterauthor=K.+Augustynsauthor=P.+Van+der+Veken&title=Selective+Inhibitors+of+Fibroblast+Activation+Protein+%28FAP%29+with+a+%284-Quinolinoyl%29-glycyl-2-cyanopyrrolidine+Scaffold&doi=10.1021%2Fml300410d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold</span></div><div class="casAuthors">Jansen, Koen; Heirbaut, Leen; Cheng, Jonathan D.; Joossens, Jurgen; Ryabtsova, Oxana; Cos, Paul; Maes, Louis; Lambeir, Anne-Marie; De Meester, Ingrid; Augustyns, Koen; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">491-496</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast activation protein (FAP) is a serine protease that is generally accepted to play an important role in tumor growth and other diseases involving tissue remodeling.  Currently there are no FAP inhibitors with reported selectivity toward both the closely related dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP).  We present the discovery of a new class of FAP inhibitors with a N-(4-quinolinoyl)-Gly-(2-cyanopyrrolidine) scaffold, e.g. I.  We have explored the effects of substituting the quinoline ring and varying the position of its sp2 hybridized nitrogen atom.  The most promising inhibitors combined low nanomolar FAP inhibition and high selectivity indexes (>103) with respect to both the DPPs and PREP.  Preliminary expts. on a representative inhibitor demonstrate that plasma stability, kinetic soly., and log D of this class of compds. can be expected to be satisfactory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7f0rayraCQLVg90H21EOLACvtfcHk0ljg0MnkbUd4bA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKnsLs%253D&md5=1836427e531f6e13264ca833613966dc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml300410d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300410d%26sid%3Dliteratum%253Aachs%26aulast%3DJansen%26aufirst%3DK.%26aulast%3DHeirbaut%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DRyabtsova%26aufirst%3DO.%26aulast%3DCos%26aufirst%3DP.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DSelective%2520Inhibitors%2520of%2520Fibroblast%2520Activation%2520Protein%2520%2528FAP%2529%2520with%2520a%2520%25284-Quinolinoyl%2529-glycyl-2-cyanopyrrolidine%2520Scaffold%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D491%26epage%3D496%26doi%3D10.1021%2Fml300410d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heirbaut, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkerk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span> <span> </span><span class="NLM_article-title">Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3053</span>â <span class="NLM_lpage">3074</span>, <span class="refDoi">Â DOI: 10.1021/jm500031w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500031w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVSjt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3053-3074&author=K.+Jansenauthor=L.+Heirbautauthor=R.+Verkerkauthor=J.+D.+Chengauthor=J.+Joossensauthor=P.+Cosauthor=L.+Maesauthor=A.-M.+Lambeirauthor=I.+De+Meesterauthor=K.+Augustynsauthor=P.+Van+der+Veken&title=Extended+structure-activity+relationship+and+pharmacokinetic+investigation+of+%284-quinolinoyl%29glycyl-2-cyanopyrrolidine+inhibitors+of+fibroblast+activation+protein+%28FAP%29&doi=10.1021%2Fjm500031w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Extended Structure-Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)</span></div><div class="casAuthors">Jansen, Koen; Heirbaut, Leen; Verkerk, Robert; Cheng, Jonathan D.; Joossens, Jurgen; Cos, Paul; Maes, Louis; Lambeir, Anne-Marie; De Meester, Ingrid; Augustyns, Koen; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3053-3074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast activation protein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV).  It has been convincingly linked to multiple disease states involving remodeling of the extracellular matrix.  FAP inhibition is investigated as a therapeutic option for several of these diseases, with most attention so far devoted to oncol. applications.  The authors previously discovered the N-4-quinolinoyl-Gly-(2S)-cyanoPro scaffold as a possible entry to highly potent and selective FAP inhibitors.  In the present study, the authors explore in detail the structure-activity relationship around this core scaffold.  The authors report extensively optimized compds. that display low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PREP).  The log D values, plasma stabilities, and microsomal stabilities of selected compds. were found to be highly satisfactory.  Pharmacokinetic evaluation in mice of selected inhibitors demonstrated high oral bioavailability, plasma half-life, and the potential to selectively and completely inhibit FAP in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogEWbN62xYn7Vg90H21EOLACvtfcHk0ljg0MnkbUd4bA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVSjt7Y%253D&md5=c52e7b0f1b7a7b056a74577c262a1d6d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm500031w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500031w%26sid%3Dliteratum%253Aachs%26aulast%3DJansen%26aufirst%3DK.%26aulast%3DHeirbaut%26aufirst%3DL.%26aulast%3DVerkerk%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DCos%26aufirst%3DP.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DExtended%2520structure-activity%2520relationship%2520and%2520pharmacokinetic%2520investigation%2520of%2520%25284-quinolinoyl%2529glycyl-2-cyanopyrrolidine%2520inhibitors%2520of%2520fibroblast%2520activation%2520protein%2520%2528FAP%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3053%26epage%3D3074%26doi%3D10.1021%2Fjm500031w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loktev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roumestand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1423</span>â <span class="NLM_lpage">1429</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.210435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.118.210435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29626120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFWmsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1423-1429&author=A.+Loktevauthor=T.+Lindnerauthor=W.+Mierauthor=J.+Debusauthor=A.+Altmannauthor=D.+J%C3%A4gerauthor=F.+Gieselauthor=C.+Kratochwilauthor=P.+Bartheauthor=C.+Roumestandauthor=U.+Haberkorn&title=A+Tumor-Imaging+Method+Targeting+Cancer-Associated+Fibroblasts&doi=10.2967%2Fjnumed.118.210435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A tumor-imaging method targeting cancer-associated fibroblasts</span></div><div class="casAuthors">Loktev, Anastasia; Lindner, Thomas; Mier, Walter; Debus, Juergen; Altmann, Annette; Jaeger, Dirk; Giesel, Frederik; Kratochwil, Clemens; Barthe, Philippe; Roumestand, Christian; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1423-1429</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The tumor stroma, which accounts for a large part of the tumor mass, represents an attractive target for the delivery of diagnostic and therapeutic compds.  Here, the focus is notably on a subpopulation of stromal cells, known as cancer-assocd. fibroblasts, which are present in more than 90% of epithelial carcinomas, including pancreatic, colon, and breast cancer.  Cancer-assocd. fibroblasts feature high expression of fibroblast activation protein (FAP), which is not detectable in adult normal tissue but is assocd. with a poor prognosis in cancer patients.  Methods: We developed an iodinated and a DOTA-coupled radiotracer based on a FAP-specific enzyme inhibitor (FAPI) and evaluated them in vitro using uptake, competition, and efflux studies as well as confocal microscopy of a fluorescence-labeled variant.  Furthermore, we performed imaging and biodistribution studies on tumor-bearing animals.  Finally, proof of concept was realized by imaging patients with 68Ga-labeled FAPI.  Results: Both FAPIs showed high specificity, affinity, and rapid internalization into FAP-expressing cells in vitro and in vivo.  Biodistribution studies on tumor-bearing mice and on the first cancer patients demonstrated high intratumoral uptake of the tracer and fast body clearance, resulting in highcontrast images and negligible exposure of healthy tissue to radiation.  A comparison with the commonly used radiotracer 18F-FDG in a patient with locally advanced lung adenocarcinoma revealed that the new FAP ligand was clearly superior.  Conclusion: Radiolabeled FAPIs allow fast imaging with very high contrast in tumors having a high stromal content and may therefore serve as pantumor agents.  Coupling of these mols. to DOTA or other chelators allows labeling not only with 68Ga but also with therapeutic isotopes such as 177Lu or 90Y.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKOEK0YEckWrVg90H21EOLACvtfcHk0li-aKOqKwd-OA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFWmsro%253D&md5=7fdfe7895a2dd8d2b4f048407d55d5de</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.210435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.210435%26sid%3Dliteratum%253Aachs%26aulast%3DLoktev%26aufirst%3DA.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DAltmann%26aufirst%3DA.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DD.%26aulast%3DGiesel%26aufirst%3DF.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DBarthe%26aufirst%3DP.%26aulast%3DRoumestand%26aufirst%3DC.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DA%2520Tumor-Imaging%2520Method%2520Targeting%2520Cancer-Associated%2520Fibroblasts%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D1423%26epage%3D1429%26doi%3D10.2967%2Fjnumed.118.210435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschalek, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loktev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehnert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flechsig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">386</span>â <span class="NLM_lpage">392</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.215913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.118.215913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30072500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yhtbfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=386-392&author=F.+L.+Gieselauthor=C.+Kratochwilauthor=T.+Lindnerauthor=M.+M.+Marschalekauthor=A.+Loktevauthor=W.+Lehnertauthor=J.+Debusauthor=D.+J%C3%A4gerauthor=P.+Flechsigauthor=A.+Altmannauthor=W.+Mierauthor=U.+Haberkorn&title=%2868%29Ga-FAPI+PET%2FCT%3A+Biodistribution+and+Preliminary+Dosimetry+Estimate+of+2+DOTA-Containing+FAP-Targeting+Agents+in+Patients+with+Various+Cancers&doi=10.2967%2Fjnumed.118.215913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers</span></div><div class="casAuthors">Giesel, Frederik L.; Kratochwil, Clemens; Lindner, Thomas; Marschalek, Manfred M.; Loktev, Anastasia; Lehnert, Wencke; Debus, Juergen; Jaeger, Dirk; Flechsig, Paul; Altmann, Annette; Mier, Walter; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">386-392</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Fibroblast activation protein (FAP) is overexpressed in cancer-assocd. fibroblasts of several tumor entities.  The recent development of quinoline-based PET tracers that act as FAP inhibitors (FAPIs) demonstrated promising results preclinically and already in a few clin. cases.  Consequently, these tracers are now applied in our hospital to amend the diagnostics of cancer patients facing the limitations of std. examns.  Here, we analyze the tissue biodistribution and preliminary dosimetry of 2 members of this new class of PET radiopharmaceutical.  A preliminary dosimetry est. for 68Ga-FAPI-2 and 68Ga-FAPI-4 was based on 2 patients examd. at 0.2, 1, and 3 h after tracer injection using the QDOSE dosimetry software suit.  Further PET/CT scans of tumor patients were acquired 1 h after injection of either 68Ga-FAPI-2 (n = 25) or 68Ga-FAPI-4 (n = 25); for 6 patients an intraindividual related 18F-FDG scan (also acquired 1 h after injection) was available.  For the normal tissue of 16 organs, a 2-cm spheric vol. of interest was placed in the parenchyma; for tumor lesions, a threshold-segmented vol. of interest was used to quantify SUVmean and SUVmax.  Similar to literature values for 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA-11, an examn. with 200 MBq of 68Ga-FAPI-2 or 68Ga-FAPI-4 corresponds to an equiv. dose of approx. 3-4 mSv.  After a fast clearance via the kidneys, the normal organs showed a low tracer uptake with only minimal changes between 10 min and 3 h after injection.  In 68Ga-FAPI-2, the tumor uptake from 1 to 3 h after injection decreased by 75%, whereas the tumor retention was prolonged with 68Ga-FAPI-4 (25% washout).  Regarding tumor-to-background ratios, at 1 h after injection both 68Ga-FAPI tracers performed equally.  In comparison to 18F-FDG, the tumor uptake was almost equal (av. SUVmax, 7.41 for 18F-FDG and 7.37 for 68Ga-FAPI-2; not statistically significant); the background uptake in brain (11.01 vs. 0.32), liver (2.77 vs. 1.69), and oral/pharyngeal mucosa (4.88 vs. 2.57) was significantly lower with 68Ga-FAPI.  Other organs did not relevantly differ between 18F-FDG and 68Ga-FAPI.  FAPI PET/CT is a new diagnostic method in imaging cancer patients.  In contrast to 18F-FDG, no diet or fasting in prepn. for the examn. is necessary, and image acquisition can potentially be started a few minutes after tracer application.  Tumor-to-background contrast ratios were equal to or even better than those of 18F-FDG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVF9NHxFhgzrVg90H21EOLACvtfcHk0li-aKOqKwd-OA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yhtbfO&md5=266c83d02ef44662656c261b2f1bf5ad</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.215913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.215913%26sid%3Dliteratum%253Aachs%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DMarschalek%26aufirst%3DM.%2BM.%26aulast%3DLoktev%26aufirst%3DA.%26aulast%3DLehnert%26aufirst%3DW.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DD.%26aulast%3DFlechsig%26aufirst%3DP.%26aulast%3DAltmann%26aufirst%3DA.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3D%252868%2529Ga-FAPI%2520PET%252FCT%253A%2520Biodistribution%2520and%2520Preliminary%2520Dosimetry%2520Estimate%2520of%25202%2520DOTA-Containing%2520FAP-Targeting%2520Agents%2520in%2520Patients%2520with%2520Various%2520Cancers%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D386%26epage%3D392%26doi%3D10.2967%2Fjnumed.118.215913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hettiarachchi, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">5778</span>â <span class="NLM_lpage">5789</span>, <span class="refDoi">Â DOI: 10.7150/thno.41409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.7150%2Fthno.41409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=32483418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGgsr3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=5778-5789&author=J.+Royauthor=S.+U.+Hettiarachchiauthor=M.+Kaakeauthor=R.+Mukkamalaauthor=P.+S.+Low&title=Design+and+validation+of+fibroblast+activation+protein+alpha+targeted+imaging+and+therapeutic+agents&doi=10.7150%2Fthno.41409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents</span></div><div class="casAuthors">Roy, Jyoti; Hettiarachchi, Suraj U.; Kaake, Miranda; Mukkamala, Ramesh; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5778-5789</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts (CAFs) comprise a major cell type in the tumor microenvironment where they support tumor growth and survival by producing extracellular matrix, secreting immunosuppressive cytokines, releasing growth factors, and facilitating metastases.  Because tumors with elevated CAFs are characterized by poorer prognosis, considerable effort is focused on developing methods to quantitate, suppress and/or eliminate CAFs.  We exploit the elevated expression of fibroblast activation protein (FAP) on CAFs to target imaging and therapeutic agents selectively to these fibroblasts in solid tumors.  FAP-targeted optical imaging, radioimaging, and chemotherapeutic agents were synthesized by conjugating FAP ligand (FL) to either a fluorescent dye, technetium-99m, or tubulysin B hydrazide.  In vitro and in vivo studies were performed to det. the specificity and selectivity of each conjugate for FAP in vitro and in vivo.  FAP-targeted imaging and therapeutic conjugates showed high binding specificity and affinity in the low nanomolar range.  Injection of FAP-targeted 99mTc into tumor-bearing mice enabled facile detection of tumor xenografts with little off-target uptake.  Optical imaging of malignant lesions was also readily achieved following i.v. injection of FAP-targeted near-IR fluorescent dye.  Finally, systemic administration of a tubulysin B conjugate of FL promoted complete eradication of solid tumors with no evidence of gross toxicity to the animals.  In view of the near absence of FAP on healthy cells, we conclude that targeting of FAP on cancer-assocd. fibroblasts can enable highly specific imaging and therapy of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmjw0e1by25bVg90H21EOLACvtfcHk0lg3jS12y-UevQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGgsr3P&md5=11619d3be6835d22979dc378baa494e2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.7150%2Fthno.41409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.41409%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DJ.%26aulast%3DHettiarachchi%26aufirst%3DS.%2BU.%26aulast%3DKaake%26aufirst%3DM.%26aulast%3DMukkamala%26aufirst%3DR.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DDesign%2520and%2520validation%2520of%2520fibroblast%2520activation%2520protein%2520alpha%2520targeted%2520imaging%2520and%2520therapeutic%2520agents%26jtitle%3DTheranostics%26date%3D2020%26volume%3D10%26spage%3D5778%26epage%3D5789%26doi%3D10.7150%2Fthno.41409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westerlund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honarvar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NorrstrÃ¶m, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson
KarlstrÃ¶m, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span> <span> </span><span class="NLM_article-title">Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1668</span>â <span class="NLM_lpage">1678</span>, <span class="refDoi">Â DOI: 10.1021/acs.molpharmaceut.6b00089</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00089" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eisLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=1668-1678&author=K.+Westerlundauthor=H.+Honarvarauthor=E.+Norrstr%C3%B6mauthor=J.+Strandauthor=B.+Mitranauthor=A.+Orlovaauthor=A.+Eriksson%0AKarlstr%C3%B6mauthor=V.+Tolmachev&title=Increasing+the+Net+Negative+Charge+by+Replacement+of+DOTA+Chelator+with+DOTAGA+Improves+the+Biodistribution+of+Radiolabeled+Second-Generation+Synthetic+Affibody+Molecules&doi=10.1021%2Facs.molpharmaceut.6b00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules</span></div><div class="casAuthors">Westerlund, Kristina; Honarvar, Hadis; Norrstroem, Emily; Strand, Joanna; Mitran, Bogdan; Orlova, Anna; Eriksson Karlstroem, Amelie; Tolmachev, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1668-1678</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A promising strategy to enable patient stratification for targeted therapies is to monitor the target expression in a tumor by radionuclide mol. imaging.  Affibody mols. (7 kDa) are nonimmunoglobulin scaffold proteins with a 25-fold smaller size than intact antibodies.  They have shown an apparent potential as mol. imaging probes both in preclin. and clin. studies.  Earlier, we found that hepatic uptake can be reduced by the incorporation of neg. charged purifn. tags at the N-terminus of Affibody mols.  We hypothesized that liver uptake might similarly be reduced by positioning the chelator at the N-terminus, where the chelator-radionuclide complex will provide neg. charges.  To test this hypothesis, a second generation synthetic anti-HER2 ZHER2:2891 Affibody mol. was synthesized and labeled with 111In and 68Ga using DOTAGA and DOTA chelators.  The chelators were manually coupled to the N-terminus of ZHER2:2891 forming an amide bond.  Labeling DOTAGA-ZHER2:2891 and DOTA-ZHER2:2891 with 68Ga and 111In resulted in stable radioconjugates.  The tumor-targeting and biodistribution properties of the 111In- and 68Ga-labeled conjugates were compared in SKOV-3 tumor-bearing nude mice at 2 h postinjection.  The HER2-specific binding of the radioconjugates was verified both in vitro and in vivo.  Using the DOTAGA chelator gave significantly lower radioactivity in liver and blood for both radionuclides.  The 111In-labeled conjugates showed more rapid blood clearance than the 68Ga-labeled conjugates.  The most pronounced influence of the chelators was found when they were labeled with 68Ga.  The DOTAGA chelator gave significantly higher tumor-to-blood (61 Â± 6 vs 23 Â± 5, p < 0.05) and tumor-to-liver (10.4 Â± 0.6 vs 4.5 Â± 0.5, p < 0.05) ratios than the DOTA chelator.  This study demonstrated that chelators may be used to alter the uptake of Affibody mols., and most likely other scaffold-based imaging probes, for improvement of imaging contrast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFFpqluORn57Vg90H21EOLACvtfcHk0lg3jS12y-UevQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eisLw%253D&md5=45fffbc349b38abfbff0082752dd0e09</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00089%26sid%3Dliteratum%253Aachs%26aulast%3DWesterlund%26aufirst%3DK.%26aulast%3DHonarvar%26aufirst%3DH.%26aulast%3DNorrstr%25C3%25B6m%26aufirst%3DE.%26aulast%3DStrand%26aufirst%3DJ.%26aulast%3DMitran%26aufirst%3DB.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DEriksson%2BKarlstr%25C3%25B6m%26aufirst%3DA.%26aulast%3DTolmachev%26aufirst%3DV.%26atitle%3DIncreasing%2520the%2520Net%2520Negative%2520Charge%2520by%2520Replacement%2520of%2520DOTA%2520Chelator%2520with%2520DOTAGA%2520Improves%2520the%2520Biodistribution%2520of%2520Radiolabeled%2520Second-Generation%2520Synthetic%2520Affibody%2520Molecules%26jtitle%3DMol.%2520Pharm.%26date%3D2016%26volume%3D13%26spage%3D1668%26epage%3D1678%26doi%3D10.1021%2Facs.molpharmaceut.6b00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, M.-A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leppla, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, B.</span></span> <span> </span><span class="NLM_article-title">Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>72â73</i></span>,  <span class="NLM_fpage">49</span>â <span class="NLM_lpage">54</span>, <span class="refDoi">Â DOI: 10.1016/j.nucmedbio.2019.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.nucmedbio.2019.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=31330412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVajtrvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72%E2%80%9373&publication_year=2019&pages=49-54&author=M.-A.+E.+Xavierauthor=S.+Liuauthor=S.+H.+Lepplaauthor=B.+Cornelissen&title=Pre-labelling+versus+direct+labelling+of+anthrax+proteins+for+imaging+of+matrix+metalloproteinases+activity+using+DOTA-GA&doi=10.1016%2Fj.nucmedbio.2019.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA</span></div><div class="casAuthors">Xavier, Mary-Ann Elvina; Liu, Shihui; Leppla, Stephen H.; Cornelissen, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">72-73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-54</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Increased activity of matrix metalloproteases (MMPs) is assocd. with reduced survival in several cancer subtypes.  Aiming to produce an MMP tumor cell-selective cytotoxin, we genetically modified both components of the AB-type lethal toxin from Bacillus anthracis.  Component A, Protective Antigen (PA-WT), was re-engineered to form an oligomeric pore in cell membranes only when cleaved by MMPs (PA-L1).  The pore-translocation domain (LFn - N-terminal, 30 kDa) of the Lethal Factor (LF), component B, was fused to the catalytic domain of Pseudomonas exotoxin-A to increase its cytotoxic effect when delivered to cancerous cells.  Here, we develop radiolabeled forms of LFn for MMP activity imaging by SPECT using the LFn/PA-L1 system.  DOTA-GA-maleimide was conjugated to LFn to allow radiolabelling with 111In via two different routes: (1) LFn was conjugated with maleimide-DOTA-GA under mild conditions, and then radiolabeled in acidic conditions at 95Â°, or (2) 111In was coordinated to maleimide-DOTA-GA first and then conjugated via maleimide chem. to LFn.  CD Spectroscopy of LFn was performed to evaluate changes in its secondary structure.  Cell uptake assays using the differently labeled forms of [111In]In-DOTA-GA-LFn in the presence or not of PA-WT or PA-L1 were performed.  LFn was successfully radiolabeled by either strategy.  Comparison of the secondary structure content of LFn exposed to 37Â° or 95Â°, showed a loss of alpha helix content at higher temps.  Cell uptake of both forms of [111In]In-DOTA-GA-LFn, labeled directly or indirectly, was significantly higher in MMP-pos. cells, in the presence of PA-L1, compared to controls.  Notably, despite being exposed to high temps., uptake of directly labeled [111In]In-DOTA-GA-LFndir was higher than indirectly labeled [111In]In-DOTA-GA-LFnindir.111In-radiolabelling of LFn results in a functional mol. that targets MMP-activity in cells when combined with PA-L1. [111In]In-LFn/PA-L1 is a promising MMP activity imaging agent for SPECT imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX1h52JISJqrVg90H21EOLACvtfcHk0lg3jS12y-UevQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVajtrvL&md5=b0fe3c93663f949844c677d1c42613d8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2019.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2019.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DXavier%26aufirst%3DM.-A.%2BE.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLeppla%26aufirst%3DS.%2BH.%26aulast%3DCornelissen%26aufirst%3DB.%26atitle%3DPre-labelling%2520versus%2520direct%2520labelling%2520of%2520anthrax%2520proteins%2520for%2520imaging%2520of%2520matrix%2520metalloproteinases%2520activity%2520using%2520DOTA-GA%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2019%26volume%3D72%25E2%2580%259373%26spage%3D49%26epage%3D54%26doi%3D10.1016%2Fj.nucmedbio.2019.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrigneaud, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tizon, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchamp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunotte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denat, F.</span></span> <span> </span><span class="NLM_article-title">DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1181</span>â <span class="NLM_lpage">1188</span>, <span class="refDoi">Â DOI: 10.1021/bc200680x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc200680x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGjtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1181-1188&author=M.+Moreauauthor=O.+Raguinauthor=J.-M.+Vrigneaudauthor=B.+Collinauthor=C.+Bernhardauthor=X.+Tizonauthor=F.+Boschettiauthor=O.+Duchampauthor=F.+Brunotteauthor=F.+Denat&title=DOTAGA-trastuzumab.+A+new+antibody+conjugate+targeting+HER2%2FNeu+antigen+for+diagnostic+purposes&doi=10.1021%2Fbc200680x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/Neu Antigen for Diagnostic Purposes</span></div><div class="casAuthors">Moreau, Mathieu; Raguin, Olivier; Vrigneaud, Jean-Marc; Collin, Bertrand; Bernhard, Claire; Tizon, Xavier; Boschetti, Frederic; Duchamp, Olivier; Brunotte, Francois; Denat, Franck</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1181-1188</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Improved bifunctional chelating agents (BFC) are required for indium-111 radiolabeling of monoclonal antibodies (mAbs) under mild conditions to yield stable, target-specific agents. 2,2,2-(10-(2,6-Dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTAGA-anhydride) was evaluated for mAb conjugation and labeling with indium-111.  The DOTA analog was synthesized and conjugated to trastuzumab which targets the HER2/neu receptor in mild conditions (PBS pH 7.4, 25 C, 30 min) and gave a mean degree of conjugation of 2.6 macrocycle per antibody.  Labeling of this immunoconjugate with indium-111 was performed in 75% yield after 1 h at 37 C, and the proportion of 111In-DOTAGA-trastuzumab reached 97% after purifn.  The affinity of DOTAGA-trastuzumab was 5.5, 0.6 nM as evaluated by in vitro satn. assays using HCC1954 breast cancer cell line.  SPECT/CT imaging and biodistribution studies were performed in mice bearing breast cancer BT-474 xenografts.  BT-474 tumors were clearly visualized on SPECT images at 24, 48, and 72 h postinjection.  The tumor uptake of [111In-DOTAGA]-trastuzumab reached 65%ID/g 72 h postinjection.  These results show that the DOTAGA BFC appears to be a valuable tool for biologics conjugation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTIrhdIOo9bVg90H21EOLACvtfcHk0lhUBRnQlh73Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGjtLk%253D&md5=a2552569ece81de76b49e12f9ee8c393</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fbc200680x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc200680x%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DM.%26aulast%3DRaguin%26aufirst%3DO.%26aulast%3DVrigneaud%26aufirst%3DJ.-M.%26aulast%3DCollin%26aufirst%3DB.%26aulast%3DBernhard%26aufirst%3DC.%26aulast%3DTizon%26aufirst%3DX.%26aulast%3DBoschetti%26aufirst%3DF.%26aulast%3DDuchamp%26aufirst%3DO.%26aulast%3DBrunotte%26aufirst%3DF.%26aulast%3DDenat%26aufirst%3DF.%26atitle%3DDOTAGA-trastuzumab.%2520A%2520new%2520antibody%2520conjugate%2520targeting%2520HER2%252FNeu%2520antigen%2520for%2520diagnostic%2520purposes%26jtitle%3DBioconjugate%2520Chem.%26date%3D2012%26volume%3D23%26spage%3D1181%26epage%3D1188%26doi%3D10.1021%2Fbc200680x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisenwiener, K.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¤cke, H. R.</span></span> <span> </span><span class="NLM_article-title">A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2133</span>â <span class="NLM_lpage">2135</span>, <span class="refDoi">Â DOI: 10.1016/s0960-894x(00)00413-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2FS0960-894X%2800%2900413-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10999487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtF2ht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2133-2135&author=K.-P.+Eisenwienerauthor=P.+Powellauthor=H.+R.+M%C3%A4cke&title=A+convenient+synthesis+of+novel+bifunctional+prochelators+for+coupling+to+bioactive+peptides+for+radiometal+labelling&doi=10.1016%2Fs0960-894x%2800%2900413-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling</span></div><div class="casAuthors">Eisenwiener, K.-P.; Powell, P.; Macke, H. R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2133-2135</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">New DOTA-based bifunctional prochelators, e.g., 1-(1-carboxy-3-carbo-tert-butoxypropyl)-4,7,10-(carbo-tert-butoxymethyl)-1,4,7,10-tetraazacyclododecane [(DOTAGA(tBu)4), (I)] for a broad application in the modification of biomols. with metal ions were prepd.  The five-step synthesis of I has an overall yield of about 20%.  The coupling of I to a bioactive peptide on solid-phase was exemplified with use of a CCK-B (cholecystokinin) analog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo47vDF-IEqBLVg90H21EOLACvtfcHk0lhUBRnQlh73Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtF2ht7Y%253D&md5=9c1bfb2974398f7641d3292207dfb826</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900413-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900413-3%26sid%3Dliteratum%253Aachs%26aulast%3DEisenwiener%26aufirst%3DK.-P.%26aulast%3DPowell%26aufirst%3DP.%26aulast%3DM%25C3%25A4cke%26aufirst%3DH.%2BR.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520novel%2520bifunctional%2520prochelators%2520for%2520coupling%2520to%2520bioactive%2520peptides%2520for%2520radiometal%2520labelling%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2133%26epage%3D2135%26doi%3D10.1016%2Fs0960-894x%2800%2900413-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masugi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii-Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, M.</span></span> <span> </span><span class="NLM_article-title">Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">107</span>â <span class="NLM_lpage">119</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-20-2298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1158%2F1078-0432.CCR-20-2298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=33046515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BB3MXltlWjsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2021&pages=107-119&author=Y.+Ogawaauthor=Y.+Masugiauthor=T.+Abeauthor=K.+Yamazakiauthor=A.+Uenoauthor=Y.+Fujii-Nishimuraauthor=S.+Horiauthor=H.+Yagiauthor=Y.+Abeauthor=M.+Kitagoauthor=M.+Sakamoto&title=Three+distinct+stroma+types+in+human+pancreatic+cancer+identified+by+image+analysis+of+fibroblast+subpopulations+and+collagen&doi=10.1158%2F1078-0432.CCR-20-2298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen</span></div><div class="casAuthors">Ogawa, Yurina; Masugi, Yohei; Abe, Tokiya; Yamazaki, Ken; Ueno, Akihisa; Fujii-Nishimura, Yoko; Hori, Shutaro; Yagi, Hiroshi; Abe, Yuta; Kitago, Minoru; Sakamoto, Michiie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-119</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts have emerged to be highly heterogenous and can play multifaceted roles in dictating pancreatic ductal adenocarcinoma (PDAC) progression, immunosuppression, and therapeutic response, highlighting the need for a deeper understanding of stromal heterogeneity between patients and even within a single tumor.  We hypothesized that image anal. of fibroblast subpopulations and collagen in PDAC tissues might guide stroma-based patient stratification to predict clin. outcomes and tumor characteristics.  A novel multiplex IHC-based image anal. system was established to digitally differentiate fibroblast subpopulations.  Using whole-tissue slides from 215 treatment-naive PDACs, we performed concurrent quantification of principal fibroblast subpopulations and collagen and defined three stroma types: collagen-rich stroma, fibroblast activation protein Î± (FAP)-dominant fibroblast-rich stroma, and Î± smooth muscle actin (ACTA2)-dominant fibroblast-rich stroma.  These stroma types were assessed for the assocns. with cancer-specific survival by multivariable Cox regression analyses and with clinicopathol. factors, including CD8+ cell d.  FAP-dominant fibroblasts and ACTA2-dominant fibroblasts represented the principal distinct fibroblast subpopulations in tumor stroma.  Stroma types were assocd. with patient survival, SMAD4 status, and transcriptome signatures.  Compared with FAP-dominant fibroblast-rich stroma, collagen-rich stroma correlated with prolonged survival [HR, 0.57; 95% confidence interval (CI), 0.33-0.99], while ACTA2-dominant fibroblast-rich stroma exhibited poorer prognosis (HR, 1.65; 95% CI, 1.06-2.58).  FAP-dominant fibroblast-rich stroma was addnl. characterized by restricted CD8+ cell infiltrates and intense neutrophil infiltration.  This study identified three distinct stroma types differentially assocd. with survival, immunity, and mol. features, thereby underscoring the importance of stromal heterogeneity in subtyping pancreatic cancers and supporting the development of antistromal therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh2O8Xx8z2MrVg90H21EOLACvtfcHk0lhUBRnQlh73Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXltlWjsL0%253D&md5=9941c0409f3456873c9765c599a15f34</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-20-2298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-20-2298%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DMasugi%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DT.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DUeno%26aufirst%3DA.%26aulast%3DFujii-Nishimura%26aufirst%3DY.%26aulast%3DHori%26aufirst%3DS.%26aulast%3DYagi%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DKitago%26aufirst%3DM.%26aulast%3DSakamoto%26aufirst%3DM.%26atitle%3DThree%2520distinct%2520stroma%2520types%2520in%2520human%2520pancreatic%2520cancer%2520identified%2520by%2520image%2520analysis%2520of%2520fibroblast%2520subpopulations%2520and%2520collagen%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2021%26volume%3D27%26spage%3D107%26epage%3D119%26doi%3D10.1158%2F1078-0432.CCR-20-2298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryabtsova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Goethem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span> <span> </span><span class="NLM_article-title">Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3412</span>â <span class="NLM_lpage">3417</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.03.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.bmcl.2012.03.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22525314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFait7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3412-3417&author=O.+Ryabtsovaauthor=K.+Jansenauthor=S.+Van+Goethemauthor=J.+Joossensauthor=J.+D.+Chengauthor=A.-M.+Lambeirauthor=I.+De+Meesterauthor=K.+Augustynsauthor=P.+Van+der+Veken&title=Acylated+Gly-%282-cyano%29pyrrolidines+as+inhibitors+of+fibroblast+activation+protein+%28FAP%29+and+the+issue+of+FAP%2Fprolyl+oligopeptidase+%28PREP%29-selectivity&doi=10.1016%2Fj.bmcl.2012.03.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity</span></div><div class="casAuthors">Ryabtsova, Oxana; Jansen, Koen; Van Goethem, Sebastiaan; Joossens, Jurgen; Cheng, Jonathan D.; Lambeir, Anne-Marie; De Meester, Ingrid; Augustyns, Koen; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3412-3417</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N-acylated glycyl-(2-cyano)pyrrolidines were synthesized with the aim of generating structure-activity relationship (SAR) data for this class of compds. as inhibitors of fibroblast activation protein (FAP).  Specifically, the influence of (1) the choice of the N-acyl group and (2) structural modification of the 2-cyanopyrrolidine residue were investigated.  The inhibitors displayed inhibitory potency in the micromolar to nanomolar range and showed good to excellent selectivity with respect to the proline selective dipeptidyl peptidases (DPPs) DPP IV, DPP9 and DPP II.  Addnl., selectivity for FAP with respect to prolyl oligopeptidase (PREP) is reported.  Not unexpectedly, the latter data suggest significant overlap in the pharmacophoric features that define FAP or PREP-inhibitory activity and underscore the importance of systematically evaluating the FAP/PREP-selectivity index for inhibitors of either of these two enzymes.  Finally, this study forwards several compds. that can serve as leads or prototypic structures for future FAP-selective-inhibitor discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVTMe5wzszb7Vg90H21EOLACvtfcHk0li3sER0Q8OrJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFait7k%253D&md5=0191b3cbe44c893935a33e13f62e4289</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.107%26sid%3Dliteratum%253Aachs%26aulast%3DRyabtsova%26aufirst%3DO.%26aulast%3DJansen%26aufirst%3DK.%26aulast%3DVan%2BGoethem%26aufirst%3DS.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DAcylated%2520Gly-%25282-cyano%2529pyrrolidines%2520as%2520inhibitors%2520of%2520fibroblast%2520activation%2520protein%2520%2528FAP%2529%2520and%2520the%2520issue%2520of%2520FAP%252Fprolyl%2520oligopeptidase%2520%2528PREP%2529-selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3412%26epage%3D3417%26doi%3D10.1016%2Fj.bmcl.2012.03.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loktev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MarmÃ©, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1421</span>â <span class="NLM_lpage">1429</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.224469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.118.224469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30850501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntVensrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=1421-1429&author=A.+Loktevauthor=T.+Lindnerauthor=E.-M.+Burgerauthor=A.+Altmannauthor=F.+Gieselauthor=C.+Kratochwilauthor=J.+Debusauthor=F.+Marm%C3%A9author=D.+J%C3%A4gerauthor=W.+Mierauthor=U.+Haberkorn&title=Development+of+Fibroblast+Activation+Protein-Targeted+Radiotracers+with+Improved+Tumor+Retention&doi=10.2967%2Fjnumed.118.224469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of fibroblast activation protein-targeted radiotracers with improved tumor retention</span></div><div class="casAuthors">Loktev, Anastasia; Lindner, Thomas; Burger, Eva-Maria; Altmann, Annette; Giesel, Frederik; Kratochwil, Clemens; Debus, Jurgen; Marme, Frederik; Jager, Dirk; Mier, Walter; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1421-1429</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts constitute a vital subpopulation of the tumor stroma and are present in more than 90% of epithelial carcinomas.  Methods: Novel quinoline-based radiotracers were synthesized by org. chem. and evaluated in radioligand binding assays using FAP-expressing HT-1080 cells.  Depending on their in vitro performance, small-animal PET imaging and biodistribution studies were performed on HT-1080-FAP tumor- bearing mice.  The most promising compds. were used for clin. PET imaging in 8 cancer patients.  Results: Compared with FAPI-04, 11 of 15 FAPI derivs. showed improved FAP binding in vitro.  Of these, 7 compds. demonstrated increased tumor uptake in tumorbearing mice.  Moreover, tumor-to-normal-organ ratios were improved for most of the compds., resulting in images with higher contrast.  Notably two of the radiotracers, FAPI-21 and -46, displayed substantially improved ratios of tumor to blood, liver, muscle, and intestinal uptake.  A first diagnostic application in cancer patients revealed high intratumoral uptake of both radiotracers already 10 min after administration but a higher uptake in oral mucosa, salivary glands, and thyroid for FAPI-21.  Conclusion: Chem. modification of the FAPI framework enabled enhanced FAP binding and improved pharmacokinetics in most of the derivs., resulting in high-contrast images.  Moreover, higher doses of radioactivity can be delivered while minimizing damage to healthy tissue, which may improve therapeutic outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTKf0_vtMQ_LVg90H21EOLACvtfcHk0li3sER0Q8OrJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntVensrw%253D&md5=f99a22fa605f5f490c5f298c3649cc7a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.224469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.224469%26sid%3Dliteratum%253Aachs%26aulast%3DLoktev%26aufirst%3DA.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DBurger%26aufirst%3DE.-M.%26aulast%3DAltmann%26aufirst%3DA.%26aulast%3DGiesel%26aufirst%3DF.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DMarm%25C3%25A9%26aufirst%3DF.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DD.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DDevelopment%2520of%2520Fibroblast%2520Activation%2520Protein-Targeted%2520Radiotracers%2520with%2520Improved%2520Tumor%2520Retention%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D1421%26epage%3D1429%26doi%3D10.2967%2Fjnumed.118.224469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiori, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Franco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stassi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Maria, R.</span></span> <span> </span><span class="NLM_article-title">Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">70</span>, <span class="refDoi">Â DOI: 10.1186/s12943-019-0994-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1186%2Fs12943-019-0994-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30927908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A280%3ADC%252BB3cbpslKntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=70&author=M.+E.+Fioriauthor=S.+Di+Francoauthor=L.+Villanovaauthor=P.+Biancaauthor=G.+Stassiauthor=R.+De+Maria&title=Cancer-associated+fibroblasts+as+abettors+of+tumor+progression+at+the+crossroads+of+EMT+and+therapy+resistance&doi=10.1186%2Fs12943-019-0994-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance</span></div><div class="casAuthors">Fiori Micol Eleonora; Di Franco Simone; Bianca Paola; Stassi Giorgio; Villanova Lidia; De Maria Ruggero; De Maria Ruggero</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the last decades, the role of the microenvironment in tumor progression and therapeutic outcome has gained increasing attention.  Cancer-associated fibroblasts (CAFs) have emerged as key players among stromal cells, owing to their abundance in most solid tumors and their diverse tumor-restraining/promoting roles.  The interplay between tumor cells and neighboring CAFs takes place by both paracrine signals (cytokines, exosomes and metabolites) or by the multifaceted functions of the surrounding extracellular matrix.  Here, we dissect the most recent identified mechanisms underlying CAF-mediated control of tumor progression and therapy resistance, which include induction of the epithelial-to-mesenchymal transition (EMT), activation of survival pathways or stemness-related programs and metabolic reprogramming in tumor cells.  Importantly, the recently unveiled heterogeneity in CAFs claims tailored therapeutic efforts aimed at eradicating the specific subset facilitating tumor progression, therapy resistance and relapse.  However, despite the large amount of pre-clinical data, much effort is still needed to translate CAF-directed anti-cancer strategies from the bench to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKsAYahu6SM7jnyZkbE8yXfW6udTcc2eaW71M-FvPNB7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbpslKntA%253D%253D&md5=6f2b5842ae818720cc75b052682b3f86</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-0994-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-0994-2%26sid%3Dliteratum%253Aachs%26aulast%3DFiori%26aufirst%3DM.%2BE.%26aulast%3DDi%2BFranco%26aufirst%3DS.%26aulast%3DVillanova%26aufirst%3DL.%26aulast%3DBianca%26aufirst%3DP.%26aulast%3DStassi%26aufirst%3DG.%26aulast%3DDe%2BMaria%26aufirst%3DR.%26atitle%3DCancer-associated%2520fibroblasts%2520as%2520abettors%2520of%2520tumor%2520progression%2520at%2520the%2520crossroads%2520of%2520EMT%2520and%2520therapy%2520resistance%26jtitle%3DMol.%2520Canc.%26date%3D2019%26volume%3D18%26spage%3D70%26doi%3D10.1186%2Fs12943-019-0994-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RiviÃ¨re, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic T cell engineering</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>545</i></span>,  <span class="NLM_fpage">423</span>â <span class="NLM_lpage">431</span>, <span class="refDoi">Â DOI: 10.1038/nature22395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fnature22395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28541315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVansrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=545&publication_year=2017&pages=423-431&author=M.+Sadelainauthor=I.+Rivi%C3%A8reauthor=S.+Riddell&title=Therapeutic+T+cell+engineering&doi=10.1038%2Fnature22395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic T cell engineering</span></div><div class="casAuthors">Sadelain, Michel; Riviere, Isabelle; Riddell, Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">545</span>
        (<span class="NLM_cas:issue">7655</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer.  Chimaeric antigen receptors (CARs) are a class of synthetic receptors that reprogram lymphocyte specificity and function.  CARs targeting CD19 have demonstrated remarkable potency in B cell malignancies.  Engineered T cells are applicable in principle to many cancers, pending further progress to identify suitable target antigens, overcome immunosuppressive tumor microenvironments, reduce toxicities, and prevent antigen escape.  Advances in the selection of optimal T cells, genetic engineering, and cell manufg. are poised to broaden T-cell-based therapies and foster new applications in infectious diseases and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI3N4jSAIySrVg90H21EOLACvtfcHk0ljsoDyR0dgffQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVansrc%253D&md5=e24a6f8f572e211e1a54a2c7823e4aa8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnature22395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22395%26sid%3Dliteratum%253Aachs%26aulast%3DSadelain%26aufirst%3DM.%26aulast%3DRivi%25C3%25A8re%26aufirst%3DI.%26aulast%3DRiddell%26aufirst%3DS.%26atitle%3DTherapeutic%2520T%2520cell%2520engineering%26jtitle%3DNature%26date%3D2017%26volume%3D545%26spage%3D423%26epage%3D431%26doi%3D10.1038%2Fnature22395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation proteins-alpha suppress tumor immunity by regulating T cells and tumor-associated macrophages</span>. <i>Exp. Mol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">29</span>â <span class="NLM_lpage">37</span>, <span class="refDoi">Â DOI: 10.1016/j.yexmp.2017.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.yexmp.2017.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29273462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVaku7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2018&pages=29-37&author=C.+M.+Houauthor=X.+M.+Quauthor=J.+Zhangauthor=T.+T.+Dingauthor=W.+Hanauthor=G.+C.+Jiauthor=Z.+H.+Zhongauthor=H.+Chenauthor=F.+Zhang&title=Fibroblast+activation+proteins-alpha+suppress+tumor+immunity+by+regulating+T+cells+and+tumor-associated+macrophages&doi=10.1016%2Fj.yexmp.2017.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation proteins-Î± suppress tumor immunity by regulating T cells and tumor-associated macrophages</span></div><div class="casAuthors">Hou, Chun Mei; Qu, Xue Mei; Zhang, Jian; Ding, Ting Ting; Han, Wei; Ji, Guang Chuan; Zhong, Zhao Hua; Chen, He; Zhang, FengMin</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Pathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">EXMPA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4800</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Fibroblast activation protein-Î± (FAPÎ±) is a type-II cell-surface-bound integral transmembrane serine protease and selectively overexpressed by tumor-assocd. stromal fibroblasts (TAFs), which are the main components in the tumor microenvironment, in > 90% of malignant epithelial carcinomas.  FAPÎ± regulates the immunosuppression of tumor cells in the tumor microenvironment.  Regulatory T cells (Tregs) and tumor-assocd. macrophages (TAMs) are the major immunosuppressive cells in the tumor microenvironment.  However, the effect of FAPÎ± on Tregs and TAMs is unknown.  The non-enzymic function of FAPÎ± on Treg and TAM was investigated.  In this study, we confirm that FAPÎ± can promote the generation of Tregs and TAMs, which suggests that FAPÎ± plays a immunosuppressive role in the tumor microenvironment and provides evidence for FAP Î± as a potent immunotherapeutic target for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTTF5DKfldWLVg90H21EOLACvtfcHk0li_fmnKnnjpMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVaku7rK&md5=5e3178ac1261956c69a96a55db7547d7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.yexmp.2017.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexmp.2017.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DC.%2BM.%26aulast%3DQu%26aufirst%3DX.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DT.%2BT.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DG.%2BC.%26aulast%3DZhong%26aufirst%3DZ.%2BH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DF.%26atitle%3DFibroblast%2520activation%2520proteins-alpha%2520suppress%2520tumor%2520immunity%2520by%2520regulating%2520T%2520cells%2520and%2520tumor-associated%2520macrophages%26jtitle%3DExp.%2520Mol.%2520Pathol.%26date%3D2018%26volume%3D104%26spage%3D29%26epage%3D37%26doi%3D10.1016%2Fj.yexmp.2017.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>, <span class="refDoi">Â DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0li_fmnKnnjpMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LehÃ¡r, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonkin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monahan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morais, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korejwa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JanÃ©-Valbuena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mapa, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bric-Furlong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipway, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engels, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspesi, P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Silva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagtap, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palescandolo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sougnez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onofrio, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liefeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConaill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span> <span> </span><span class="NLM_article-title">The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>483</i></span>,  <span class="NLM_fpage">603</span>â <span class="NLM_lpage">607</span>, <span class="refDoi">Â DOI: 10.1038/nature11003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fnature11003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22460905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVequ7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=483&publication_year=2012&pages=603-607&author=J.+Barretinaauthor=G.+Caponigroauthor=N.+Stranskyauthor=K.+Venkatesanauthor=A.+A.+Margolinauthor=S.+Kimauthor=C.+J.+Wilsonauthor=J.+Leh%C3%A1rauthor=G.+V.+Kryukovauthor=D.+Sonkinauthor=A.+Reddyauthor=M.+Liuauthor=L.+Murrayauthor=M.+F.+Bergerauthor=J.+E.+Monahanauthor=P.+Moraisauthor=J.+Meltzerauthor=A.+Korejwaauthor=J.+Jan%C3%A9-Valbuenaauthor=F.+A.+Mapaauthor=J.+Thibaultauthor=E.+Bric-Furlongauthor=P.+Ramanauthor=A.+Shipwayauthor=I.+H.+Engelsauthor=J.+Chengauthor=G.+K.+Yuauthor=J.+Yuauthor=P.+Aspesiauthor=M.+de+Silvaauthor=K.+Jagtapauthor=M.+D.+Jonesauthor=L.+Wangauthor=C.+Hattonauthor=E.+Palescandoloauthor=S.+Guptaauthor=S.+Mahanauthor=C.+Sougnezauthor=R.+C.+Onofrioauthor=T.+Liefeldauthor=L.+MacConaillauthor=W.+Wincklerauthor=M.+Reichauthor=N.+Liauthor=J.+P.+Mesirovauthor=S.+B.+Gabrielauthor=G.+Getzauthor=K.+Ardlieauthor=V.+Chanauthor=V.+E.+Myerauthor=B.+L.+Weberauthor=J.+Porterauthor=M.+Warmuthauthor=P.+Finanauthor=J.+L.+Harrisauthor=M.+Meyersonauthor=T.+R.+Golubauthor=M.+P.+Morrisseyauthor=W.+R.+Sellersauthor=R.+Schlegelauthor=L.+A.+Garraway&title=The+Cancer+Cell+Line+Encyclopedia+enables+predictive+modelling+of+anticancer+drug+sensitivity&doi=10.1038%2Fnature11003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</span></div><div class="casAuthors">Barretina, Jordi; Caponigro, Giordano; Stransky, Nicolas; Venkatesan, Kavitha; Margolin, Adam A.; Kim, Sungjoon; Wilson, Christopher J.; Lehar, Joseph; Kryukov, Gregory V.; Sonkin, Dmitriy; Reddy, Anupama; Liu, Manway; Murray, Lauren; Berger, Michael F.; Monahan, John E.; Morais, Paula; Meltzer, Jodi; Korejwa, Adam; Jane-Valbuena, Judit; Mapa, Felipa A.; Thibault, Joseph; Bric-Furlong, Eva; Raman, Pichai; Shipway, Aaron; Engels, Ingo H.; Cheng, Jill; Yu, Guoying K.; Yu, Jianjun; Aspesi, Peter; de Silva, Melanie; Jagtap, Kalpana; Jones, Michael D.; Wang, Li; Hatton, Charles; Palescandolo, Emanuele; Gupta, Supriya; Mahan, Scott; Sougnez, Carrie; Onofrio, Robert C.; Liefeld, Ted; MacConaill, Laura; Winckler, Wendy; Reich, Michael; Li, Nanxin; Mesirov, Jill P.; Gabriel, Stacey B.; Getz, Gad; Ardlie, Kristin; Chan, Vivien; Myer, Vic E.; Weber, Barbara L.; Porter, Jeff; Warmuth, Markus; Finan, Peter; Harris, Jennifer L.; Meyerson, Matthew; Golub, Todd R.; Morrissey, Michael P.; Sellers, William R.; Schlegel, Robert; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">483</span>
        (<span class="NLM_cas:issue">7391</span>),
    <span class="NLM_cas:pages">603-607</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The systematic translation of cancer genomic data into knowledge of tumor biol. and therapeutic possibilities remains challenging.  Such efforts should be greatly aided by robust preclin. model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacol. annotation is available.  Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy no. and massively parallel sequencing data from 947 human cancer cell lines.  When coupled with pharmacol. profiles for 24 anticancer drugs across 479 of the cell lines, this collection allowed identification of genetic, lineage, and gene-expression-based predictors of drug sensitivity.  In addn. to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was assocd. with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors.  Together, our results indicate that large, annotated cell-line collections may help to enable preclin. stratification schemata for anticancer agents.  The generation of genetic predictions of drug response in the preclin. setting and their incorporation into cancer clin. trial design could speed the emergence of personalized' therapeutic regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHUeZ7mtYpwLVg90H21EOLACvtfcHk0li_fmnKnnjpMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVequ7o%253D&md5=4aefaa8c7abd1e30c35c4eeca811687b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnature11003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11003%26sid%3Dliteratum%253Aachs%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DMargolin%26aufirst%3DA.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKryukov%26aufirst%3DG.%2BV.%26aulast%3DSonkin%26aufirst%3DD.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DMonahan%26aufirst%3DJ.%2BE.%26aulast%3DMorais%26aufirst%3DP.%26aulast%3DMeltzer%26aufirst%3DJ.%26aulast%3DKorejwa%26aufirst%3DA.%26aulast%3DJan%25C3%25A9-Valbuena%26aufirst%3DJ.%26aulast%3DMapa%26aufirst%3DF.%2BA.%26aulast%3DThibault%26aufirst%3DJ.%26aulast%3DBric-Furlong%26aufirst%3DE.%26aulast%3DRaman%26aufirst%3DP.%26aulast%3DShipway%26aufirst%3DA.%26aulast%3DEngels%26aufirst%3DI.%2BH.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%2BK.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DAspesi%26aufirst%3DP.%26aulast%3Dde%2BSilva%26aufirst%3DM.%26aulast%3DJagtap%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DM.%2BD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DPalescandolo%26aufirst%3DE.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DMahan%26aufirst%3DS.%26aulast%3DSougnez%26aufirst%3DC.%26aulast%3DOnofrio%26aufirst%3DR.%2BC.%26aulast%3DLiefeld%26aufirst%3DT.%26aulast%3DMacConaill%26aufirst%3DL.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3DGabriel%26aufirst%3DS.%2BB.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DArdlie%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DPorter%26aufirst%3DJ.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DMorrissey%26aufirst%3DM.%2BP.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DThe%2520Cancer%2520Cell%2520Line%2520Encyclopedia%2520enables%2520predictive%2520modelling%2520of%2520anticancer%2520drug%2520sensitivity%26jtitle%3DNature%26date%3D2012%26volume%3D483%26spage%3D603%26epage%3D607%26doi%3D10.1038%2Fnature11003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repecka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDade, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haussler, D.</span></span> <span> </span><span class="NLM_article-title">The UCSC Xena platform for public and private cancer genomics data visualization and interpretation</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi">Â DOI: 10.1101/326470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1101%2F326470" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Goldmanauthor=B.+Craftauthor=M.+Hastieauthor=K.+Repeckaauthor=F.+McDadeauthor=A.+A.+Kamathauthor=A.+Banerjeeauthor=Y.+Luoauthor=D.+Rogersauthor=A.+Brooksauthor=J.+Zhuauthor=D.+Haussler&title=The+UCSC+Xena+platform+for+public+and+private+cancer+genomics+data+visualization+and+interpretation&doi=10.1101%2F326470"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1101%2F326470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F326470%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DM.%26aulast%3DCraft%26aufirst%3DB.%26aulast%3DHastie%26aufirst%3DM.%26aulast%3DRepecka%26aufirst%3DK.%26aulast%3DMcDade%26aufirst%3DF.%26aulast%3DKamath%26aufirst%3DA.%2BA.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DRogers%26aufirst%3DD.%26aulast%3DBrooks%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHaussler%26aufirst%3DD.%26atitle%3DThe%2520UCSC%2520Xena%2520platform%2520for%2520public%2520and%2520private%2520cancer%2520genomics%2520data%2520visualization%2520and%2520interpretation%26jtitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F326470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. FAP Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Synthesis of <b>QCP01</b> and <b>QCP02</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) glycine methyl ester hydrochloride, HOBt, HBTU, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, RT, 6 h, 76%; (b) 3-(Boc-amino) propyl bromide, Cs<sub>2</sub>CO<sub>3</sub>, DMF, RT, 16 h, 54%; (c) LiOH, H<sub>2</sub>O/THF, RT, 6 h, 99%; (d) (<i>S</i>)-pyrrolidine-2-carbonitrile hydrochloride, HOBt, HBTU, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, RT, 6 h, 80%; (e) TFA/CH<sub>2</sub>Cl<sub>2</sub>, RT, 1 h; (f) IRDye 800CW-NHS ester, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, RT, 2 h, 81% (total yield e and f); (g) 1. DOTA-GA(<i>t</i>-Bu)<sub>4</sub>-NHS, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, RT, 4 h, 2. TFA/H<sub>2</sub>O/TES, RT, 1 h, 35%.</p></p></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FAP expression in human cancers. FAP mRNA expression in human cancer cell lines from the CCLE (A) and in human primary tumors from TCGA (B) was analyzed. FAP mRNA expression in primary tumors and normal tissues from TCGA data was also analyzed (C); NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer; DLBCL = diffuse large B-cell lymphoma; AML = acute myeloid leukemia; CML = chronic myelogenous leukemia; PAAD = pancreatic cancer; BRCA = breast cancer; MESO = mesothelioma; HNSC = head and neck cancer; LUAD = lung adenocarcinoma; LUSC = lung squamous cell carcinoma; STAD = stomach cancer; UCS = uterine carcinosarcoma; ESCA = esophageal cancer; READ = rectal cancer; DLBC = large-B-cell lymphoma; COAD = colon cancer; SKCM = melanoma; CHOL = bile duct cancer; BLCA = bladder cancer; CESC = cervical cancer; UCEC = endometrioid cancer; OV = ovarian cancer; KIRC = kidney clear cell carcinoma; TGCT = testicular cancer; THCA = thyroid cancer; GBM = glioblastoma; PRAD = prostate cancer; ACC = adrenocortical cancer; PCPG = pheochomocytoma; LIHC = liver cancer; LGG = lower-grade glioma; KIRP = kidney papillary cell carcinoma; UVM = ocular melanomas; KICH = kidney chromophobe; THYM = thymoma; LAML = acute myeloid leukemia.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>In vitro</i> binding and specificity of <b>QCP01</b> and [<sup>111</sup>In]<b>QCP02</b>. (A) Cells incubated with various concentrations (range: 50â0.78 nM) of <b>QCP01</b> were imaged with the LI-COR Pearl Impulse Imager to assess binding of the agent in various FAP-positive (+) and FAP-negative (â) cell lines (left). Doseâresponse curves of <b>QCP01</b> binding in FAP-positive cell lines (NCIH2228, U87, and SKMEL24) and FAP-negative cell lines (PC3, NCIH226, and HCT116) were generated (right). (B) Cells were incubated with 0.037 MBq [<sup>111</sup>In]<b>QCP02</b> and were washed with cold phosphate-buffered saline (PBS). The radioactivity of the cell pellets was measured and normalized to the incubated dose; ****, <i>P</i> < 0.0001. (C) Cells incubated with 25 nM <b>QCP01</b> were incubated with various concentrations of either a DPP-IV and FAP inhibitor, Val-boroPro, or a DPPIV-only inhibitor, sitagliptin. The binding of <b>QCP01</b> was measured, and semi-log inhibitorâresponse curves were generated for both Val-boroPro (left) and sitagliptin (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. NIRF imaging of <b>QCP01</b> in a tumor-bearing mouse. NOD/SCID mice bearing FAP-positive U87 (red) and FAP-negative PC3 (white) tumor xenografts (<i>n</i> = 4) were injected with 5 nmol of <b>QCP01</b><i>via</i> the tail vein, followed by serial NIRF imaging on the LI-COR Pearl Impulse Imager. Representative images of <b>QCP01</b> full body (left) distribution at 5 h after injection and organ-specific (right) distribution at 5, 24, and 48 h after injection are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/medium/jm0c02171_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Serial SPECT-CT imaging of [<sup>111</sup>In]<b>QCP02</b> in a tumor-bearing mouse. A NOD/SCID mouse bearing FAP-positive U87 (red) and FAP-negative PC3 (blue) tumor xenografts was injected with 7.4 MBq [<sup>111</sup>In]<b>QCP02</b><i>via</i> the tail vein, followed by serial SPECT-CT imaging. Representative three-dimensional SPECT-CT images  at various time points after injection (1, 3, 6, 10, and 28 h) are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02171/20210331/images/large/jm0c02171_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02171&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55262" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55262" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pure, E.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein in remodeling tissues</span>. <i>Curr. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1220</span>â <span class="NLM_lpage">1243</span>, <span class="refDoi">Â DOI: 10.2174/156652412803833607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2174%2F156652412803833607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22834826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVSltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1220-1243&author=M.+Jacobauthor=L.+Changauthor=E.+Pure&title=Fibroblast+activation+protein+in+remodeling+tissues&doi=10.2174%2F156652412803833607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein in remodeling tissues</span></div><div class="casAuthors">Jacob, M.; Chang, L.; Pure, E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1220-1243</span>CODEN:
                <span class="NLM_cas:coden">CMMUBP</span>;
        ISSN:<span class="NLM_cas:issn">1566-5240</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tissue remodeling is crit. during development and wound healing.  It also characterizes a no. of pathol. conditions, including chronic inflammation, fibrosis and cancer.  It is well appreciated that reactive stromal cells play crit. roles in these settings.  However, understanding of the mechanisms involved in the differentiation of reactive stromal cells and their biol. activities has been hampered by the fact that they are generated from diverse progenitors, and by their phenotypic and function heterogeneity.  Furthermore, mol. markers that are expressed by all reactive stromal cells and that distinguish them from all other cell types have been lacking.  Fibroblast activation protein (FAP) is a serine protease that was originally discovered as a cell surface protein expressed on astrocytomas and sarcomas.  Over the last two decades, FAP has attracted increasing attention as a selective marker of carcinoma-assocd. fibroblasts (CAFs) and more broadly, of activated fibroblasts in tissues undergoing remodeling of their extracellular matrix (ECM) due to chronic inflammation, fibrosis or wound healing.  Herein we review the evidence that FAP is indeed a robust and selective marker for reactive mesenchymal stromal cells assocd. with pathophysiol. tissue remodeling.  We also review recent insights obtained using FAP as a tool to define the relationship between subpopulations of reactive stromal cells in various settings of tissue remodeling.  Furthermore, we review recent genetic and pharmacol. data indicating that FAP and FAP-expressing cells play important roles in such conditions.  Finally, we discuss the potential risks and therapeutic benefits of targeting FAP and FAP-expressing cells, as well as approaches to do so.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW5D-MzwCIN7Vg90H21EOLACvtfcHk0liaRcQPfXq6Fg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVSltg%253D%253D&md5=edb22a8c889e95e97b9e023530274a43</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F156652412803833607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156652412803833607%26sid%3Dliteratum%253Aachs%26aulast%3DJacob%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DPure%26aufirst%3DE.%26atitle%3DFibroblast%2520activation%2520protein%2520in%2520remodeling%2520tissues%26jtitle%3DCurr.%2520Mol.%2520Med.%26date%3D2012%26volume%3D12%26spage%3D1220%26epage%3D1243%26doi%3D10.2174%2F156652412803833607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PurÃ©, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomberg, R.</span></span> <span> </span><span class="NLM_article-title">Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4343</span>â <span class="NLM_lpage">4357</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0275-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fs41388-018-0275-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29720723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVCqtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=4343-4357&author=E.+Pur%C3%A9author=R.+Blomberg&title=Pro-tumorigenic+roles+of+fibroblast+activation+protein+in+cancer%3A+back+to+the+basics&doi=10.1038%2Fs41388-018-0275-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics</span></div><div class="casAuthors">Pure, Ellen; Blomberg, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4343-4357</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components.  FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma.  It has also been proposed as a mol. target of cancer therapies, and, esp. in recent years, a great deal of research has gone into design and testing of diverse FAP-targeted treatments.  Yet despite this growing field of research, our knowledge of FAP's basic biol. and functional roles in various cancers has lagged behind its use as a tumor-stromal marker.  In this review, we summarize and analyze recent advances in understanding the functions of FAP in cancer, most notably its prognostic value in various tumor types, cellular effects on various cell types, and potential as a therapeutic target.  We highlight outstanding questions in the field, the answers to which could shape preclin. and clin. studies of FAP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-SoG71uv287Vg90H21EOLACvtfcHk0lihZTs8FPo_aA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVCqtLg%253D&md5=840fdb5e306b61906acb0c24755f5a2d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0275-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0275-3%26sid%3Dliteratum%253Aachs%26aulast%3DPur%25C3%25A9%26aufirst%3DE.%26aulast%3DBlomberg%26aufirst%3DR.%26atitle%3DPro-tumorigenic%2520roles%2520of%2520fibroblast%2520activation%2520protein%2520in%2520cancer%253A%2520back%2520to%2520the%2520basics%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D4343%26epage%3D4357%26doi%3D10.1038%2Fs41388-018-0275-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiraja, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, K.</span></span> <span> </span><span class="NLM_article-title">Near-Infrared Fluorescent Molecular Probe for Sensitive Imaging of Keloid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1256</span>â <span class="NLM_lpage">1260</span>, <span class="refDoi">Â DOI: 10.1002/anie.201710727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1002%2Fanie.201710727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1ersw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1256-1260&author=Q.+Miaoauthor=D.+C.+Yeoauthor=C.+Wirajaauthor=J.+Zhangauthor=X.+Ningauthor=C.+Xuauthor=K.+Pu&title=Near-Infrared+Fluorescent+Molecular+Probe+for+Sensitive+Imaging+of+Keloid&doi=10.1002%2Fanie.201710727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Near-Infrared Fluorescent Molecular Probe for Sensitive Imaging of Keloid</span></div><div class="casAuthors">Miao, Qingqing; Yeo, David C.; Wiraja, Christian; Zhang, Jianjian; Ning, Xiaoyu; Xu, Chenjie; Pu, Kanyi</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1256-1260</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Early detection of skin diseases is imperative for their effective treatment.  However, fluorescence mol. probes that allow this are rare.  The first activatable near-IR (NIR) fluorescent mol. probe is reported for sensitive imaging of keloid cells, skin cells from abnormal scar fibrous lesions.  As keloid cells have high expression levels of fibroblast activation protein-alpha (FAPÎ±), the probe (FNP1) is designed to have a caged NIR dye and a FAPÎ±-cleavable peptide substrate linked by a self-immolative segment.  FNP1 can quickly and specifically turn on its fluorescence at 710 nm by 45-fold in the presence of FAPÎ±, allowing it to effectively recognize keloid cells from normal skin cells.  Integration of FNP1 with a simple microneedle-assisted topical application enables sensitive detection of keloid cells in metabolically-active human skin tissue with a theor. limit of detection down to 20 000 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAYD4nFFZGgLVg90H21EOLACvtfcHk0lihZTs8FPo_aA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1ersw%253D%253D&md5=55b46295ecd424d14123d5ab5939a0e0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710727%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DQ.%26aulast%3DYeo%26aufirst%3DD.%2BC.%26aulast%3DWiraja%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DPu%26aufirst%3DK.%26atitle%3DNear-Infrared%2520Fluorescent%2520Molecular%2520Probe%2520for%2520Sensitive%2520Imaging%2520of%2520Keloid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D1256%26epage%3D1260%26doi%3D10.1002%2Fanie.201710727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Geest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeleveld, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgreen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helsen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metselaar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berg, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Kraan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laverman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerman, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenders, M. I.</span></span> <span> </span><span class="NLM_article-title">Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">737</span>â <span class="NLM_lpage">747</span>, <span class="refDoi">Â DOI: 10.1093/rheumatology/kex456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1093%2Frheumatology%2Fkex456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29361119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpslyis7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=737-747&author=T.+van%0Ader+Geestauthor=D.+M.+Roeleveldauthor=B.+Walgreenauthor=M.+M.+Helsenauthor=T.+K.+Nayakauthor=C.+Kleinauthor=M.+Hegenauthor=G.+Stormauthor=J.+M.+Metselaarauthor=W.+B.+van+den+Bergauthor=P.+M.+van+der+Kraanauthor=P.+Lavermanauthor=O.+C.+Boermanauthor=M.+I.+Koenders&title=Imaging+fibroblast+activation+protein+to+monitor+therapeutic+effects+of+neutralizing+interleukin-22+in+collagen-induced+arthritis&doi=10.1093%2Frheumatology%2Fkex456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis</span></div><div class="casAuthors">van der Geest, Tessa; Roeleveld, Debbie M.; Walgreen, Birgitte; Helsen, Monique M.; Nayak, Tapan K.; Klein, Christian; Hegen, Martin; Storm, Gert; Metselaar, Josbert M.; van den Berg, Wim B.; van den Kraan, Peter M.; Laverman, Peter; Boerman, Otto C.; Koenders, Marije I.</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">737-747</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0332</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: RA is a chronic autoimmune disease leading to progressive destruction of cartilage and bone.  RA patients show elevated IL-22 levels and the amt. of IL-22-producing Th cells pos. correlates with the extent of erosive disease, suggesting a role for this cytokine in RA pathogenesis.  The purpose of this study was to det. the feasibility of SPECT/CT imaging with 111In-labeled anti-fibroblast activation protein antibody (28H1) to monitor the therapeutic effect of neutralizing IL-22 in exptl. arthritis.  Methods: Mice (six mice/group) with CIA received anti-IL-22 or isotype control antibodies.  To monitor therapeutic effects after treatment, SPECT/CT images were acquired 24 h after injection of 111In-28H1.  Imaging results were compared with macroscopic, histol. and radiog. arthritis scores.  Results: Neutralizing IL-22 before CIA onset effectively prevented arthritis development, reaching a disease incidence of only 50%, vs 100% in the control group.  SPECT imaging showed significantly lower joint tracer uptake in mice treated early with anti-IL-22 antibodies compared with the control-treated group.  Redn. of disease activity in those mice was confirmed by macroscopic, histol. and radiog. pathol. scores.  However, when treatment was initiated in a later phase of CIA, progression of joint pathol. could not be prevented.  Conclusions: These findings suggest that IL-22 plays an important role in CIA development, and neutralizing this cytokine seems an attractive new strategy in RA treatment.  Most importantly, SPECT/CT imaging with 111In-28H1 can be used to specifically monitor therapy responses, and is potentially more sensitive in disease monitoring than the gold std. method of macroscopic arthritis scoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYJDeedA0jlbVg90H21EOLACvtfcHk0lihZTs8FPo_aA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpslyis7g%253D&md5=969ce3d26f81ba3b58225f0386d484a2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkex456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkex456%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BGeest%26aufirst%3DT.%26aulast%3DRoeleveld%26aufirst%3DD.%2BM.%26aulast%3DWalgreen%26aufirst%3DB.%26aulast%3DHelsen%26aufirst%3DM.%2BM.%26aulast%3DNayak%26aufirst%3DT.%2BK.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DStorm%26aufirst%3DG.%26aulast%3DMetselaar%26aufirst%3DJ.%2BM.%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DW.%2BB.%26aulast%3Dvan%2Bder%2BKraan%26aufirst%3DP.%2BM.%26aulast%3DLaverman%26aufirst%3DP.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26aulast%3DKoenders%26aufirst%3DM.%2BI.%26atitle%3DImaging%2520fibroblast%2520activation%2520protein%2520to%2520monitor%2520therapeutic%2520effects%2520of%2520neutralizing%2520interleukin-22%2520in%2520collagen-induced%2520arthritis%26jtitle%3DRheumatology%26date%3D2018%26volume%3D57%26spage%3D737%26epage%3D747%26doi%3D10.1093%2Frheumatology%2Fkex456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadvi, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaughan, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrell, M. D.</span></span> <span> </span><span class="NLM_article-title">The dipeptidyl peptidase IV family in cancer and cell biology</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">1126</span>â <span class="NLM_lpage">1144</span>, <span class="refDoi">Â DOI: 10.1111/j.1742-4658.2009.07526.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1111%2Fj.1742-4658.2009.07526.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=20074209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVSmtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2010&pages=1126-1144&author=D.+M.+T.+Yuauthor=T.-W.+Yaoauthor=S.+Chowdhuryauthor=N.+A.+Nadviauthor=B.+Osborneauthor=W.+B.+Churchauthor=G.+W.+McCaughanauthor=M.+D.+Gorrell&title=The+dipeptidyl+peptidase+IV+family+in+cancer+and+cell+biology&doi=10.1111%2Fj.1742-4658.2009.07526.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The dipeptidyl peptidase IV family in cancer and cell biology</span></div><div class="casAuthors">Yu, Denise M. T.; Yao, Tsun-Wen; Chowdhury, Sumaiya; Nadvi, Naveed A.; Osborne, Brenna; Church, W. Bret; McCaughan, Geoffrey W.; Gorrell, Mark D.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1126-1144</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Of the 600+ known proteases identified to date in mammals, a significant percentage is involved or implicated in pathogenic and cancer processes.  The dipeptidyl peptidase IV (DPIV) gene family, comprising 4 enzyme members [DPIV (EC 3.4.14.5), fibroblast activation protein, DP8 and DP9] and 2 non-enzyme members [DP6 (DPL1) and DP10 (DPL2)], are interesting in this regard because of their multiple diverse functions, varying patterns of distribution/localization and subtle, but significant, differences in structure/substrate recognition.  In addn., their engagement in cell biol. processes involves both enzymic and nonenzymic capabilities.  Here, the authors examine, in detail, the current understanding of the biol. involvement of this unique enzyme family and their overall potential as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEodr7pwXK6LVg90H21EOLACvtfcHk0ljSDo4xs9_f3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVSmtr8%253D&md5=4c1423e97c4688e223982737ebe76d2d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2009.07526.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2009.07526.x%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DD.%2BM.%2BT.%26aulast%3DYao%26aufirst%3DT.-W.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DNadvi%26aufirst%3DN.%2BA.%26aulast%3DOsborne%26aufirst%3DB.%26aulast%3DChurch%26aufirst%3DW.%2BB.%26aulast%3DMcCaughan%26aufirst%3DG.%2BW.%26aulast%3DGorrell%26aufirst%3DM.%2BD.%26atitle%3DThe%2520dipeptidyl%2520peptidase%2520IV%2520family%2520in%2520cancer%2520and%2520cell%2520biology%26jtitle%3DFEBS%2520J.%26date%3D2010%26volume%3D277%26spage%3D1126%26epage%3D1144%26doi%3D10.1111%2Fj.1742-4658.2009.07526.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brennen, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denmeade, S. R.</span></span> <span> </span><span class="NLM_article-title">Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">257</span>â <span class="NLM_lpage">266</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-11-0340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1158%2F1535-7163.MCT-11-0340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22323494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWlt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=257-266&author=W.+N.+Brennenauthor=J.+T.+Isaacsauthor=S.+R.+Denmeade&title=Rationale+behind+targeting+fibroblast+activation+protein-expressing+carcinoma-associated+fibroblasts+as+a+novel+chemotherapeutic+strategy&doi=10.1158%2F1535-7163.mct-11-0340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale Behind Targeting Fibroblast Activation Protein-Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy</span></div><div class="casAuthors">Brennen, W. Nathaniel; Isaacs, John T.; Denmeade, Samuel R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-266</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The tumor microenvironment has emerged as a novel chemotherapeutic strategy in the treatment of cancer.  This is most clearly exemplified by the antiangiogenesis class of compds.  Therapeutic strategies that target fibroblasts within the tumor stroma offer another treatment option.  However, despite promising data obtained in preclin. models, such strategies have not been widely used in the clin. setting, largely due to a lack of effective treatments that specifically target this population of cells.  The identification of fibroblast activation protein Î± (FAP) as a target selectively expressed on fibroblasts within the tumor stroma or on carcinoma-assocd. fibroblasts led to intensive efforts to exploit this novel cellular target for clin. benefit.  FAP is a membrane-bound serine protease of the prolyl oligopeptidase family with unique post-prolyl endopeptidase activity.  Until recently, the majority of FAP-based therapeutic approaches focused on the development of small-mol. inhibitors of enzymic activity.  Evidence suggests, however, that FAP's pathophysiol. role in carcinogenesis may be highly contextual, depending on both the exact nature of the tumor microenvironment present and the cancer type in question to det. its tumor-promoting or tumor-suppressing phenotype.  As an alternative strategy, we are taking advantage of FAP's restricted expression and unique substrate preferences to develop a FAP-activated prodrug to target the activation of a cytotoxic compd. within the tumor stroma.  Of note, this strategy would be effective independently of FAP's role in tumor progression because its therapeutic benefit would rely on FAP's localization and activity within the tumor microenvironment rather than strictly on inhibition of its function.  Mol Cancer Ther; 11(2); 257-66.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIsKiWvE8RALVg90H21EOLACvtfcHk0ljSDo4xs9_f3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWlt7o%253D&md5=3eaf9c277128da6a1b0d042033da92ab</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0340%26sid%3Dliteratum%253Aachs%26aulast%3DBrennen%26aufirst%3DW.%2BN.%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26aulast%3DDenmeade%26aufirst%3DS.%2BR.%26atitle%3DRationale%2520behind%2520targeting%2520fibroblast%2520activation%2520protein-expressing%2520carcinoma-associated%2520fibroblasts%2520as%2520a%2520novel%2520chemotherapeutic%2520strategy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D257%26epage%3D266%26doi%3D10.1158%2F1535-7163.mct-11-0340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waumans, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baerts, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehoe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span> <span> </span><span class="NLM_article-title">The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">387</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2015.00387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.3389%2Ffimmu.2015.00387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=26300881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=387&author=Y.+Waumansauthor=L.+Baertsauthor=K.+Kehoeauthor=A.+M.+Lambeirauthor=I.+De+Meester&title=The+Dipeptidyl+Peptidase+Family%2C+Prolyl+Oligopeptidase%2C+and+Prolyl+Carboxypeptidase+in+the+Immune+System+and+Inflammatory+Disease%2C+Including+Atherosclerosis&doi=10.3389%2Ffimmu.2015.00387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis</span></div><div class="casAuthors">Waumans, Yannick; Baerts, Lesley; Kehoe, Kaat; Lambeir, Anne-Marie; De Meester, Ingrid</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">387/1-387/18</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Research from over the past 20 years has implicated dipeptidyl peptidase (DPP) IV and its family members in many processes and different pathologies of the immune system.  Most research has been focused on either DPPIV or just a few of its family members.  It is, however, essential to consider the entire DPP family when discussing any one of its members.  There is a substantial overlap between family members in their substrate specificity, inhibitors, and functions.  In this review, we provide a comprehensive discussion on the role of prolyl-specific peptidases DPPIV, FAP, DPP8, DPP9, dipeptidyl peptidase II, prolyl carboxypeptidase, and prolyl oligopeptidase in the immune system and its diseases.  We highlight possible therapeutic targets for the prevention and treatment of atherosclerosis, a condition that lies at the frontier between inflammation and cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB98L7gAzAqrVg90H21EOLACvtfcHk0lic0xZ10SNkcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurjN&md5=6bb76e8a88d4cd20fec0e7707bd7865d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2015.00387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2015.00387%26sid%3Dliteratum%253Aachs%26aulast%3DWaumans%26aufirst%3DY.%26aulast%3DBaerts%26aufirst%3DL.%26aulast%3DKehoe%26aufirst%3DK.%26aulast%3DLambeir%26aufirst%3DA.%2BM.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26atitle%3DThe%2520Dipeptidyl%2520Peptidase%2520Family%252C%2520Prolyl%2520Oligopeptidase%252C%2520and%2520Prolyl%2520Carboxypeptidase%2520in%2520the%2520Immune%2520System%2520and%2520Inflammatory%2520Disease%252C%2520Including%2520Atherosclerosis%26jtitle%3DFront.%2520Immunol.%26date%3D2015%26volume%3D6%26spage%3D387%26doi%3D10.3389%2Ffimmu.2015.00387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span> <span> </span><span class="NLM_article-title">Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1447</span>â <span class="NLM_lpage">1463</span>, <span class="refDoi">Â DOI: 10.2174/156802611795860933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2174%2F156802611795860933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=21510839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOrtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1447-1463&author=S.-J.+Chenauthor=W.-T.+Jiaang&title=Current+advances+and+therapeutic+potential+of+agents+targeting+dipeptidyl+peptidases-IV%2C+-II%2C+8%2F9+and+fibroblast+activation+protein&doi=10.2174%2F156802611795860933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein</span></div><div class="casAuthors">Chen, Shu-Jen; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1447-1463</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Dipeptidyl peptidase-IV (DPP-IV), a serine protease that specifically cleaves the N-terminal dipeptide with a preference for L-proline or L-alanine at the penultimate position, is involved in the degrdn. of incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).  GLP-1 regulates glucose homeostasis by stimulating insulin secretion, inhibiting glucagon release, and delaying gastric emptying.  I.v. GLP-1 has been shown to increase insulin secretion in response to elevated glucose levels and offers therapeutic benefit for patients with type 2 diabetes.  However, the therapeutic application of GLP-1 is severely compromised by its lack of oral activity and its rapid degrdn. by plasma DPP-IV.  Consequently, small-mol. DPP-IV inhibitors that could extend the duration of action of GLP-1 and prolong its beneficial effects were investigated as promising therapeutics for type 2 diabetes.  This review summarizes important structural classes of DPP-IV inhibitors, focusing mainly on their inhibitory potency and selectivity for DPP-IV over other related peptidases such as DPP-II, DPP8, DPP9, and FAP.  Because inhibition of DPP8 and/or DPP9 has been shown to cause severe toxicity in preclin. species, high selectivity is an important criterion in selecting DPP-IV inhibitors for clin. development.  As of today, several DPP-IV inhibitors have completed phase III clin. studies for the treatment of type 2 diabetes.  A brief overview of clin. efficacy data on these inhibitor drugs is provided here.  In addn., biol. activities of other related dipeptidyl peptidases (DPP-II, DPP8, DPP9, and FAP) will be summarized.  Selective inhibitors for these peptidases and their therapeutic potential will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ5h8U-FUCG7Vg90H21EOLACvtfcHk0lic0xZ10SNkcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOrtbs%253D&md5=45b5edc768d45d2e62e6588c334bdcdb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F156802611795860933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795860933%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DJiaang%26aufirst%3DW.-T.%26atitle%3DCurrent%2520advances%2520and%2520therapeutic%2520potential%2520of%2520agents%2520targeting%2520dipeptidyl%2520peptidases-IV%252C%2520-II%252C%25208%252F9%2520and%2520fibroblast%2520activation%2520protein%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1447%26epage%3D1463%26doi%3D10.2174%2F156802611795860933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafelmeyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein-alpha in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">977</span>â <span class="NLM_lpage">991</span>, <span class="refDoi">Â DOI: 10.1080/14728222.2017.1370455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1080%2F14728222.2017.1370455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28829211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVarsLvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=977-991&author=L.+Juillerat-Jeanneretauthor=P.+Tafelmeyerauthor=D.+Golshayan&title=Fibroblast+activation+protein-alpha+in+fibrogenic+disorders+and+cancer%3A+more+than+a+prolyl-specific+peptidase%3F&doi=10.1080%2F14728222.2017.1370455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein-Î± in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne; Tafelmeyer, Petra; Golshayan, Dela</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">977-991</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Fibroblast activation protein-Î± (FAP-Î±) belongs to the family of prolyl-specific serine proteases.  FAP-Î± displays both exopeptidase and endopeptidase/gelatinase/collagenase activities.  FAP-Î± protein and/or activity have been assocd. with fibrosis, inflammation and cancer, but the protein is undetectable in most normal tissues.  FAP-Î± is selectively expressed at sites of tissue remodeling and repair and enhances tumor progression, suggesting that this protease may be a therapeutic target to treat human disorders assocd. with fibrotic dysregulation.  In this review, we summarize the mechanisms driving tissue fibrosis and describe some of the enzymes involved in fibrosis, concg. on FAP-Î±.  We describe its enzymic properties, discuss the tools developed to control its activity and the problem of selectivity toward the other proteases of the family and outline its potential biol. substrates.  We also consider non-enzymic functions of this protein and suggest that repression of FAP-Î± expression may represent therapeutic options.  Questions remain regarding the biol. functions of FAP-Î±, either dependent or independent of its enzyme activity.  However, as progress is underway to develop FAP-Î±-specific inhibitors and therapeutic antibodies, its role in diseases assocd. with fibrosis is starting to emerge, ultimately leading to novel therapeutic options for inflammatory and oncol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcbPSAqAMjn7Vg90H21EOLACvtfcHk0liviwxYuwwNRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVarsLvJ&md5=596669985733b4eb79e68a66031f7e7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1080%2F14728222.2017.1370455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2017.1370455%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DTafelmeyer%26aufirst%3DP.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DFibroblast%2520activation%2520protein-alpha%2520in%2520fibrogenic%2520disorders%2520and%2520cancer%253A%2520more%2520than%2520a%2520prolyl-specific%2520peptidase%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2017%26volume%3D21%26spage%3D977%26epage%3D991%26doi%3D10.1080%2F14728222.2017.1370455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yazbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenisch, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, C. A.</span></span> <span> </span><span class="NLM_article-title">Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein</span>. <i>Protoplasma</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">375</span>â <span class="NLM_lpage">386</span>, <span class="refDoi">Â DOI: 10.1007/s00709-017-1129-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1007%2Fs00709-017-1129-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28620698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjs7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2018&pages=375-386&author=R.+Yazbeckauthor=S.+E.+Jaenischauthor=C.+A.+Abbott&title=Potential+disease+biomarkers%3A+dipeptidyl+peptidase+4+and+fibroblast+activation+protein&doi=10.1007%2Fs00709-017-1129-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein</span></div><div class="casAuthors">Yazbeck, Roger; Jaenisch, Simone E.; Abbott, Catherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Protoplasma</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">375-386</span>CODEN:
                <span class="NLM_cas:coden">PROTA5</span>;
        ISSN:<span class="NLM_cas:issn">0033-183X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">The importance of the dipeptidyl peptidase 4 (DPP4) gene family in regulating crit. biochem. pathways continues to emerge.  The two most well-studied members of the family, DPP4 and fibroblast activation protein (FAP), have been investigated both as therapeutic targets for disease and as diagnostic biomarkers.  The interest in DPP4 and FAP as potential disease biomarkers has been driven primarily by observations of altered expression profiles in inflammatory diseases and cancer.  Furthermore, the stability and persistence of sol. DPP4 and FAP in the serum make them attractive candidate serol. markers.  This review summarizes investigations into DPP4 and FAP as biomarkers of autoimmune disease, gut inflammation, psychosomatic disorders and malignancy and discusses their potential likelihood as clin. useful tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4SrnDaedoG7Vg90H21EOLACvtfcHk0liviwxYuwwNRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjs7zI&md5=f931d730985cc3b3e889c692d9fa5bda</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00709-017-1129-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00709-017-1129-5%26sid%3Dliteratum%253Aachs%26aulast%3DYazbeck%26aufirst%3DR.%26aulast%3DJaenisch%26aufirst%3DS.%2BE.%26aulast%3DAbbott%26aufirst%3DC.%2BA.%26atitle%3DPotential%2520disease%2520biomarkers%253A%2520dipeptidyl%2520peptidase%25204%2520and%2520fibroblast%2520activation%2520protein%26jtitle%3DProtoplasma%26date%3D2018%26volume%3D255%26spage%3D375%26epage%3D386%26doi%3D10.1007%2Fs00709-017-1129-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, A.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein-alpha: a key modulator of the microenvironment in multiple pathologies</span>. <i>Int. Rev. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">83</span>â <span class="NLM_lpage">116</span>, <span class="refDoi">Â DOI: 10.1016/b978-0-12-394308-8.00003-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2FB978-0-12-394308-8.00003-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22608558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKgtbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2012&pages=83-116&author=T.+Kellyauthor=Y.+Huangauthor=A.+E.+Simmsauthor=A.+Mazur&title=Fibroblast+activation+protein-alpha%3A+a+key+modulator+of+the+microenvironment+in+multiple+pathologies&doi=10.1016%2Fb978-0-12-394308-8.00003-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein-Î±: a key modulator of the microenvironment in multiple pathologies</span></div><div class="casAuthors">Kelly, Thomas; Huang, Yan; Simms, Avis E.; Mazur, Anna</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-116</span>CODEN:
                <span class="NLM_cas:coden">IRCMAH</span>;
        ISSN:<span class="NLM_cas:issn">1937-6448</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Fibroblast activation protein-Î± (FAP) is a serine protease that can provide target specificity to therapeutic agents because in adults its expression is restricted to pathol. sites, including cancer, fibrosis, arthritis, wounding, or inflammation.  It is not expressed in most normal tissues.  The majority of FAP is expressed by activated fibroblasts responding to the pathol. situations.  FAP is typically found as a type II transmembrane protein phys. attached to cells and with the bulk of the protein, including the catalytic domain, exposed to the extracellular space and accessible to small mols.  In this chapter, we review the structure, substrate specificities, signaling functions, and current design of FAP inhibitors.  Evidence indicating the presence of FAP in multiple cancers, arthritis, fibrosis, keloids, and other pathologies is described and indicates possible roles for FAP in facilitating cell invasion and growth.  Sep. sections are devoted to the role of FAP in coordinating the stromal response to cancer, including a role in angiogenesis and a potential role in modulation of the antitumor immune response.  Finally studies attempting to demonstrate the clin. potential of FAP are discussed, as well as some novel applications employing FAP in therapy or diagnosis.  Throughout this review, effort is made to highlight areas where information is lacking and to highlight important questions that require further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl6m1rj-1CzLVg90H21EOLACvtfcHk0lgvFlMBcuSRgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKgtbjL&md5=e21de80d77e6b473d8c6fc3d17156a36</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-394308-8.00003-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-394308-8.00003-0%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DSimms%26aufirst%3DA.%2BE.%26aulast%3DMazur%26aufirst%3DA.%26atitle%3DFibroblast%2520activation%2520protein-alpha%253A%2520a%2520key%2520modulator%2520of%2520the%2520microenvironment%2520in%2520multiple%2520pathologies%26jtitle%3DInt.%2520Rev.%2520Cell%2520Mol.%2520Biol.%26date%3D2012%26volume%3D297%26spage%3D83%26epage%3D116%26doi%3D10.1016%2Fb978-0-12-394308-8.00003-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, E.</span></span> <span> </span><span class="NLM_article-title">Turning foes to friends: targeting cancer-associated fibroblasts</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">99</span>â <span class="NLM_lpage">115</span>, <span class="refDoi">Â DOI: 10.1038/s41573-018-0004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fs41573-018-0004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30470818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlClsL7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=99-115&author=X.+Chenauthor=E.+Song&title=Turning+foes+to+friends%3A+targeting+cancer-associated+fibroblasts&doi=10.1038%2Fs41573-018-0004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Turning foes to friends: targeting cancer-associated fibroblasts</span></div><div class="casAuthors">Chen, Xueman; Song, Erwei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-115</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Current paradigms of cancer-centric therapeutics are usually not sufficient to eradicate the malignancy, as the cancer stroma may prompt tumor relapse and therapeutic resistance.  Among all the stromal cells that populate the tumor microenvironment, cancer-assocd. fibroblasts (CAFs) are the most abundant and are critically involved in cancer progression.  CAFs regulate the biol. of tumor cells and other stromal cells via cell-cell contact, releasing numerous regulatory factors and synthesizing and remodelling the extracellular matrix, and thus these cells affect cancer initiation and development.  The recent characterization of CAFs based on specific cell surface markers not only deepens our insight into their phenotypic heterogeneity and functional diversity but also brings CAF-targeting therapies for cancer treatment onto the agenda.  In this Review, we discuss the current knowledge of biol. hallmarks, cellular origins, phenotypical plasticity and functional heterogeneity of CAFs and underscore their contribution to cancer progression.  Moreover, we highlight relevant translational advances and potential therapeutic strategies that target CAFs for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt_XifgrPYT7Vg90H21EOLACvtfcHk0lgvFlMBcuSRgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlClsL7J&md5=468c018a319141be0e27f9166132facc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41573-018-0004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-018-0004-1%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DE.%26atitle%3DTurning%2520foes%2520to%2520friends%253A%2520targeting%2520cancer-associated%2520fibroblasts%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2019%26volume%3D18%26spage%3D99%26epage%3D115%26doi%3D10.1038%2Fs41573-018-0004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quail, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span> <span> </span><span class="NLM_article-title">Microenvironmental regulation of tumor progression and metastasis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1423</span>â <span class="NLM_lpage">1437</span>, <span class="refDoi">Â DOI: 10.1038/nm.3394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fnm.3394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=24202395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCmsrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1423-1437&author=D.+F.+Quailauthor=J.+A.+Joyce&title=Microenvironmental+regulation+of+tumor+progression+and+metastasis&doi=10.1038%2Fnm.3394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Microenvironmental regulation of tumor progression and metastasis</span></div><div class="casAuthors">Quail, Daniela F.; Joyce, Johanna A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1423-1437</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis.  Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence.  However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis.  Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer.  Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3iXox3-NemLVg90H21EOLACvtfcHk0lhBCZrCd2SsSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCmsrjL&md5=52d5ff0b56fb4749d0a42fedb3b83eb2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnm.3394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3394%26sid%3Dliteratum%253Aachs%26aulast%3DQuail%26aufirst%3DD.%2BF.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26atitle%3DMicroenvironmental%2520regulation%2520of%2520tumor%2520progression%2520and%2520metastasis%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1423%26epage%3D1437%26doi%3D10.1038%2Fnm.3394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. H.</span></span> <span> </span><span class="NLM_article-title">Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">840</span>â <span class="NLM_lpage">846</span>, <span class="refDoi">Â DOI: 10.3748/wjg.v18.i8.840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.3748%2Fwjg.v18.i8.840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22371645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XjslOlsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=840-846&author=M.+Shiauthor=D.+H.+Yuauthor=Y.+Chenauthor=C.+Y.+Zhaoauthor=J.+Zhangauthor=Q.+H.+Liuauthor=C.+R.+Niauthor=M.+H.+Zhu&title=Expression+of+fibroblast+activation+protein+in+human+pancreatic+adenocarcinoma+and+its+clinicopathological+significance&doi=10.3748%2Fwjg.v18.i8.840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance</span></div><div class="casAuthors">Shi, Min; Yu, Dang-Hui; Chen, Ying; Zhao, Chen-Yan; Zhang, Jing; Liu, Qing-Hua; Ni, Can-Rong; Zhu, Ming-Hua</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">840-846</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">Aim: To examine fibroblast activation protein (FAP) expression in pancreatic ductal adenocarcinoma (PDAC) and to analyze its relationship with the clinicopathol. of PDAC.  Methods: FAP expression was examd. in 134 PDAC specimens by immunohistochem. and in four pancreatic cancer cell lines (SW1990, Miapaca-2, AsPC-1 and BxPC-3) by Western blotting assay.  We also analyzed the assocn. between FAP expression in PDAC cells and the clinicopathol. of PDAC patients.  Results: The results showed that the FAP was expressed in both stromal fibroblast cells (98/134, 73.1%) and carcinoma cells (102/134, 76.1 %).  All 4 pancreatic cancer cell lines expressed FAP protein at different levels.  Protein bands corresponding to the proteolytically active 170-kDa seprase dimer and its 88-kDa seprase subunit were identified.  Higher FAP expression in carcinoma cells was assocd. with tumor size (P < 0.001), fibrotic focus (P = 0.003), perineural invasion (P = 0.009) and worse clin. outcome (P = 0.0085).  Conclusion: FAP is highly expressed in carcinoma cells and fibroblasts in PDAC tissues and its expression is assocd. with desmoplasia and worse prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxNJB6yGpISbVg90H21EOLACvtfcHk0lhBCZrCd2SsSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjslOlsr4%253D&md5=3e73023ef7a37f9d8eba9decdf4b72e6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v18.i8.840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v18.i8.840%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DD.%2BH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%2BH.%26aulast%3DNi%26aufirst%3DC.%2BR.%26aulast%3DZhu%26aufirst%3DM.%2BH.%26atitle%3DExpression%2520of%2520fibroblast%2520activation%2520protein%2520in%2520human%2520pancreatic%2520adenocarcinoma%2520and%2520its%2520clinicopathological%2520significance%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2012%26volume%3D18%26spage%3D840%26epage%3D846%26doi%3D10.3748%2Fwjg.v18.i8.840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein alpha in tumor microenvironment: recent progression and implications (review)</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3203</span>â <span class="NLM_lpage">3211</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2015.3197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.3892%2Fmmr.2015.3197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=25593080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVyqt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=3203-3211&author=F.+Ziauthor=J.+Heauthor=D.+Heauthor=Y.+Liauthor=L.+Yangauthor=Z.+Cai&title=Fibroblast+activation+protein+alpha+in+tumor+microenvironment%3A+recent+progression+and+implications+%28review%29&doi=10.3892%2Fmmr.2015.3197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein Î± in tumor microenvironment: recent progression and implications (Review)</span></div><div class="casAuthors">Zi, Fuming; He, Jingsong; He, Donghua; Li, Yi; Yang, Li; Cai, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3203-3211</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-2997</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Accumulated evidence has demonstrated that the microenvironment of a given tumor is important in detg. its drug resistance, tumorigenesis, progression and metastasis.  These microenvironments, like tumor cells, are vital targets for cancer therapy.  The cross-talk between tumor cells and cancer-assocd. fibroblasts (CAFs, alternatively termed activated fibroblasts) is crucial in regulating the drug resistance, tumorigenesis, neoplastic progression, angiogenesis, invasion and metastasis of a tumor.  Fibroblast activation protein Î± (FAPÎ±) is a transmembrane serine protease and is highly expressed on CAFs present in >90% of human epithelial neoplasms.  FAPÎ± activity, alongside that of gelatinase and type I collagenase, has become increasingly important in cancer therapy due to its effectiveness in modulating tumor behavior.  In this review, recent progression in the knowledge of the role of FAPÎ± in tumor microenvironments is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKNDxkdT7UU7Vg90H21EOLACvtfcHk0lhBCZrCd2SsSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVyqt7s%253D&md5=f81b4233a1aa58afe12bcc184c578c3c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2015.3197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2015.3197%26sid%3Dliteratum%253Aachs%26aulast%3DZi%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DCai%26aufirst%3DZ.%26atitle%3DFibroblast%2520activation%2520protein%2520alpha%2520in%2520tumor%2520microenvironment%253A%2520recent%2520progression%2520and%2520implications%2520%2528review%2529%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2015%26volume%3D11%26spage%3D3203%26epage%3D3211%26doi%3D10.3892%2Fmmr.2015.3197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandberg, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosting, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollenaar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sier, C. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesker, W. E.</span></span> <span> </span><span class="NLM_article-title">Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer</span>. <i>BMC Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">284</span>, <span class="refDoi">Â DOI: 10.1186/s12885-019-5462-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1186%2Fs12885-019-5462-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30922247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A280%3ADC%252BB3cbptF2rtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=284&author=T.+P.+Sandbergauthor=M.+Stuartauthor=J.+Oostingauthor=R.+Tollenaarauthor=C.+F.+M.+Sierauthor=W.+E.+Mesker&title=Increased+expression+of+cancer-associated+fibroblast+markers+at+the+invasive+front+and+its+association+with+tumor-stroma+ratio+in+colorectal+cancer&doi=10.1186%2Fs12885-019-5462-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer</span></div><div class="casAuthors">Sandberg Tessa P; Stuart Maaike P M E; Tollenaar Rob A E M; Sier Cornelis F M; Mesker Wilma E; Sandberg Tessa P; Oosting Jan</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">284</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The tumor microenvironment has a critical role in regulating cancer cell behavior.  Tumors with high stromal content are associated with poor patient outcome.  The tumor-stroma ratio (TSR) identifies colorectal cancers (CRC) with poor patient prognosis based on hematoxylin & eosin stained sections.  The desmoplastic reaction consists to a great extent of cancer-associated fibroblasts (CAFs) of which different subtypes are known.  The aim of this study is to investigate and quantify CAFs present in the tumor stroma of CRC stratified by the TSR to possibly add prognostic significance to the TSR.  METHODS:  The expression of established CAF markers was compared between stroma-low and stroma-high tumors using transcriptomic data of 71 stage I - III CRC.  Based on literature, fibroblast and stromal markers were selected to perform multiplex immunofluorescent staining on formalin fixed, paraffin-embedded tumor sections of patients diagnosed with stage III colon cancer.  Antibodies against the following markers were used: Î±SMA, PDGFR -Î², FAP, FSP1 and the stromal markers CD45 and CD31 as reference.  The markers were subsequently quantified in the stroma using the Vectra imaging microscope.  RESULTS:  The transcriptomic data showed that all CAF markers except one were higher expressed in stroma-high compared to stroma-low tumors.  Histologically, stroma-high tumors showed a decreased number of FSP1(+)/CD45(+) cells and a trend of an increased expression of FAP compared to stroma-low tumors.  FAP was higher expressed at the invasive part compared to the tumor center in both stroma-high and stroma-low tumors.  CONCLUSIONS:  The increased expression of FAP at the invasive part and in stroma-high tumors might contribute to the invasive behavior of cancer cells.  Future functional experiments should investigate the contribution of FAP to cancer cell invasion.  Combining the quantity of the stroma as defined by the TSR with the activity level of CAFs using the expression of FAP may result in an expanded stroma-based tool for patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7CRJaefcy5bxanA7vODO6fW6udTcc2ebxkeCwT-IGV7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbptF2rtg%253D%253D&md5=afd1ca01868243e7120ef8ca77a7eb2a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs12885-019-5462-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-019-5462-2%26sid%3Dliteratum%253Aachs%26aulast%3DSandberg%26aufirst%3DT.%2BP.%26aulast%3DStuart%26aufirst%3DM.%26aulast%3DOosting%26aufirst%3DJ.%26aulast%3DTollenaar%26aufirst%3DR.%26aulast%3DSier%26aufirst%3DC.%2BF.%2BM.%26aulast%3DMesker%26aufirst%3DW.%2BE.%26atitle%3DIncreased%2520expression%2520of%2520cancer-associated%2520fibroblast%2520markers%2520at%2520the%2520invasive%2520front%2520and%2520its%2520association%2520with%2520tumor-stroma%2520ratio%2520in%2520colorectal%2520cancer%26jtitle%3DBMC%2520Canc.%26date%3D2019%26volume%3D19%26spage%3D284%26doi%3D10.1186%2Fs12885-019-5462-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span> <span> </span><span class="NLM_article-title">FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">8</span>â <span class="NLM_lpage">14</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2017.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.bbrc.2017.03.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28302482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1alur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2017&pages=8-14&author=L.+Chenauthor=X.+Qiuauthor=X.+Wangauthor=J.+He&title=FAP+positive+fibroblasts+induce+immune+checkpoint+blockade+resistance+in+colorectal+cancer+via+promoting+immunosuppression&doi=10.1016%2Fj.bbrc.2017.03.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression</span></div><div class="casAuthors">Chen, Lingling; Qiu, Xiangting; Wang, Xinhua; He, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-14</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Immune checkpoint blockades that significantly prolonged survival of melanoma patients have been less effective on colorectal cancer (CRC) patients.  Growing evidence suggested that fibroblast activation protein-alpha (FAP) on cancer assoc. fibroblasts (CAFs) has crit. roles in regulating antitumor immune response by inducing tumor-promoting inflammation.  In this study, we explored the roles of FAP in regulating the tumor immunity and immune checkpoint blockades resistance in CRC exptl. systems.  We found that CAFs with high FAP expression could induce immune checkpoint blockade resistance in CRC mouse model.  Mechanistically, CAFs with high FAP expression promoted immunosuppression in the CRC tumor immune microenvironment by up-regulating CCL2 secretion, recruiting myeloid cells, and decreasing T-cell activity.  In human CRC samples, FAP expression was proportional to myeloid cells no., but inversely related to T-cell no.  High FAP expression also predicted poor survival of CRC patients.  Taken together, our study suggested that high FAP expression in CAFs is one reason leading to immune checkpoint blockades resistance in CRC patients and FAP is an optional target for reversing immune checkpoint blockades resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs1Gr9-py6brVg90H21EOLACvtfcHk0lhTcpBpyqvOQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1alur0%253D&md5=53fb3ef60d253b2a0e172e85fbaa23b6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DJ.%26atitle%3DFAP%2520positive%2520fibroblasts%2520induce%2520immune%2520checkpoint%2520blockade%2520resistance%2520in%2520colorectal%2520cancer%2520via%2520promoting%2520immunosuppression%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D487%26spage%3D8%26epage%3D14%26doi%3D10.1016%2Fj.bbrc.2017.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buza, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindaraju, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monslow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pure, E.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e92232</span> <span class="refDoi">Â DOI: 10.1172/jci.insight.92232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1172%2Fjci.insight.92232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28978805" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&author=A.+Loauthor=C.+P.+Liauthor=E.+L.+Buzaauthor=R.+Blombergauthor=P.+Govindarajuauthor=D.+Averyauthor=J.+Monslowauthor=M.+Hsiaoauthor=E.+Pure&title=Fibroblast+activation+protein+augments+progression+and+metastasis+of+pancreatic+ductal+adenocarcinoma&doi=10.1172%2Fjci.insight.92232"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.92232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.92232%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DC.%2BP.%26aulast%3DBuza%26aufirst%3DE.%2BL.%26aulast%3DBlomberg%26aufirst%3DR.%26aulast%3DGovindaraju%26aufirst%3DP.%26aulast%3DAvery%26aufirst%3DD.%26aulast%3DMonslow%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DM.%26aulast%3DPure%26aufirst%3DE.%26atitle%3DFibroblast%2520activation%2520protein%2520augments%2520progression%2520and%2520metastasis%2520of%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DJCI%2520Insight%26date%3D2017%26volume%3D2%26doi%3D10.1172%2Fjci.insight.92232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span> <span> </span><span class="NLM_article-title">Clinical implications of fibroblast activation protein-alpha in non-small cell lung cancer after curative resection: a new predictor for prognosis</span>. <i>J. Canc. Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1523</span>â <span class="NLM_lpage">1528</span>, <span class="refDoi">Â DOI: 10.1007/s00432-013-1471-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1007%2Fs00432-013-1471-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=23835897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlShsLzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2013&pages=1523-1528&author=Y.+Liaoauthor=Y.+Niauthor=R.+Heauthor=W.+Liuauthor=J.+Du&title=Clinical+implications+of+fibroblast+activation+protein-alpha+in+non-small+cell+lung+cancer+after+curative+resection%3A+a+new+predictor+for+prognosis&doi=10.1007%2Fs00432-013-1471-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical implications of fibroblast activation protein-Î± in non-small cell lung cancer after curative resection: a new predictor for prognosis</span></div><div class="casAuthors">Liao, Yida; Ni, Yang; He, Ren; Liu, Weidong; Du, Jiajun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1523-1528</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Fibroblast activation protein-Î± (FAP-Î±), which is a serine protease specially expressed on the surface of the cancer stromal cells, plays an important role in the progression and prognosis in diverse malignancies.  However, the role of FAP-Î± in non-small cell lung cancer (NSCLC) is still unknown.  Materials and methods: We enrolled 59 NSCLC patients who received complete resection.  Sections of paraffin-embedded primary NSCLC specimens of all the patients were stained with antibody directed against FAP-Î±.  Overall, percentage (Grade 0-3) and intensity (0-3+) of stromal FAP-Î± staining of the tumor were assessed.  Results: FAP-Î± was detected in >76 % of the specimens examd., and its high expression seemed to be correlated with poor tumor differentiation (P = 0.06).  Furthermore, both increased FAP-Î± staining percentage and intensity were assocd. with worse overall survival of the patients (percentage, P = 0.0087; intensity, P = 0.05).  Higher FAP-Î± staining percentage was obsd. in those patients with increased peripheral neutrophil and lymphocyte count ratio (P = 0.034).  Conclusions: FAP-Î± is highly expressed in cancer stroma and also a predictor of poor survival of NSCLC patients.  Elevated FAP-Î± expression may be assocd. with inflammation and suppressed lymphocyte-dependent immune response, which then result in the tumor progression.  Therefore, FAP-Î± plays an important role in the progression of NSCLC, and its high expression is a predictor of poor survival.  Targeting FAP-Î± may be a novel strategy for NSCLC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt_AndbnpT5rVg90H21EOLACvtfcHk0ljDNt2Jrmh5CA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlShsLzE&md5=97ca27f16944fc3a3497e26b1e8edf9c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00432-013-1471-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-013-1471-8%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26atitle%3DClinical%2520implications%2520of%2520fibroblast%2520activation%2520protein-alpha%2520in%2520non-small%2520cell%2520lung%2520cancer%2520after%2520curative%2520resection%253A%2520a%2520new%2520predictor%2520for%2520prognosis%26jtitle%3DJ.%2520Canc.%2520Res.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D139%26spage%3D1523%26epage%3D1528%26doi%3D10.1007%2Fs00432-013-1471-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein-Szanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span> <span> </span><span class="NLM_article-title">Clinical implications of fibroblast activation protein in patients with colon cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1736</span>â <span class="NLM_lpage">1741</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-06-1746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1158%2F1078-0432.CCR-06-1746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=17363526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2gt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1736-1741&author=L.+R.+Henryauthor=H.-O.+Leeauthor=J.+S.+Leeauthor=A.+Klein-Szantoauthor=P.+Wattsauthor=E.+A.+Rossauthor=W.-T.+Chenauthor=J.+D.+Cheng&title=Clinical+implications+of+fibroblast+activation+protein+in+patients+with+colon+cancer&doi=10.1158%2F1078-0432.ccr-06-1746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer</span></div><div class="casAuthors">Henry, Leonard R.; Lee, Hyung-Ok; Lee, John S.; Klein-Szanto, Andres; Watts, Perry; Ross, Eric A.; Chen, Wen-Tien; Cheng, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1736-1741</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Human fibroblast activation protein (FAP)/seprase is a 97-kDa surface glycoprotein expressed on tumor assocd. fibroblasts in the majority of epithelial cancers including colon adenocarcinomas.  FAP overexpression in human tumor cells has been shown to promote tumor growth in animal models, and clin. trials targeting FAP enzymic activity have been initiated.  The primary objective of this study was to evaluate the clin. significance of stromal FAP in human colon cancers by immunohistochemisty.  Exptl. Design: Sections of paraffin-embedded resected primary human colon cancer specimens from 1996 through 2001 within the Fox Chase Cancer Center tumor bank were stained with D8 antibody directed against FAP/seprase.  Xenotransplanted human colorectal tumors in mice were examd. similarly for stromal FAP in tumors of different sizes.  Overall percentage of stromal FAP staining of the primary tumor was assessed semiquant. (0, 1+, 2+, 3+) and staining intensity was also graded (none, weak, intermediate, strong).  Survival time and time to recurrence data were analyzed using Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models.  RESULTS: One hundred thirty-eight patients with resected specimens were available for study (mean follow-up, 1,050 days) with 6 (4%) stage I, 52 (38%) stage II, 43 (31%) stage III, and 37 (27%) stage IV patients. FAP was detected in >93% of specimens.  Semiquant. staining was scored as 1+ in 28 (20%), 2+ in 52 (38%), and 3+ in 49 (35%).  FAP staining intensity was graded as weak in 45 (33%), intermediate in 48 (35%), and dark in 36 (26%).  Stromal FAP was found to correlate inversely with tumor stage (semiquant., P = 0.01; intensity, P = 0.009) and with tumor size of the tumor xenograft model (correlation coeff., -0.61; P = 0.047), suggesting that stromal FAP may have a greater role in the early development of tumors.  Furthermore, greater stromal FAP for patients with known metastatic disease was assocd. with a decreased survival.  CONCLUSION: Our data indicate that patients whose colon tumors have high levels of stromal FAP are more likely to have aggressive disease progression and potential development of metastases or recurrence.  This study affirms the rationale for ongoing clin. investigations using FAP as a therapeutic target to disrupt FAP-driven tumor progression in patients with metastatic disease.  It also suggests that the effects of FAP inhibition should be investigated in earlier-stage tumors, given its high levels and potential effect earlier in the course of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgsCCFFALY2bVg90H21EOLACvtfcHk0ljDNt2Jrmh5CA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2gt7o%253D&md5=9521921702b2ab2100c05e79c8eb07cf</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1746%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DL.%2BR.%26aulast%3DLee%26aufirst%3DH.-O.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DWatts%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DW.-T.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26atitle%3DClinical%2520implications%2520of%2520fibroblast%2520activation%2520protein%2520in%2520patients%2520with%2520colon%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1736%26epage%3D1741%26doi%3D10.1158%2F1078-0432.ccr-06-1746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Welt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divgi, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carswell, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Old, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span> <span> </span><span class="NLM_article-title">Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1193</span>â <span class="NLM_lpage">1203</span>, <span class="refDoi">Â DOI: 10.1200/jco.1994.12.6.1193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1200%2FJCO.1994.12.6.1193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=8201382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A280%3ADyaK2c3mtValtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1994&pages=1193-1203&author=S.+Weltauthor=C.+R.+Divgiauthor=A.+M.+Scottauthor=P.+Garin-Chesaauthor=R.+D.+Finnauthor=M.+Grahamauthor=E.+A.+Carswellauthor=A.+Cohenauthor=S.+M.+Larsonauthor=L.+J.+Oldauthor=W.+J.+Rettig&title=Antibody+targeting+in+metastatic+colon+cancer%3A+a+phase+I+study+of+monoclonal+antibody+F19+against+a+cell-surface+protein+of+reactive+tumor+stromal+fibroblasts&doi=10.1200%2Fjco.1994.12.6.1193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts</span></div><div class="casAuthors">Welt S; Divgi C R; Scott A M; Garin-Chesa P; Finn R D; Graham M; Carswell E A; Cohen A; Larson S M; Old L J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1193-203</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  To define the toxicity, imaging, and biodistribution characteristics of iodine 131-labeled monoclonal antibody F19 (131I-mAbF19).  MAbF19 recognizes the fibroblast activation protein (FAP), a cell-surface glycoprotein not present in most normal tissues, but abundantly expressed by reactive stromal fibroblasts of epithelial cancers, including more than 95% of primary and metastatic colorectal carcinomas.  PATIENTS AND METHODS:  131I-mAbF19 was administered intravenously to 17 patients with hepatic metastases from colorectal carcinoma who were scheduled for resection of localized metastases or insertion of hepatic artery catheter for regional chemotherapy.  Seven to 8 days before surgery, patients received 131I-mAbF19 at three dose levels, with at least four patients entered at each level.  RESULTS:  No toxicity associated with intravenous 131I-mAbF19 administration was observed.  Tumor images were obtained on planar and single-photon emission tomography (SPECT) scans in 15 of 17 patients with hepatic metastases, tumor-infiltrated portal lymph nodes, and/or recurrent pelvic disease.  The smallest lesion visualized was 1 cm in diameter.  The optimal time for tumor imaging was 3 to 5 days after 131I-mAbF19 administration.  The use of image registration techniques allowed precise anatomic localization of 131I-mAbF19 accumulation.  Immunohistochemical analysis of biopsy tissues showed expression of FAP in the tumor stroma (but not in normal liver) in all patients studied and confirmed that the FAP-positive tumor stromal fibroblasts were interposed between the tumor capillaries and the malignant colon epithelial cells.  At the time of surgery, tumor-to-liver ratios up to 21:1 and tumor-to-serum ratios up to 9:1 were obtained.  The fraction of the injected 131I-mAbF19 dose per gram tumor (%ID/g tumor) localized to hepatic metastases at the time of surgery ranged from 0.001% to 0.016%.  CONCLUSION:  The FAP tumor fibroblast antigen is highly expressed in primary and metastatic colorectal carcinomas and shows limited expression in normal adult tissues.  This highly selective expression pattern allows imaging of colorectal carcinoma lesions as small as 1 cm in diameter on 131I-mAbF19 scans.  Because of the consistent presence of FAP in the stroma of epithelial cancers and the accessibility of FAP-positive tumor stromal fibroblasts to circulating monoclonal antibodies (mAbs), this study suggests possible diagnostic and therapeutic applications of humanized mAbF19 and mAbF19 constructs with novel immune and nonimmune effector functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUDgydeJD4dJQHPYJuLg8TfW6udTcc2eZPOr3ukVJe3bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3mtValtA%253D%253D&md5=53dff2e4869797546a8c14c925bc5ef4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.1994.12.6.1193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1994.12.6.1193%26sid%3Dliteratum%253Aachs%26aulast%3DWelt%26aufirst%3DS.%26aulast%3DDivgi%26aufirst%3DC.%2BR.%26aulast%3DScott%26aufirst%3DA.%2BM.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DFinn%26aufirst%3DR.%2BD.%26aulast%3DGraham%26aufirst%3DM.%26aulast%3DCarswell%26aufirst%3DE.%2BA.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DAntibody%2520targeting%2520in%2520metastatic%2520colon%2520cancer%253A%2520a%2520phase%2520I%2520study%2520of%2520monoclonal%2520antibody%2520F19%2520against%2520a%2520cell-surface%2520protein%2520of%2520reactive%2520tumor%2520stromal%2520fibroblasts%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1994%26volume%3D12%26spage%3D1193%26epage%3D1203%26doi%3D10.1200%2Fjco.1994.12.6.1193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laverman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Geest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, S. Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerrits, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgreen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helsen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freimoser-Grundschober, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldhauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosse, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moessner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyen, W. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenders, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerman, O. C.</span></span> <span> </span><span class="NLM_article-title">Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">778</span>â <span class="NLM_lpage">783</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.114.152959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.114.152959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=25858044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFaktr3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=778-783&author=P.+Lavermanauthor=T.+van+der+Geestauthor=S.+Y.+A.+Terryauthor=D.+Gerritsauthor=B.+Walgreenauthor=M.+M.+Helsenauthor=T.+K.+Nayakauthor=A.+Freimoser-Grundschoberauthor=I.+Waldhauerauthor=R.+J.+Hosseauthor=E.+Moessnerauthor=P.+Umanaauthor=C.+Kleinauthor=W.+J.+G.+Oyenauthor=M.+I.+Koendersauthor=O.+C.+Boerman&title=Immuno-PET+and+Immuno-SPECT+of+Rheumatoid+Arthritis+with+Radiolabeled+Anti-Fibroblast+Activation+Protein+Antibody+Correlates+with+Severity+of+Arthritis&doi=10.2967%2Fjnumed.114.152959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis</span></div><div class="casAuthors">Laverman, Peter; van der Geest, Tessa; Terry, Samantha Y. A.; Gerrits, Danny; Walgreen, Birgitte; Helsen, Monique M.; Nayak, Tapan K.; Freimoser-Grundschober, Anne; Waldhauer, Inja; Hosse, Ralf J.; Moessner, Ekkerhard; Umana, Pablo; Klein, Christian; Oyen, Wim J. G.; Koenders, Marjie I.; Boerman, Otto C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">778-783</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">One of the most prominent cell populations playing a role in rheumatoid arthritis (RA) is activated fibroblast-like synoviocytes.  Among many other proteins, fibroblast-like synoviocytes dominantly express fibroblast activation protein (FAP).  Because of the high expression of FAP in arthritic joints, radioimmunoimaging of activated fibroblasts with anti-FAP antibodies might be an attractive noninvasive imaging tool in RA.  Methods: SPECT and PET with 111In- and 89Zr-labeled anti-FAP antibody 28H1 was performed in mice with CIA.  The radioactivity uptake in joints was quantified and correlated with arthritis score.  Results: Both 111In-28H1 and 89Zr-28H1 showed high uptake in inflamed joints, being 3-fold higher than that of the irrelevant isotype-matched control antibody DP47GS, clearly indicating specific accumulation of 28H1.  Uptake of 111In-28H1 ranged from 2.2 percentage injected dose per g (%ID/g) in noninflamed joints to 32.1 %ID/g in severely inflamed joints.  DP47GS accumulation ranged from 1.6 %ID/g in noninflamed tissue to 12.0 %ID/g in severely inflamed joints.  Uptake of 28H1 in inflamed joints correlated with arthritis score (Spearman Ï, 0.69; P < 0.0001) and increased with severity of arthritis.  Conclusion: SPECT/CT imaging with the anti-FAP antibody 111In-28H1 specifically visualized arthritic joints with high resoln., and tracer accumulation correlated with the severity of the inflammation in murine exptl. arthritis.  Background uptake of the radiolabeled antibody was low, resulting in excellent image quality. 89Zr-28H1 was less favorable for RA imaging because of an elevated bone uptake of 89Zr.  Future studies will focus on the potential role of 28H1 as a tool to monitor therapy response early on.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaYZGEf70NP7Vg90H21EOLACvtfcHk0lgW6VnV_qc2kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFaktr3O&md5=e19e343e750cc081e5d476a303d92997</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.114.152959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.114.152959%26sid%3Dliteratum%253Aachs%26aulast%3DLaverman%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BGeest%26aufirst%3DT.%26aulast%3DTerry%26aufirst%3DS.%2BY.%2BA.%26aulast%3DGerrits%26aufirst%3DD.%26aulast%3DWalgreen%26aufirst%3DB.%26aulast%3DHelsen%26aufirst%3DM.%2BM.%26aulast%3DNayak%26aufirst%3DT.%2BK.%26aulast%3DFreimoser-Grundschober%26aufirst%3DA.%26aulast%3DWaldhauer%26aufirst%3DI.%26aulast%3DHosse%26aufirst%3DR.%2BJ.%26aulast%3DMoessner%26aufirst%3DE.%26aulast%3DUmana%26aufirst%3DP.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26aulast%3DKoenders%26aufirst%3DM.%2BI.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26atitle%3DImmuno-PET%2520and%2520Immuno-SPECT%2520of%2520Rheumatoid%2520Arthritis%2520with%2520Radiolabeled%2520Anti-Fibroblast%2520Activation%2520Protein%2520Antibody%2520Correlates%2520with%2520Severity%2520of%2520Arthritis%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26spage%3D778%26epage%3D783%26doi%3D10.2967%2Fjnumed.114.152959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meletta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller Herde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiotellis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rancic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¤mer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2081</span>â <span class="NLM_lpage">2099</span>, <span class="refDoi">Â DOI: 10.3390/molecules20022081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.3390%2Fmolecules20022081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=25633335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitF2gs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=2081-2099&author=R.+Melettaauthor=A.+M%C3%BCller+Herdeauthor=A.+Chiotellisauthor=M.+Isaauthor=Z.+Rancicauthor=N.+Borelauthor=S.+Ametameyauthor=S.+Kr%C3%A4merauthor=R.+Schibli&title=Evaluation+of+the+radiolabeled+boronic+acid-based+FAP+inhibitor+MIP-1232+for+atherosclerotic+plaque+imaging&doi=10.3390%2Fmolecules20022081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging</span></div><div class="casAuthors">Meletta, Romana; Herde, Adrienne Muller; Chiotellis, Aristeidis; Isa, Malsor; Rancic, Zoran; Borel, Nicole; Ametamey, Simon M.; Kramer, Stefanie D.; Schibli, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2081-2099, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Research towards the non-invasive imaging of atherosclerotic plaques is of high clin. priority as early recognition of vulnerable plaques may reduce the incidence of cardiovascular events.  The fibroblast activation protein alpha (FAP) was recently proposed as inflammation-induced protease involved in the process of plaque vulnerability.  In this study, FAP mRNA and protein levels were investigated by quant. polymerase chain reaction and immunohistochem., resp., in human endarterectomized carotid plaques.  A published boronic-acid based FAP inhibitor, MIP-1232, was synthesized and radiolabeled with iodine-125.  The potential of this radiotracer to image plaques was evaluated by in vitro autoradiog. with human carotid plaques.  Specificity was assessed with a xenograft with high and one with low FAP level, grown in mice.  Target expression analyses revealed a moderately higher protein level in atherosclerotic plaques than normal arteries correlating with plaque vulnerability.  No difference in expression was detd. on mRNA level.  The radiotracer was successfully produced and accumulated strongly in the FAP-pos. SK-Mel-187 melanoma xenograft in vitro while accumulation was negligible in an NCI-H69 xenograft with low FAP levels.  Binding of the tracer to endarterectomized tissue was similar in plaques and normal arteries, hampering its use for atherosclerosis imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCElQwBPeOS7Vg90H21EOLACvtfcHk0lgW6VnV_qc2kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitF2gs7Y%253D&md5=5900591e2f9af2274b2e699be2cc8ee1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3390%2Fmolecules20022081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules20022081%26sid%3Dliteratum%253Aachs%26aulast%3DMeletta%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%2BHerde%26aufirst%3DA.%26aulast%3DChiotellis%26aufirst%3DA.%26aulast%3DIsa%26aufirst%3DM.%26aulast%3DRancic%26aufirst%3DZ.%26aulast%3DBorel%26aufirst%3DN.%26aulast%3DAmetamey%26aufirst%3DS.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DS.%26aulast%3DSchibli%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520the%2520radiolabeled%2520boronic%2520acid-based%2520FAP%2520inhibitor%2520MIP-1232%2520for%2520atherosclerotic%2520plaque%2520imaging%26jtitle%3DMolecules%26date%3D2015%26volume%3D20%26spage%3D2081%26epage%3D2099%26doi%3D10.3390%2Fmolecules20022081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D.</span></span> <span> </span><span class="NLM_article-title">On the edge of validation--cancer protease fibroblast activation protein</span>. <i>Mini Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">719</span>â <span class="NLM_lpage">727</span>, <span class="refDoi">Â DOI: 10.2174/138955708784567449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2174%2F138955708784567449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=18537727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnslWkurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=719-727&author=B.+Wolfauthor=C.+Quanauthor=T.+Tranauthor=C.+Wiesmannauthor=D.+Sutherlin&title=On+the+edge+of+validation%2D%2Dcancer+protease+fibroblast+activation+protein&doi=10.2174%2F138955708784567449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">On the edge of validation - cancer protease fibroblast activation protein</span></div><div class="casAuthors">Wolf, Beni B.; Quan, Clifford; Tran, Thuy; Wiesmann, Christian; Sutherlin, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">719-727</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Numerous studies implicate the prolyl peptidase, fibroblast activation protein (FAP) in tumorigenesis; however, FAP-selective inhibitors have not yet been developed to fully validate FAP as a therapeutic target.  Herein, we review recent efforts aimed at validating and inhibiting FAP for cancer therapy and highlight future directions for successful targeting of this prolyl peptidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraYmP1yHrDjrVg90H21EOLACvtfcHk0ljtHiKWFogihw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnslWkurg%253D&md5=2f69de69d02154c3a8aa456eab8f05ed</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F138955708784567449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708784567449%26sid%3Dliteratum%253Aachs%26aulast%3DWolf%26aufirst%3DB.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DSutherlin%26aufirst%3DD.%26atitle%3DOn%2520the%2520edge%2520of%2520validation--cancer%2520protease%2520fibroblast%2520activation%2520protein%26jtitle%3DMini%2520Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D719%26epage%3D727%26doi%3D10.2174%2F138955708784567449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemayehu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenkrants, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minimo, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripka, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szardenings, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozarich, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreder, K. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4239</span>â <span class="NLM_lpage">4242</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2005.06.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.bmcl.2005.06.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=16085416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1Wns7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=4239-4242&author=Y.+Huauthor=L.+Maauthor=M.+Wuauthor=M.+S.+Wongauthor=B.+Liauthor=S.+Corralauthor=Z.+Yuauthor=T.+Nomanbhoyauthor=S.+Alemayehuauthor=S.+R.+Fullerauthor=J.+S.+Rosenblumauthor=N.+Rozenkrantsauthor=L.+C.+Minimoauthor=W.+C.+Ripkaauthor=A.+K.+Szardeningsauthor=J.+W.+Kozarichauthor=K.+R.+Shreder&title=Synthesis+and+structure-activity+relationship+of+N-alkyl+Gly-boro-Pro+inhibitors+of+DPP4%2C+FAP%2C+and+DPP7&doi=10.1016%2Fj.bmcl.2005.06.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7</span></div><div class="casAuthors">Hu, Yi; Ma, Lifu; Wu, Min; Wong, Melissa S.; Li, Bei; Corral, Sergio; Yu, Zhizhou; Nomanbhoy, Tyzoon; Alemayehu, Senaiet; Fuller, Stacy R.; Rosenblum, Jonathan S.; Rozenkrants, Natasha; Minimo, Lauro C.; Ripka, William C.; Szardenings, Anna K.; Kozarich, John W.; Shreder, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4239-4242</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity relationship of various N-alkyl Gly-boro-Pro derivs. against three dipeptidyl peptidases (DPPs) was studied.  In a series of N-cycloalkyl analogs, DPP4 and fibroblast activation protein-Î± (FAP) optimally preferred N-cycloheptyl whereas DPP7 tolerated even larger cycloalkyl rings.  Gly Î±-carbon derivatization of N-cyclohexyl or N-(2-adamantyl) Gly-boro-Pro resulted in a significant decrease in potency against all the three DPPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3KP4LcEmwSbVg90H21EOLACvtfcHk0ljtHiKWFogihw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1Wns7g%253D&md5=a9393433dff6f834f9dd457a9c643a3f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.06.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.06.075%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DM.%2BS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCorral%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DAlemayehu%26aufirst%3DS.%26aulast%3DFuller%26aufirst%3DS.%2BR.%26aulast%3DRosenblum%26aufirst%3DJ.%2BS.%26aulast%3DRozenkrants%26aufirst%3DN.%26aulast%3DMinimo%26aufirst%3DL.%2BC.%26aulast%3DRipka%26aufirst%3DW.%2BC.%26aulast%3DSzardenings%26aufirst%3DA.%2BK.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26aulast%3DShreder%26aufirst%3DK.%2BR.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%2520N-alkyl%2520Gly-boro-Pro%2520inhibitors%2520of%2520DPP4%252C%2520FAP%252C%2520and%2520DPP7%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D4239%26epage%3D4242%26doi%3D10.1016%2Fj.bmcl.2005.06.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loktev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1415</span>â <span class="NLM_lpage">1422</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.210443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.118.210443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29626119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFWnu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1415-1422&author=T.+Lindnerauthor=A.+Loktevauthor=A.+Altmannauthor=F.+Gieselauthor=C.+Kratochwilauthor=J.+Debusauthor=D.+J%C3%A4gerauthor=W.+Mierauthor=U.+Haberkorn&title=Development+of+Quinoline-Based+Theranostic+Ligands+for+the+Targeting+of+Fibroblast+Activation+Protein&doi=10.2967%2Fjnumed.118.210443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein</span></div><div class="casAuthors">Lindner, Thomas; Loktev, Anastasia; Altmann, Annette; Giesel, Frederik; Kratochwil, Clemens; Debus, Juergen; Jaeger, Dirk; Mier, Walter; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1415-1423</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Fibroblast activation protein (FAP) is overexpressed in cancer assocd. fibroblasts and is involved in a variety of tumor-promoting activities such as matrix remodeling, angiogenesis, chemotherapy resistance, and immunosuppression.  Because FAP shows low expression in most normal organs, it presents an interesting target for imaging and endoradiotherapy.  In this investigation, FAP inhibitors (FAPIs) were modified and optimized for use as theranostic tracers.  FAPIs based on a quinoline structure were synthesized and characterized with respect to binding, internalization, and efflux in cells expressing human and murine FAP as well as CD26.  Preclin. pharmacokinetics were detd. in tumor-bearing animals with biodistribution expts. and smallanimal PET.  Finally, a proof-of-concept approach toward imaging and therapy was chosen for 2 patients with metastasized breast cancer.  Of 15 synthesized FAPIs, FAPI-04 was identified as the most promising tracer for clin. application.  Compared with the previously published ligand, FAPI-02, FAPI-04 showed excellent stability in human serum, higher affinity for FAP as opposed to CD26, and slower excretion in vitro.  In vivo, a higher SUV was reached in tumor-bearing animals, leading to larger areas under the curve as calcd. from biodistribution expts.  Finally, PET/CT scans with 68Ga-FAPI-04 in 2 patients withmetastasized breast cancer revealed high tracer uptake in metastases and a redn. in pain symptoms after therapy with a considerably low dose of 90Y-FAPI-04.  FAPI-04 represents a promising tracer for both diagnostic imaging and, possibly, targeted therapy of malignant tumors with a high content of activated fibroblasts, such as breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_tGKFNSoNl7Vg90H21EOLACvtfcHk0ljtHiKWFogihw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFWnu74%253D&md5=8a47c1c15ec3d7e16462d7712865f94f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.210443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.210443%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DLoktev%26aufirst%3DA.%26aulast%3DAltmann%26aufirst%3DA.%26aulast%3DGiesel%26aufirst%3DF.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DD.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DDevelopment%2520of%2520Quinoline-Based%2520Theranostic%2520Ligands%2520for%2520the%2520Targeting%2520of%2520Fibroblast%2520Activation%2520Protein%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D1415%26epage%3D1422%26doi%3D10.2967%2Fjnumed.118.210443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heirbaut, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabtsova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">491</span>â <span class="NLM_lpage">496</span>, <span class="refDoi">Â DOI: 10.1021/ml300410d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300410d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKnsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=491-496&author=K.+Jansenauthor=L.+Heirbautauthor=J.+D.+Chengauthor=J.+Joossensauthor=O.+Ryabtsovaauthor=P.+Cosauthor=L.+Maesauthor=A.-M.+Lambeirauthor=I.+De+Meesterauthor=K.+Augustynsauthor=P.+Van+der+Veken&title=Selective+Inhibitors+of+Fibroblast+Activation+Protein+%28FAP%29+with+a+%284-Quinolinoyl%29-glycyl-2-cyanopyrrolidine+Scaffold&doi=10.1021%2Fml300410d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold</span></div><div class="casAuthors">Jansen, Koen; Heirbaut, Leen; Cheng, Jonathan D.; Joossens, Jurgen; Ryabtsova, Oxana; Cos, Paul; Maes, Louis; Lambeir, Anne-Marie; De Meester, Ingrid; Augustyns, Koen; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">491-496</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast activation protein (FAP) is a serine protease that is generally accepted to play an important role in tumor growth and other diseases involving tissue remodeling.  Currently there are no FAP inhibitors with reported selectivity toward both the closely related dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP).  We present the discovery of a new class of FAP inhibitors with a N-(4-quinolinoyl)-Gly-(2-cyanopyrrolidine) scaffold, e.g. I.  We have explored the effects of substituting the quinoline ring and varying the position of its sp2 hybridized nitrogen atom.  The most promising inhibitors combined low nanomolar FAP inhibition and high selectivity indexes (>103) with respect to both the DPPs and PREP.  Preliminary expts. on a representative inhibitor demonstrate that plasma stability, kinetic soly., and log D of this class of compds. can be expected to be satisfactory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7f0rayraCQLVg90H21EOLACvtfcHk0ljMWkXj8TeOpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKnsLs%253D&md5=1836427e531f6e13264ca833613966dc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml300410d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300410d%26sid%3Dliteratum%253Aachs%26aulast%3DJansen%26aufirst%3DK.%26aulast%3DHeirbaut%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DRyabtsova%26aufirst%3DO.%26aulast%3DCos%26aufirst%3DP.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DSelective%2520Inhibitors%2520of%2520Fibroblast%2520Activation%2520Protein%2520%2528FAP%2529%2520with%2520a%2520%25284-Quinolinoyl%2529-glycyl-2-cyanopyrrolidine%2520Scaffold%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D491%26epage%3D496%26doi%3D10.1021%2Fml300410d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heirbaut, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkerk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span> <span> </span><span class="NLM_article-title">Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3053</span>â <span class="NLM_lpage">3074</span>, <span class="refDoi">Â DOI: 10.1021/jm500031w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500031w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVSjt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3053-3074&author=K.+Jansenauthor=L.+Heirbautauthor=R.+Verkerkauthor=J.+D.+Chengauthor=J.+Joossensauthor=P.+Cosauthor=L.+Maesauthor=A.-M.+Lambeirauthor=I.+De+Meesterauthor=K.+Augustynsauthor=P.+Van+der+Veken&title=Extended+structure-activity+relationship+and+pharmacokinetic+investigation+of+%284-quinolinoyl%29glycyl-2-cyanopyrrolidine+inhibitors+of+fibroblast+activation+protein+%28FAP%29&doi=10.1021%2Fjm500031w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Extended Structure-Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)</span></div><div class="casAuthors">Jansen, Koen; Heirbaut, Leen; Verkerk, Robert; Cheng, Jonathan D.; Joossens, Jurgen; Cos, Paul; Maes, Louis; Lambeir, Anne-Marie; De Meester, Ingrid; Augustyns, Koen; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3053-3074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast activation protein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV).  It has been convincingly linked to multiple disease states involving remodeling of the extracellular matrix.  FAP inhibition is investigated as a therapeutic option for several of these diseases, with most attention so far devoted to oncol. applications.  The authors previously discovered the N-4-quinolinoyl-Gly-(2S)-cyanoPro scaffold as a possible entry to highly potent and selective FAP inhibitors.  In the present study, the authors explore in detail the structure-activity relationship around this core scaffold.  The authors report extensively optimized compds. that display low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PREP).  The log D values, plasma stabilities, and microsomal stabilities of selected compds. were found to be highly satisfactory.  Pharmacokinetic evaluation in mice of selected inhibitors demonstrated high oral bioavailability, plasma half-life, and the potential to selectively and completely inhibit FAP in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogEWbN62xYn7Vg90H21EOLACvtfcHk0lhn35jrQ-T8Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVSjt7Y%253D&md5=c52e7b0f1b7a7b056a74577c262a1d6d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm500031w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500031w%26sid%3Dliteratum%253Aachs%26aulast%3DJansen%26aufirst%3DK.%26aulast%3DHeirbaut%26aufirst%3DL.%26aulast%3DVerkerk%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DCos%26aufirst%3DP.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DExtended%2520structure-activity%2520relationship%2520and%2520pharmacokinetic%2520investigation%2520of%2520%25284-quinolinoyl%2529glycyl-2-cyanopyrrolidine%2520inhibitors%2520of%2520fibroblast%2520activation%2520protein%2520%2528FAP%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3053%26epage%3D3074%26doi%3D10.1021%2Fjm500031w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loktev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roumestand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1423</span>â <span class="NLM_lpage">1429</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.210435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.118.210435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29626120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFWmsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1423-1429&author=A.+Loktevauthor=T.+Lindnerauthor=W.+Mierauthor=J.+Debusauthor=A.+Altmannauthor=D.+J%C3%A4gerauthor=F.+Gieselauthor=C.+Kratochwilauthor=P.+Bartheauthor=C.+Roumestandauthor=U.+Haberkorn&title=A+Tumor-Imaging+Method+Targeting+Cancer-Associated+Fibroblasts&doi=10.2967%2Fjnumed.118.210435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A tumor-imaging method targeting cancer-associated fibroblasts</span></div><div class="casAuthors">Loktev, Anastasia; Lindner, Thomas; Mier, Walter; Debus, Juergen; Altmann, Annette; Jaeger, Dirk; Giesel, Frederik; Kratochwil, Clemens; Barthe, Philippe; Roumestand, Christian; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1423-1429</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The tumor stroma, which accounts for a large part of the tumor mass, represents an attractive target for the delivery of diagnostic and therapeutic compds.  Here, the focus is notably on a subpopulation of stromal cells, known as cancer-assocd. fibroblasts, which are present in more than 90% of epithelial carcinomas, including pancreatic, colon, and breast cancer.  Cancer-assocd. fibroblasts feature high expression of fibroblast activation protein (FAP), which is not detectable in adult normal tissue but is assocd. with a poor prognosis in cancer patients.  Methods: We developed an iodinated and a DOTA-coupled radiotracer based on a FAP-specific enzyme inhibitor (FAPI) and evaluated them in vitro using uptake, competition, and efflux studies as well as confocal microscopy of a fluorescence-labeled variant.  Furthermore, we performed imaging and biodistribution studies on tumor-bearing animals.  Finally, proof of concept was realized by imaging patients with 68Ga-labeled FAPI.  Results: Both FAPIs showed high specificity, affinity, and rapid internalization into FAP-expressing cells in vitro and in vivo.  Biodistribution studies on tumor-bearing mice and on the first cancer patients demonstrated high intratumoral uptake of the tracer and fast body clearance, resulting in highcontrast images and negligible exposure of healthy tissue to radiation.  A comparison with the commonly used radiotracer 18F-FDG in a patient with locally advanced lung adenocarcinoma revealed that the new FAP ligand was clearly superior.  Conclusion: Radiolabeled FAPIs allow fast imaging with very high contrast in tumors having a high stromal content and may therefore serve as pantumor agents.  Coupling of these mols. to DOTA or other chelators allows labeling not only with 68Ga but also with therapeutic isotopes such as 177Lu or 90Y.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKOEK0YEckWrVg90H21EOLACvtfcHk0lhn35jrQ-T8Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFWmsro%253D&md5=7fdfe7895a2dd8d2b4f048407d55d5de</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.210435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.210435%26sid%3Dliteratum%253Aachs%26aulast%3DLoktev%26aufirst%3DA.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DAltmann%26aufirst%3DA.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DD.%26aulast%3DGiesel%26aufirst%3DF.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DBarthe%26aufirst%3DP.%26aulast%3DRoumestand%26aufirst%3DC.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DA%2520Tumor-Imaging%2520Method%2520Targeting%2520Cancer-Associated%2520Fibroblasts%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D1423%26epage%3D1429%26doi%3D10.2967%2Fjnumed.118.210435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschalek, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loktev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehnert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flechsig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">386</span>â <span class="NLM_lpage">392</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.215913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.118.215913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30072500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yhtbfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=386-392&author=F.+L.+Gieselauthor=C.+Kratochwilauthor=T.+Lindnerauthor=M.+M.+Marschalekauthor=A.+Loktevauthor=W.+Lehnertauthor=J.+Debusauthor=D.+J%C3%A4gerauthor=P.+Flechsigauthor=A.+Altmannauthor=W.+Mierauthor=U.+Haberkorn&title=%2868%29Ga-FAPI+PET%2FCT%3A+Biodistribution+and+Preliminary+Dosimetry+Estimate+of+2+DOTA-Containing+FAP-Targeting+Agents+in+Patients+with+Various+Cancers&doi=10.2967%2Fjnumed.118.215913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers</span></div><div class="casAuthors">Giesel, Frederik L.; Kratochwil, Clemens; Lindner, Thomas; Marschalek, Manfred M.; Loktev, Anastasia; Lehnert, Wencke; Debus, Juergen; Jaeger, Dirk; Flechsig, Paul; Altmann, Annette; Mier, Walter; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">386-392</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Fibroblast activation protein (FAP) is overexpressed in cancer-assocd. fibroblasts of several tumor entities.  The recent development of quinoline-based PET tracers that act as FAP inhibitors (FAPIs) demonstrated promising results preclinically and already in a few clin. cases.  Consequently, these tracers are now applied in our hospital to amend the diagnostics of cancer patients facing the limitations of std. examns.  Here, we analyze the tissue biodistribution and preliminary dosimetry of 2 members of this new class of PET radiopharmaceutical.  A preliminary dosimetry est. for 68Ga-FAPI-2 and 68Ga-FAPI-4 was based on 2 patients examd. at 0.2, 1, and 3 h after tracer injection using the QDOSE dosimetry software suit.  Further PET/CT scans of tumor patients were acquired 1 h after injection of either 68Ga-FAPI-2 (n = 25) or 68Ga-FAPI-4 (n = 25); for 6 patients an intraindividual related 18F-FDG scan (also acquired 1 h after injection) was available.  For the normal tissue of 16 organs, a 2-cm spheric vol. of interest was placed in the parenchyma; for tumor lesions, a threshold-segmented vol. of interest was used to quantify SUVmean and SUVmax.  Similar to literature values for 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA-11, an examn. with 200 MBq of 68Ga-FAPI-2 or 68Ga-FAPI-4 corresponds to an equiv. dose of approx. 3-4 mSv.  After a fast clearance via the kidneys, the normal organs showed a low tracer uptake with only minimal changes between 10 min and 3 h after injection.  In 68Ga-FAPI-2, the tumor uptake from 1 to 3 h after injection decreased by 75%, whereas the tumor retention was prolonged with 68Ga-FAPI-4 (25% washout).  Regarding tumor-to-background ratios, at 1 h after injection both 68Ga-FAPI tracers performed equally.  In comparison to 18F-FDG, the tumor uptake was almost equal (av. SUVmax, 7.41 for 18F-FDG and 7.37 for 68Ga-FAPI-2; not statistically significant); the background uptake in brain (11.01 vs. 0.32), liver (2.77 vs. 1.69), and oral/pharyngeal mucosa (4.88 vs. 2.57) was significantly lower with 68Ga-FAPI.  Other organs did not relevantly differ between 18F-FDG and 68Ga-FAPI.  FAPI PET/CT is a new diagnostic method in imaging cancer patients.  In contrast to 18F-FDG, no diet or fasting in prepn. for the examn. is necessary, and image acquisition can potentially be started a few minutes after tracer application.  Tumor-to-background contrast ratios were equal to or even better than those of 18F-FDG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVF9NHxFhgzrVg90H21EOLACvtfcHk0lgENISActcp3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yhtbfO&md5=266c83d02ef44662656c261b2f1bf5ad</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.215913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.215913%26sid%3Dliteratum%253Aachs%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DMarschalek%26aufirst%3DM.%2BM.%26aulast%3DLoktev%26aufirst%3DA.%26aulast%3DLehnert%26aufirst%3DW.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DD.%26aulast%3DFlechsig%26aufirst%3DP.%26aulast%3DAltmann%26aufirst%3DA.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3D%252868%2529Ga-FAPI%2520PET%252FCT%253A%2520Biodistribution%2520and%2520Preliminary%2520Dosimetry%2520Estimate%2520of%25202%2520DOTA-Containing%2520FAP-Targeting%2520Agents%2520in%2520Patients%2520with%2520Various%2520Cancers%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D386%26epage%3D392%26doi%3D10.2967%2Fjnumed.118.215913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hettiarachchi, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">5778</span>â <span class="NLM_lpage">5789</span>, <span class="refDoi">Â DOI: 10.7150/thno.41409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.7150%2Fthno.41409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=32483418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGgsr3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=5778-5789&author=J.+Royauthor=S.+U.+Hettiarachchiauthor=M.+Kaakeauthor=R.+Mukkamalaauthor=P.+S.+Low&title=Design+and+validation+of+fibroblast+activation+protein+alpha+targeted+imaging+and+therapeutic+agents&doi=10.7150%2Fthno.41409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents</span></div><div class="casAuthors">Roy, Jyoti; Hettiarachchi, Suraj U.; Kaake, Miranda; Mukkamala, Ramesh; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5778-5789</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts (CAFs) comprise a major cell type in the tumor microenvironment where they support tumor growth and survival by producing extracellular matrix, secreting immunosuppressive cytokines, releasing growth factors, and facilitating metastases.  Because tumors with elevated CAFs are characterized by poorer prognosis, considerable effort is focused on developing methods to quantitate, suppress and/or eliminate CAFs.  We exploit the elevated expression of fibroblast activation protein (FAP) on CAFs to target imaging and therapeutic agents selectively to these fibroblasts in solid tumors.  FAP-targeted optical imaging, radioimaging, and chemotherapeutic agents were synthesized by conjugating FAP ligand (FL) to either a fluorescent dye, technetium-99m, or tubulysin B hydrazide.  In vitro and in vivo studies were performed to det. the specificity and selectivity of each conjugate for FAP in vitro and in vivo.  FAP-targeted imaging and therapeutic conjugates showed high binding specificity and affinity in the low nanomolar range.  Injection of FAP-targeted 99mTc into tumor-bearing mice enabled facile detection of tumor xenografts with little off-target uptake.  Optical imaging of malignant lesions was also readily achieved following i.v. injection of FAP-targeted near-IR fluorescent dye.  Finally, systemic administration of a tubulysin B conjugate of FL promoted complete eradication of solid tumors with no evidence of gross toxicity to the animals.  In view of the near absence of FAP on healthy cells, we conclude that targeting of FAP on cancer-assocd. fibroblasts can enable highly specific imaging and therapy of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmjw0e1by25bVg90H21EOLACvtfcHk0lgENISActcp3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGgsr3P&md5=11619d3be6835d22979dc378baa494e2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.7150%2Fthno.41409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.41409%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DJ.%26aulast%3DHettiarachchi%26aufirst%3DS.%2BU.%26aulast%3DKaake%26aufirst%3DM.%26aulast%3DMukkamala%26aufirst%3DR.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DDesign%2520and%2520validation%2520of%2520fibroblast%2520activation%2520protein%2520alpha%2520targeted%2520imaging%2520and%2520therapeutic%2520agents%26jtitle%3DTheranostics%26date%3D2020%26volume%3D10%26spage%3D5778%26epage%3D5789%26doi%3D10.7150%2Fthno.41409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westerlund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honarvar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NorrstrÃ¶m, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson
KarlstrÃ¶m, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span> <span> </span><span class="NLM_article-title">Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1668</span>â <span class="NLM_lpage">1678</span>, <span class="refDoi">Â DOI: 10.1021/acs.molpharmaceut.6b00089</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00089" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eisLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=1668-1678&author=K.+Westerlundauthor=H.+Honarvarauthor=E.+Norrstr%C3%B6mauthor=J.+Strandauthor=B.+Mitranauthor=A.+Orlovaauthor=A.+Eriksson%0AKarlstr%C3%B6mauthor=V.+Tolmachev&title=Increasing+the+Net+Negative+Charge+by+Replacement+of+DOTA+Chelator+with+DOTAGA+Improves+the+Biodistribution+of+Radiolabeled+Second-Generation+Synthetic+Affibody+Molecules&doi=10.1021%2Facs.molpharmaceut.6b00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules</span></div><div class="casAuthors">Westerlund, Kristina; Honarvar, Hadis; Norrstroem, Emily; Strand, Joanna; Mitran, Bogdan; Orlova, Anna; Eriksson Karlstroem, Amelie; Tolmachev, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1668-1678</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A promising strategy to enable patient stratification for targeted therapies is to monitor the target expression in a tumor by radionuclide mol. imaging.  Affibody mols. (7 kDa) are nonimmunoglobulin scaffold proteins with a 25-fold smaller size than intact antibodies.  They have shown an apparent potential as mol. imaging probes both in preclin. and clin. studies.  Earlier, we found that hepatic uptake can be reduced by the incorporation of neg. charged purifn. tags at the N-terminus of Affibody mols.  We hypothesized that liver uptake might similarly be reduced by positioning the chelator at the N-terminus, where the chelator-radionuclide complex will provide neg. charges.  To test this hypothesis, a second generation synthetic anti-HER2 ZHER2:2891 Affibody mol. was synthesized and labeled with 111In and 68Ga using DOTAGA and DOTA chelators.  The chelators were manually coupled to the N-terminus of ZHER2:2891 forming an amide bond.  Labeling DOTAGA-ZHER2:2891 and DOTA-ZHER2:2891 with 68Ga and 111In resulted in stable radioconjugates.  The tumor-targeting and biodistribution properties of the 111In- and 68Ga-labeled conjugates were compared in SKOV-3 tumor-bearing nude mice at 2 h postinjection.  The HER2-specific binding of the radioconjugates was verified both in vitro and in vivo.  Using the DOTAGA chelator gave significantly lower radioactivity in liver and blood for both radionuclides.  The 111In-labeled conjugates showed more rapid blood clearance than the 68Ga-labeled conjugates.  The most pronounced influence of the chelators was found when they were labeled with 68Ga.  The DOTAGA chelator gave significantly higher tumor-to-blood (61 Â± 6 vs 23 Â± 5, p < 0.05) and tumor-to-liver (10.4 Â± 0.6 vs 4.5 Â± 0.5, p < 0.05) ratios than the DOTA chelator.  This study demonstrated that chelators may be used to alter the uptake of Affibody mols., and most likely other scaffold-based imaging probes, for improvement of imaging contrast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFFpqluORn57Vg90H21EOLACvtfcHk0lhrRpCm8_0nMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eisLw%253D&md5=45fffbc349b38abfbff0082752dd0e09</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00089%26sid%3Dliteratum%253Aachs%26aulast%3DWesterlund%26aufirst%3DK.%26aulast%3DHonarvar%26aufirst%3DH.%26aulast%3DNorrstr%25C3%25B6m%26aufirst%3DE.%26aulast%3DStrand%26aufirst%3DJ.%26aulast%3DMitran%26aufirst%3DB.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DEriksson%2BKarlstr%25C3%25B6m%26aufirst%3DA.%26aulast%3DTolmachev%26aufirst%3DV.%26atitle%3DIncreasing%2520the%2520Net%2520Negative%2520Charge%2520by%2520Replacement%2520of%2520DOTA%2520Chelator%2520with%2520DOTAGA%2520Improves%2520the%2520Biodistribution%2520of%2520Radiolabeled%2520Second-Generation%2520Synthetic%2520Affibody%2520Molecules%26jtitle%3DMol.%2520Pharm.%26date%3D2016%26volume%3D13%26spage%3D1668%26epage%3D1678%26doi%3D10.1021%2Facs.molpharmaceut.6b00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, M.-A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leppla, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, B.</span></span> <span> </span><span class="NLM_article-title">Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>72â73</i></span>,  <span class="NLM_fpage">49</span>â <span class="NLM_lpage">54</span>, <span class="refDoi">Â DOI: 10.1016/j.nucmedbio.2019.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.nucmedbio.2019.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=31330412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVajtrvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72%E2%80%9373&publication_year=2019&pages=49-54&author=M.-A.+E.+Xavierauthor=S.+Liuauthor=S.+H.+Lepplaauthor=B.+Cornelissen&title=Pre-labelling+versus+direct+labelling+of+anthrax+proteins+for+imaging+of+matrix+metalloproteinases+activity+using+DOTA-GA&doi=10.1016%2Fj.nucmedbio.2019.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA</span></div><div class="casAuthors">Xavier, Mary-Ann Elvina; Liu, Shihui; Leppla, Stephen H.; Cornelissen, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">72-73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-54</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Increased activity of matrix metalloproteases (MMPs) is assocd. with reduced survival in several cancer subtypes.  Aiming to produce an MMP tumor cell-selective cytotoxin, we genetically modified both components of the AB-type lethal toxin from Bacillus anthracis.  Component A, Protective Antigen (PA-WT), was re-engineered to form an oligomeric pore in cell membranes only when cleaved by MMPs (PA-L1).  The pore-translocation domain (LFn - N-terminal, 30 kDa) of the Lethal Factor (LF), component B, was fused to the catalytic domain of Pseudomonas exotoxin-A to increase its cytotoxic effect when delivered to cancerous cells.  Here, we develop radiolabeled forms of LFn for MMP activity imaging by SPECT using the LFn/PA-L1 system.  DOTA-GA-maleimide was conjugated to LFn to allow radiolabelling with 111In via two different routes: (1) LFn was conjugated with maleimide-DOTA-GA under mild conditions, and then radiolabeled in acidic conditions at 95Â°, or (2) 111In was coordinated to maleimide-DOTA-GA first and then conjugated via maleimide chem. to LFn.  CD Spectroscopy of LFn was performed to evaluate changes in its secondary structure.  Cell uptake assays using the differently labeled forms of [111In]In-DOTA-GA-LFn in the presence or not of PA-WT or PA-L1 were performed.  LFn was successfully radiolabeled by either strategy.  Comparison of the secondary structure content of LFn exposed to 37Â° or 95Â°, showed a loss of alpha helix content at higher temps.  Cell uptake of both forms of [111In]In-DOTA-GA-LFn, labeled directly or indirectly, was significantly higher in MMP-pos. cells, in the presence of PA-L1, compared to controls.  Notably, despite being exposed to high temps., uptake of directly labeled [111In]In-DOTA-GA-LFndir was higher than indirectly labeled [111In]In-DOTA-GA-LFnindir.111In-radiolabelling of LFn results in a functional mol. that targets MMP-activity in cells when combined with PA-L1. [111In]In-LFn/PA-L1 is a promising MMP activity imaging agent for SPECT imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX1h52JISJqrVg90H21EOLACvtfcHk0lhrRpCm8_0nMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVajtrvL&md5=b0fe3c93663f949844c677d1c42613d8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2019.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2019.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DXavier%26aufirst%3DM.-A.%2BE.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLeppla%26aufirst%3DS.%2BH.%26aulast%3DCornelissen%26aufirst%3DB.%26atitle%3DPre-labelling%2520versus%2520direct%2520labelling%2520of%2520anthrax%2520proteins%2520for%2520imaging%2520of%2520matrix%2520metalloproteinases%2520activity%2520using%2520DOTA-GA%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2019%26volume%3D72%25E2%2580%259373%26spage%3D49%26epage%3D54%26doi%3D10.1016%2Fj.nucmedbio.2019.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrigneaud, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tizon, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchamp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunotte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denat, F.</span></span> <span> </span><span class="NLM_article-title">DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1181</span>â <span class="NLM_lpage">1188</span>, <span class="refDoi">Â DOI: 10.1021/bc200680x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc200680x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGjtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1181-1188&author=M.+Moreauauthor=O.+Raguinauthor=J.-M.+Vrigneaudauthor=B.+Collinauthor=C.+Bernhardauthor=X.+Tizonauthor=F.+Boschettiauthor=O.+Duchampauthor=F.+Brunotteauthor=F.+Denat&title=DOTAGA-trastuzumab.+A+new+antibody+conjugate+targeting+HER2%2FNeu+antigen+for+diagnostic+purposes&doi=10.1021%2Fbc200680x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/Neu Antigen for Diagnostic Purposes</span></div><div class="casAuthors">Moreau, Mathieu; Raguin, Olivier; Vrigneaud, Jean-Marc; Collin, Bertrand; Bernhard, Claire; Tizon, Xavier; Boschetti, Frederic; Duchamp, Olivier; Brunotte, Francois; Denat, Franck</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1181-1188</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Improved bifunctional chelating agents (BFC) are required for indium-111 radiolabeling of monoclonal antibodies (mAbs) under mild conditions to yield stable, target-specific agents. 2,2,2-(10-(2,6-Dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTAGA-anhydride) was evaluated for mAb conjugation and labeling with indium-111.  The DOTA analog was synthesized and conjugated to trastuzumab which targets the HER2/neu receptor in mild conditions (PBS pH 7.4, 25 C, 30 min) and gave a mean degree of conjugation of 2.6 macrocycle per antibody.  Labeling of this immunoconjugate with indium-111 was performed in 75% yield after 1 h at 37 C, and the proportion of 111In-DOTAGA-trastuzumab reached 97% after purifn.  The affinity of DOTAGA-trastuzumab was 5.5, 0.6 nM as evaluated by in vitro satn. assays using HCC1954 breast cancer cell line.  SPECT/CT imaging and biodistribution studies were performed in mice bearing breast cancer BT-474 xenografts.  BT-474 tumors were clearly visualized on SPECT images at 24, 48, and 72 h postinjection.  The tumor uptake of [111In-DOTAGA]-trastuzumab reached 65%ID/g 72 h postinjection.  These results show that the DOTAGA BFC appears to be a valuable tool for biologics conjugation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTIrhdIOo9bVg90H21EOLACvtfcHk0lggvO4j9dJY7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGjtLk%253D&md5=a2552569ece81de76b49e12f9ee8c393</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fbc200680x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc200680x%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DM.%26aulast%3DRaguin%26aufirst%3DO.%26aulast%3DVrigneaud%26aufirst%3DJ.-M.%26aulast%3DCollin%26aufirst%3DB.%26aulast%3DBernhard%26aufirst%3DC.%26aulast%3DTizon%26aufirst%3DX.%26aulast%3DBoschetti%26aufirst%3DF.%26aulast%3DDuchamp%26aufirst%3DO.%26aulast%3DBrunotte%26aufirst%3DF.%26aulast%3DDenat%26aufirst%3DF.%26atitle%3DDOTAGA-trastuzumab.%2520A%2520new%2520antibody%2520conjugate%2520targeting%2520HER2%252FNeu%2520antigen%2520for%2520diagnostic%2520purposes%26jtitle%3DBioconjugate%2520Chem.%26date%3D2012%26volume%3D23%26spage%3D1181%26epage%3D1188%26doi%3D10.1021%2Fbc200680x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisenwiener, K.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¤cke, H. R.</span></span> <span> </span><span class="NLM_article-title">A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2133</span>â <span class="NLM_lpage">2135</span>, <span class="refDoi">Â DOI: 10.1016/s0960-894x(00)00413-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2FS0960-894X%2800%2900413-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10999487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtF2ht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2133-2135&author=K.-P.+Eisenwienerauthor=P.+Powellauthor=H.+R.+M%C3%A4cke&title=A+convenient+synthesis+of+novel+bifunctional+prochelators+for+coupling+to+bioactive+peptides+for+radiometal+labelling&doi=10.1016%2Fs0960-894x%2800%2900413-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling</span></div><div class="casAuthors">Eisenwiener, K.-P.; Powell, P.; Macke, H. R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2133-2135</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">New DOTA-based bifunctional prochelators, e.g., 1-(1-carboxy-3-carbo-tert-butoxypropyl)-4,7,10-(carbo-tert-butoxymethyl)-1,4,7,10-tetraazacyclododecane [(DOTAGA(tBu)4), (I)] for a broad application in the modification of biomols. with metal ions were prepd.  The five-step synthesis of I has an overall yield of about 20%.  The coupling of I to a bioactive peptide on solid-phase was exemplified with use of a CCK-B (cholecystokinin) analog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo47vDF-IEqBLVg90H21EOLACvtfcHk0lggvO4j9dJY7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtF2ht7Y%253D&md5=9c1bfb2974398f7641d3292207dfb826</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900413-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900413-3%26sid%3Dliteratum%253Aachs%26aulast%3DEisenwiener%26aufirst%3DK.-P.%26aulast%3DPowell%26aufirst%3DP.%26aulast%3DM%25C3%25A4cke%26aufirst%3DH.%2BR.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520novel%2520bifunctional%2520prochelators%2520for%2520coupling%2520to%2520bioactive%2520peptides%2520for%2520radiometal%2520labelling%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2133%26epage%3D2135%26doi%3D10.1016%2Fs0960-894x%2800%2900413-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masugi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii-Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, M.</span></span> <span> </span><span class="NLM_article-title">Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">107</span>â <span class="NLM_lpage">119</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-20-2298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1158%2F1078-0432.CCR-20-2298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=33046515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BB3MXltlWjsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2021&pages=107-119&author=Y.+Ogawaauthor=Y.+Masugiauthor=T.+Abeauthor=K.+Yamazakiauthor=A.+Uenoauthor=Y.+Fujii-Nishimuraauthor=S.+Horiauthor=H.+Yagiauthor=Y.+Abeauthor=M.+Kitagoauthor=M.+Sakamoto&title=Three+distinct+stroma+types+in+human+pancreatic+cancer+identified+by+image+analysis+of+fibroblast+subpopulations+and+collagen&doi=10.1158%2F1078-0432.CCR-20-2298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen</span></div><div class="casAuthors">Ogawa, Yurina; Masugi, Yohei; Abe, Tokiya; Yamazaki, Ken; Ueno, Akihisa; Fujii-Nishimura, Yoko; Hori, Shutaro; Yagi, Hiroshi; Abe, Yuta; Kitago, Minoru; Sakamoto, Michiie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-119</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts have emerged to be highly heterogenous and can play multifaceted roles in dictating pancreatic ductal adenocarcinoma (PDAC) progression, immunosuppression, and therapeutic response, highlighting the need for a deeper understanding of stromal heterogeneity between patients and even within a single tumor.  We hypothesized that image anal. of fibroblast subpopulations and collagen in PDAC tissues might guide stroma-based patient stratification to predict clin. outcomes and tumor characteristics.  A novel multiplex IHC-based image anal. system was established to digitally differentiate fibroblast subpopulations.  Using whole-tissue slides from 215 treatment-naive PDACs, we performed concurrent quantification of principal fibroblast subpopulations and collagen and defined three stroma types: collagen-rich stroma, fibroblast activation protein Î± (FAP)-dominant fibroblast-rich stroma, and Î± smooth muscle actin (ACTA2)-dominant fibroblast-rich stroma.  These stroma types were assessed for the assocns. with cancer-specific survival by multivariable Cox regression analyses and with clinicopathol. factors, including CD8+ cell d.  FAP-dominant fibroblasts and ACTA2-dominant fibroblasts represented the principal distinct fibroblast subpopulations in tumor stroma.  Stroma types were assocd. with patient survival, SMAD4 status, and transcriptome signatures.  Compared with FAP-dominant fibroblast-rich stroma, collagen-rich stroma correlated with prolonged survival [HR, 0.57; 95% confidence interval (CI), 0.33-0.99], while ACTA2-dominant fibroblast-rich stroma exhibited poorer prognosis (HR, 1.65; 95% CI, 1.06-2.58).  FAP-dominant fibroblast-rich stroma was addnl. characterized by restricted CD8+ cell infiltrates and intense neutrophil infiltration.  This study identified three distinct stroma types differentially assocd. with survival, immunity, and mol. features, thereby underscoring the importance of stromal heterogeneity in subtyping pancreatic cancers and supporting the development of antistromal therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh2O8Xx8z2MrVg90H21EOLACvtfcHk0ljEWC_gic333A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXltlWjsL0%253D&md5=9941c0409f3456873c9765c599a15f34</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-20-2298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-20-2298%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DMasugi%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DT.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DUeno%26aufirst%3DA.%26aulast%3DFujii-Nishimura%26aufirst%3DY.%26aulast%3DHori%26aufirst%3DS.%26aulast%3DYagi%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DKitago%26aufirst%3DM.%26aulast%3DSakamoto%26aufirst%3DM.%26atitle%3DThree%2520distinct%2520stroma%2520types%2520in%2520human%2520pancreatic%2520cancer%2520identified%2520by%2520image%2520analysis%2520of%2520fibroblast%2520subpopulations%2520and%2520collagen%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2021%26volume%3D27%26spage%3D107%26epage%3D119%26doi%3D10.1158%2F1078-0432.CCR-20-2298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryabtsova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Goethem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span> <span> </span><span class="NLM_article-title">Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3412</span>â <span class="NLM_lpage">3417</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.03.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.bmcl.2012.03.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22525314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFait7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3412-3417&author=O.+Ryabtsovaauthor=K.+Jansenauthor=S.+Van+Goethemauthor=J.+Joossensauthor=J.+D.+Chengauthor=A.-M.+Lambeirauthor=I.+De+Meesterauthor=K.+Augustynsauthor=P.+Van+der+Veken&title=Acylated+Gly-%282-cyano%29pyrrolidines+as+inhibitors+of+fibroblast+activation+protein+%28FAP%29+and+the+issue+of+FAP%2Fprolyl+oligopeptidase+%28PREP%29-selectivity&doi=10.1016%2Fj.bmcl.2012.03.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity</span></div><div class="casAuthors">Ryabtsova, Oxana; Jansen, Koen; Van Goethem, Sebastiaan; Joossens, Jurgen; Cheng, Jonathan D.; Lambeir, Anne-Marie; De Meester, Ingrid; Augustyns, Koen; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3412-3417</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N-acylated glycyl-(2-cyano)pyrrolidines were synthesized with the aim of generating structure-activity relationship (SAR) data for this class of compds. as inhibitors of fibroblast activation protein (FAP).  Specifically, the influence of (1) the choice of the N-acyl group and (2) structural modification of the 2-cyanopyrrolidine residue were investigated.  The inhibitors displayed inhibitory potency in the micromolar to nanomolar range and showed good to excellent selectivity with respect to the proline selective dipeptidyl peptidases (DPPs) DPP IV, DPP9 and DPP II.  Addnl., selectivity for FAP with respect to prolyl oligopeptidase (PREP) is reported.  Not unexpectedly, the latter data suggest significant overlap in the pharmacophoric features that define FAP or PREP-inhibitory activity and underscore the importance of systematically evaluating the FAP/PREP-selectivity index for inhibitors of either of these two enzymes.  Finally, this study forwards several compds. that can serve as leads or prototypic structures for future FAP-selective-inhibitor discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVTMe5wzszb7Vg90H21EOLACvtfcHk0ljEWC_gic333A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFait7k%253D&md5=0191b3cbe44c893935a33e13f62e4289</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.107%26sid%3Dliteratum%253Aachs%26aulast%3DRyabtsova%26aufirst%3DO.%26aulast%3DJansen%26aufirst%3DK.%26aulast%3DVan%2BGoethem%26aufirst%3DS.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DAcylated%2520Gly-%25282-cyano%2529pyrrolidines%2520as%2520inhibitors%2520of%2520fibroblast%2520activation%2520protein%2520%2528FAP%2529%2520and%2520the%2520issue%2520of%2520FAP%252Fprolyl%2520oligopeptidase%2520%2528PREP%2529-selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3412%26epage%3D3417%26doi%3D10.1016%2Fj.bmcl.2012.03.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loktev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MarmÃ©, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1421</span>â <span class="NLM_lpage">1429</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.224469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.2967%2Fjnumed.118.224469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30850501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntVensrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=1421-1429&author=A.+Loktevauthor=T.+Lindnerauthor=E.-M.+Burgerauthor=A.+Altmannauthor=F.+Gieselauthor=C.+Kratochwilauthor=J.+Debusauthor=F.+Marm%C3%A9author=D.+J%C3%A4gerauthor=W.+Mierauthor=U.+Haberkorn&title=Development+of+Fibroblast+Activation+Protein-Targeted+Radiotracers+with+Improved+Tumor+Retention&doi=10.2967%2Fjnumed.118.224469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of fibroblast activation protein-targeted radiotracers with improved tumor retention</span></div><div class="casAuthors">Loktev, Anastasia; Lindner, Thomas; Burger, Eva-Maria; Altmann, Annette; Giesel, Frederik; Kratochwil, Clemens; Debus, Jurgen; Marme, Frederik; Jager, Dirk; Mier, Walter; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1421-1429</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts constitute a vital subpopulation of the tumor stroma and are present in more than 90% of epithelial carcinomas.  Methods: Novel quinoline-based radiotracers were synthesized by org. chem. and evaluated in radioligand binding assays using FAP-expressing HT-1080 cells.  Depending on their in vitro performance, small-animal PET imaging and biodistribution studies were performed on HT-1080-FAP tumor- bearing mice.  The most promising compds. were used for clin. PET imaging in 8 cancer patients.  Results: Compared with FAPI-04, 11 of 15 FAPI derivs. showed improved FAP binding in vitro.  Of these, 7 compds. demonstrated increased tumor uptake in tumorbearing mice.  Moreover, tumor-to-normal-organ ratios were improved for most of the compds., resulting in images with higher contrast.  Notably two of the radiotracers, FAPI-21 and -46, displayed substantially improved ratios of tumor to blood, liver, muscle, and intestinal uptake.  A first diagnostic application in cancer patients revealed high intratumoral uptake of both radiotracers already 10 min after administration but a higher uptake in oral mucosa, salivary glands, and thyroid for FAPI-21.  Conclusion: Chem. modification of the FAPI framework enabled enhanced FAP binding and improved pharmacokinetics in most of the derivs., resulting in high-contrast images.  Moreover, higher doses of radioactivity can be delivered while minimizing damage to healthy tissue, which may improve therapeutic outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTKf0_vtMQ_LVg90H21EOLACvtfcHk0liquUqkXkpbsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntVensrw%253D&md5=f99a22fa605f5f490c5f298c3649cc7a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.224469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.224469%26sid%3Dliteratum%253Aachs%26aulast%3DLoktev%26aufirst%3DA.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DBurger%26aufirst%3DE.-M.%26aulast%3DAltmann%26aufirst%3DA.%26aulast%3DGiesel%26aufirst%3DF.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DMarm%25C3%25A9%26aufirst%3DF.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DD.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DDevelopment%2520of%2520Fibroblast%2520Activation%2520Protein-Targeted%2520Radiotracers%2520with%2520Improved%2520Tumor%2520Retention%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D1421%26epage%3D1429%26doi%3D10.2967%2Fjnumed.118.224469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiori, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Franco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stassi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Maria, R.</span></span> <span> </span><span class="NLM_article-title">Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">70</span>, <span class="refDoi">Â DOI: 10.1186/s12943-019-0994-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1186%2Fs12943-019-0994-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=30927908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A280%3ADC%252BB3cbpslKntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=70&author=M.+E.+Fioriauthor=S.+Di+Francoauthor=L.+Villanovaauthor=P.+Biancaauthor=G.+Stassiauthor=R.+De+Maria&title=Cancer-associated+fibroblasts+as+abettors+of+tumor+progression+at+the+crossroads+of+EMT+and+therapy+resistance&doi=10.1186%2Fs12943-019-0994-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance</span></div><div class="casAuthors">Fiori Micol Eleonora; Di Franco Simone; Bianca Paola; Stassi Giorgio; Villanova Lidia; De Maria Ruggero; De Maria Ruggero</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the last decades, the role of the microenvironment in tumor progression and therapeutic outcome has gained increasing attention.  Cancer-associated fibroblasts (CAFs) have emerged as key players among stromal cells, owing to their abundance in most solid tumors and their diverse tumor-restraining/promoting roles.  The interplay between tumor cells and neighboring CAFs takes place by both paracrine signals (cytokines, exosomes and metabolites) or by the multifaceted functions of the surrounding extracellular matrix.  Here, we dissect the most recent identified mechanisms underlying CAF-mediated control of tumor progression and therapy resistance, which include induction of the epithelial-to-mesenchymal transition (EMT), activation of survival pathways or stemness-related programs and metabolic reprogramming in tumor cells.  Importantly, the recently unveiled heterogeneity in CAFs claims tailored therapeutic efforts aimed at eradicating the specific subset facilitating tumor progression, therapy resistance and relapse.  However, despite the large amount of pre-clinical data, much effort is still needed to translate CAF-directed anti-cancer strategies from the bench to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKsAYahu6SM7jnyZkbE8yXfW6udTcc2eYAZu85IQSVR7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbpslKntA%253D%253D&md5=6f2b5842ae818720cc75b052682b3f86</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-0994-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-0994-2%26sid%3Dliteratum%253Aachs%26aulast%3DFiori%26aufirst%3DM.%2BE.%26aulast%3DDi%2BFranco%26aufirst%3DS.%26aulast%3DVillanova%26aufirst%3DL.%26aulast%3DBianca%26aufirst%3DP.%26aulast%3DStassi%26aufirst%3DG.%26aulast%3DDe%2BMaria%26aufirst%3DR.%26atitle%3DCancer-associated%2520fibroblasts%2520as%2520abettors%2520of%2520tumor%2520progression%2520at%2520the%2520crossroads%2520of%2520EMT%2520and%2520therapy%2520resistance%26jtitle%3DMol.%2520Canc.%26date%3D2019%26volume%3D18%26spage%3D70%26doi%3D10.1186%2Fs12943-019-0994-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RiviÃ¨re, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic T cell engineering</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>545</i></span>,  <span class="NLM_fpage">423</span>â <span class="NLM_lpage">431</span>, <span class="refDoi">Â DOI: 10.1038/nature22395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fnature22395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=28541315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVansrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=545&publication_year=2017&pages=423-431&author=M.+Sadelainauthor=I.+Rivi%C3%A8reauthor=S.+Riddell&title=Therapeutic+T+cell+engineering&doi=10.1038%2Fnature22395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic T cell engineering</span></div><div class="casAuthors">Sadelain, Michel; Riviere, Isabelle; Riddell, Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">545</span>
        (<span class="NLM_cas:issue">7655</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer.  Chimaeric antigen receptors (CARs) are a class of synthetic receptors that reprogram lymphocyte specificity and function.  CARs targeting CD19 have demonstrated remarkable potency in B cell malignancies.  Engineered T cells are applicable in principle to many cancers, pending further progress to identify suitable target antigens, overcome immunosuppressive tumor microenvironments, reduce toxicities, and prevent antigen escape.  Advances in the selection of optimal T cells, genetic engineering, and cell manufg. are poised to broaden T-cell-based therapies and foster new applications in infectious diseases and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI3N4jSAIySrVg90H21EOLACvtfcHk0liquUqkXkpbsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVansrc%253D&md5=e24a6f8f572e211e1a54a2c7823e4aa8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnature22395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22395%26sid%3Dliteratum%253Aachs%26aulast%3DSadelain%26aufirst%3DM.%26aulast%3DRivi%25C3%25A8re%26aufirst%3DI.%26aulast%3DRiddell%26aufirst%3DS.%26atitle%3DTherapeutic%2520T%2520cell%2520engineering%26jtitle%3DNature%26date%3D2017%26volume%3D545%26spage%3D423%26epage%3D431%26doi%3D10.1038%2Fnature22395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation proteins-alpha suppress tumor immunity by regulating T cells and tumor-associated macrophages</span>. <i>Exp. Mol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">29</span>â <span class="NLM_lpage">37</span>, <span class="refDoi">Â DOI: 10.1016/j.yexmp.2017.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2Fj.yexmp.2017.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=29273462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVaku7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2018&pages=29-37&author=C.+M.+Houauthor=X.+M.+Quauthor=J.+Zhangauthor=T.+T.+Dingauthor=W.+Hanauthor=G.+C.+Jiauthor=Z.+H.+Zhongauthor=H.+Chenauthor=F.+Zhang&title=Fibroblast+activation+proteins-alpha+suppress+tumor+immunity+by+regulating+T+cells+and+tumor-associated+macrophages&doi=10.1016%2Fj.yexmp.2017.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation proteins-Î± suppress tumor immunity by regulating T cells and tumor-associated macrophages</span></div><div class="casAuthors">Hou, Chun Mei; Qu, Xue Mei; Zhang, Jian; Ding, Ting Ting; Han, Wei; Ji, Guang Chuan; Zhong, Zhao Hua; Chen, He; Zhang, FengMin</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Pathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">EXMPA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4800</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Fibroblast activation protein-Î± (FAPÎ±) is a type-II cell-surface-bound integral transmembrane serine protease and selectively overexpressed by tumor-assocd. stromal fibroblasts (TAFs), which are the main components in the tumor microenvironment, in > 90% of malignant epithelial carcinomas.  FAPÎ± regulates the immunosuppression of tumor cells in the tumor microenvironment.  Regulatory T cells (Tregs) and tumor-assocd. macrophages (TAMs) are the major immunosuppressive cells in the tumor microenvironment.  However, the effect of FAPÎ± on Tregs and TAMs is unknown.  The non-enzymic function of FAPÎ± on Treg and TAM was investigated.  In this study, we confirm that FAPÎ± can promote the generation of Tregs and TAMs, which suggests that FAPÎ± plays a immunosuppressive role in the tumor microenvironment and provides evidence for FAP Î± as a potent immunotherapeutic target for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTTF5DKfldWLVg90H21EOLACvtfcHk0lg76l4nGTWwTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVaku7rK&md5=5e3178ac1261956c69a96a55db7547d7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.yexmp.2017.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexmp.2017.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DC.%2BM.%26aulast%3DQu%26aufirst%3DX.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DT.%2BT.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DG.%2BC.%26aulast%3DZhong%26aufirst%3DZ.%2BH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DF.%26atitle%3DFibroblast%2520activation%2520proteins-alpha%2520suppress%2520tumor%2520immunity%2520by%2520regulating%2520T%2520cells%2520and%2520tumor-associated%2520macrophages%26jtitle%3DExp.%2520Mol.%2520Pathol.%26date%3D2018%26volume%3D104%26spage%3D29%26epage%3D37%26doi%3D10.1016%2Fj.yexmp.2017.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>, <span class="refDoi">Â DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lg76l4nGTWwTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LehÃ¡r, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonkin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monahan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morais, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korejwa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JanÃ©-Valbuena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mapa, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bric-Furlong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipway, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engels, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspesi, P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Silva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagtap, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palescandolo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sougnez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onofrio, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liefeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConaill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span> <span> </span><span class="NLM_article-title">The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>483</i></span>,  <span class="NLM_fpage">603</span>â <span class="NLM_lpage">607</span>, <span class="refDoi">Â DOI: 10.1038/nature11003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1038%2Fnature11003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=22460905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVequ7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=483&publication_year=2012&pages=603-607&author=J.+Barretinaauthor=G.+Caponigroauthor=N.+Stranskyauthor=K.+Venkatesanauthor=A.+A.+Margolinauthor=S.+Kimauthor=C.+J.+Wilsonauthor=J.+Leh%C3%A1rauthor=G.+V.+Kryukovauthor=D.+Sonkinauthor=A.+Reddyauthor=M.+Liuauthor=L.+Murrayauthor=M.+F.+Bergerauthor=J.+E.+Monahanauthor=P.+Moraisauthor=J.+Meltzerauthor=A.+Korejwaauthor=J.+Jan%C3%A9-Valbuenaauthor=F.+A.+Mapaauthor=J.+Thibaultauthor=E.+Bric-Furlongauthor=P.+Ramanauthor=A.+Shipwayauthor=I.+H.+Engelsauthor=J.+Chengauthor=G.+K.+Yuauthor=J.+Yuauthor=P.+Aspesiauthor=M.+de+Silvaauthor=K.+Jagtapauthor=M.+D.+Jonesauthor=L.+Wangauthor=C.+Hattonauthor=E.+Palescandoloauthor=S.+Guptaauthor=S.+Mahanauthor=C.+Sougnezauthor=R.+C.+Onofrioauthor=T.+Liefeldauthor=L.+MacConaillauthor=W.+Wincklerauthor=M.+Reichauthor=N.+Liauthor=J.+P.+Mesirovauthor=S.+B.+Gabrielauthor=G.+Getzauthor=K.+Ardlieauthor=V.+Chanauthor=V.+E.+Myerauthor=B.+L.+Weberauthor=J.+Porterauthor=M.+Warmuthauthor=P.+Finanauthor=J.+L.+Harrisauthor=M.+Meyersonauthor=T.+R.+Golubauthor=M.+P.+Morrisseyauthor=W.+R.+Sellersauthor=R.+Schlegelauthor=L.+A.+Garraway&title=The+Cancer+Cell+Line+Encyclopedia+enables+predictive+modelling+of+anticancer+drug+sensitivity&doi=10.1038%2Fnature11003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</span></div><div class="casAuthors">Barretina, Jordi; Caponigro, Giordano; Stransky, Nicolas; Venkatesan, Kavitha; Margolin, Adam A.; Kim, Sungjoon; Wilson, Christopher J.; Lehar, Joseph; Kryukov, Gregory V.; Sonkin, Dmitriy; Reddy, Anupama; Liu, Manway; Murray, Lauren; Berger, Michael F.; Monahan, John E.; Morais, Paula; Meltzer, Jodi; Korejwa, Adam; Jane-Valbuena, Judit; Mapa, Felipa A.; Thibault, Joseph; Bric-Furlong, Eva; Raman, Pichai; Shipway, Aaron; Engels, Ingo H.; Cheng, Jill; Yu, Guoying K.; Yu, Jianjun; Aspesi, Peter; de Silva, Melanie; Jagtap, Kalpana; Jones, Michael D.; Wang, Li; Hatton, Charles; Palescandolo, Emanuele; Gupta, Supriya; Mahan, Scott; Sougnez, Carrie; Onofrio, Robert C.; Liefeld, Ted; MacConaill, Laura; Winckler, Wendy; Reich, Michael; Li, Nanxin; Mesirov, Jill P.; Gabriel, Stacey B.; Getz, Gad; Ardlie, Kristin; Chan, Vivien; Myer, Vic E.; Weber, Barbara L.; Porter, Jeff; Warmuth, Markus; Finan, Peter; Harris, Jennifer L.; Meyerson, Matthew; Golub, Todd R.; Morrissey, Michael P.; Sellers, William R.; Schlegel, Robert; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">483</span>
        (<span class="NLM_cas:issue">7391</span>),
    <span class="NLM_cas:pages">603-607</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The systematic translation of cancer genomic data into knowledge of tumor biol. and therapeutic possibilities remains challenging.  Such efforts should be greatly aided by robust preclin. model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacol. annotation is available.  Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy no. and massively parallel sequencing data from 947 human cancer cell lines.  When coupled with pharmacol. profiles for 24 anticancer drugs across 479 of the cell lines, this collection allowed identification of genetic, lineage, and gene-expression-based predictors of drug sensitivity.  In addn. to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was assocd. with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors.  Together, our results indicate that large, annotated cell-line collections may help to enable preclin. stratification schemata for anticancer agents.  The generation of genetic predictions of drug response in the preclin. setting and their incorporation into cancer clin. trial design could speed the emergence of personalized' therapeutic regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHUeZ7mtYpwLVg90H21EOLACvtfcHk0lhNoWEOOYUBbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVequ7o%253D&md5=4aefaa8c7abd1e30c35c4eeca811687b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnature11003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11003%26sid%3Dliteratum%253Aachs%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DMargolin%26aufirst%3DA.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKryukov%26aufirst%3DG.%2BV.%26aulast%3DSonkin%26aufirst%3DD.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DMonahan%26aufirst%3DJ.%2BE.%26aulast%3DMorais%26aufirst%3DP.%26aulast%3DMeltzer%26aufirst%3DJ.%26aulast%3DKorejwa%26aufirst%3DA.%26aulast%3DJan%25C3%25A9-Valbuena%26aufirst%3DJ.%26aulast%3DMapa%26aufirst%3DF.%2BA.%26aulast%3DThibault%26aufirst%3DJ.%26aulast%3DBric-Furlong%26aufirst%3DE.%26aulast%3DRaman%26aufirst%3DP.%26aulast%3DShipway%26aufirst%3DA.%26aulast%3DEngels%26aufirst%3DI.%2BH.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%2BK.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DAspesi%26aufirst%3DP.%26aulast%3Dde%2BSilva%26aufirst%3DM.%26aulast%3DJagtap%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DM.%2BD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DPalescandolo%26aufirst%3DE.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DMahan%26aufirst%3DS.%26aulast%3DSougnez%26aufirst%3DC.%26aulast%3DOnofrio%26aufirst%3DR.%2BC.%26aulast%3DLiefeld%26aufirst%3DT.%26aulast%3DMacConaill%26aufirst%3DL.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3DGabriel%26aufirst%3DS.%2BB.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DArdlie%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DPorter%26aufirst%3DJ.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DMorrissey%26aufirst%3DM.%2BP.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DThe%2520Cancer%2520Cell%2520Line%2520Encyclopedia%2520enables%2520predictive%2520modelling%2520of%2520anticancer%2520drug%2520sensitivity%26jtitle%3DNature%26date%3D2012%26volume%3D483%26spage%3D603%26epage%3D607%26doi%3D10.1038%2Fnature11003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repecka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDade, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haussler, D.</span></span> <span> </span><span class="NLM_article-title">The UCSC Xena platform for public and private cancer genomics data visualization and interpretation</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi">Â DOI: 10.1101/326470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;key=10.1101%2F326470" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Goldmanauthor=B.+Craftauthor=M.+Hastieauthor=K.+Repeckaauthor=F.+McDadeauthor=A.+A.+Kamathauthor=A.+Banerjeeauthor=Y.+Luoauthor=D.+Rogersauthor=A.+Brooksauthor=J.+Zhuauthor=D.+Haussler&title=The+UCSC+Xena+platform+for+public+and+private+cancer+genomics+data+visualization+and+interpretation&doi=10.1101%2F326470"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1101%2F326470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F326470%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DM.%26aulast%3DCraft%26aufirst%3DB.%26aulast%3DHastie%26aufirst%3DM.%26aulast%3DRepecka%26aufirst%3DK.%26aulast%3DMcDade%26aufirst%3DF.%26aulast%3DKamath%26aufirst%3DA.%2BA.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DRogers%26aufirst%3DD.%26aulast%3DBrooks%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHaussler%26aufirst%3DD.%26atitle%3DThe%2520UCSC%2520Xena%2520platform%2520for%2520public%2520and%2520private%2520cancer%2520genomics%2520data%2520visualization%2520and%2520interpretation%26jtitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F326470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i31"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02171">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48260"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02171?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02171</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chromatography of [<sup>113/115</sup>In]<b>QCP02</b> and [<sup>111</sup>In]<b>QCP02</b> and [<sup>113/115</sup>In]<b>QCP02</b>, inhibitory potency, FAP surface expression of cell lines used, and serial NIRF imaging of <b>QPC01</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02171/suppl_file/jm0c02171_si_001.pdf">jm0c02171_si_001.pdf (555.18 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02171&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02171%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02171" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a3045f3f1252","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
